


Republic of Ghana

NATIONAL GUIDELINES FOR THE MANAGEMENT OF CARDIOVASCULAR DISEASES




Ministry of Health First Edition

2019



Republic of Ghana

NATIONAL GUIDELINES FOR THE MANAGEMENT OF CARDIOVASCULAR DISEASES



Ministry of Health First Edition

2019

IMPRINT

© 2019 Ministry of Health Ghana

All rights reserved. No part of this publication may be reproduced, stored in any retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording and/or otherwise, without prior written permission of the Ministry of Health.

NATIONAL GUIDELINES FOR THE MANAGEMENT OF CARDIOVASCULAR DISEASES

1st Edition, 2019

For all enquiries write to the publishers: Ministry of Health P.O. Box M44, Ministries, Accra, Ghana, West Africa Tel: +233 302 665651 Fax: +233 302 665651 Email: info@moh.gov.gh Website: www.moh.gov.gh

Legal Disclaimer

Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the authors, editors and publishers are not responsible for errors and omissions or any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the content of the publication.

Design and Layout by: odecologne, Olivia Ockenfels Cologne, Germany

Printed by: Jusjay Media Accra, Ghana

FOREWORD

Non-communicable diseases (NCDs) account for 60% of the 58 million deaths worldwide; 80% of which occur in low- and middle-income countries (LMIC). People in LMICs tend to get NCDs at younger ages, suffer longer and die sooner than those in high income countries. Almost half of all NCD deaths are attributable to cardiovascular diseases (CVDs).

In sub-Saharan Africa, individuals at high risk of CVDs are usually at the peak of their productive years. As a low to middle income country in sub-Saharan Africa, the topic of CVDs is an extremely important one for Ghana.

The health system in Ghana is confronted with a double burden of diseases. A high prevalence of infectious diseases still exists while there is a growing prevalence of chronic NCDs.

The vision of the health sector in Ghana is to have a healthy population for national development. The objectives of the Ghana NCD Policy 2011 include reducing the incidence of chronic NCDs; reducing the unhealthy lifestyles that contribute to NCDs; reducing morbidity associated with NCDs and improving the overall quality of life in persons with NCDs.

On the achievement of this milestone of the development of national guidelines for the assessment of risk and management of CVDs in Ghana, I congratulate all parties involved and call on all concerned health workers to adhere to this standard and by so doing contribute to reducing morbidity and mortality related to NCDs in Ghana.

Hon. Kwaku Agyeman-Manu (MP)

Minister for Health Ghana

December 2019

PREFACE

Cardiovascular diseases (CVDs) are a growing public health problem in Ghana and other African countries. Strokes and other CVDs have become a leading cause of death due to increasing risk factors such as hypertension. According to the Global Burden of Disease study (GBD), ischaemic heart disease was the fourth leading cause of death in Ghana in 2016. The prevalence of hyper-tension, a major risk factor for CVDs, is increasing rapidly and ranges from 19% to 48%, according to the Ghana Health Service Annual Report, 2017, due to rising life expectancy and the increasing prevalence of contributing factors such as overweight/obesity. Early diagnosis and adequate management of the risk factors can reduce the fatal consequences of CVDs.

At the heart of improving risk assessment and management of CVDs are nationally approved guidelines, which facilitate standardisation of care approaches.

These guidelines developed by experts from all levels of health care and stakeholders capture all recommended approaches and necessary information for clinicians and other healthcare workers on CVDs. They also serve as a practical guide for assessing and managing the most important CVDs prevalent in Ghana and can be used at all levels of care namely health facilities without a doctor; with a general practitioner and with a physician specialist.

We hope that these guidelines will prove to be a useful and a beneficial tool for all its users.

Dr. Patrick Kuma-Aboagye

Director-General Ghana Health Service

December 2019

ACKNOWLEDGEMENT

We wish to express our heartfelt gratitude to the following institutions and individuals, who have contributed in diverse ways towards the successful development of these guidelines:

- The Minister, Hon. Kwaku Agyeman-Manu (MP) and the Ministry of Health for providing overall guidance for the development process.
- The Director General, Dr. Anthony Nsiah-Asare and the Ghana Health Service for their support that ensured a successful development process.
- The Dean, Prof. Margaret Lartey and the University of Ghana School of Medicine and Dentistry for providing technical assistance.
- The CEO, Dr. Daniel Asare and Korle Bu Teaching Hospital for their support to ensure a successful development process.
- The Ghanaian Society of Cardiology for providing technical input.
- Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH, for providing technical expertise and operational management of the CVD guideline development process and the entire Ghana Heart Initiative (GHI) team.

We wish to acknowledge as well the following persons/groups for their tremendous contributions in the development of these guidelines:

MINISTRY OF HEALTH

Nana Kwabena Adjei-Mensah Chief Director Dr. Emmanuel Ankrah Odame Ag. Director, Policy Planning Monitoring and Evaluation (PPME) Dr. Baffour Awuah NCD Advisor to the Minister of Health Alhaji Inua Yusuf Legal Unit Office of the Chief Director

GHANA HEALTH SERVICE

Dr. Koku Awoonor Director, Policy Planning Monitoring and Evaluation Division (PPMED)
Dr. Charity Sarpong Regional Director of Health Services, Greater Accra Region (GAR)
Ms. Sarah Amissah-Bamfo Deputy Director, Clinical Care Division, Greater Accra Regional Health Directorate
Mr. Emmanuel Asare Quality Focal Person, Greater Accra Regional Health Directorate
Office of the Director General

NCD CONTROL PROGRAMME

Dr. Dennis Laryea Programme Manager Dr. Mary Commeh Deputy Programme Manager

GHANA HEART INITIATIVE GOVERNANCE COMMITTEE

Prof. Jacob Plange-Rhule Chair of GHI Governance Committee/Rector, Ghana College of Physicians and Surgeons (GCPS)
Dr. Koku Awoonor Director, PPMED, GHS
Dr. Baffour Awuah NCD Advisor to Minister for Health
Prof. Fred Binka University of Health and Allied Sciences (UHAS)
Dr. Dennis Laryea Manager, NCD Control Programme
Prof. Mark Tettey University of Ghana School of Medicine and Dentistry

COORDINATOR OF GUIDELINE DEVELOPMENT

Dr. Cynthia Bannerman

GUIDELINE WRITERS

Dr. Aba Folson Greater Accra Regional Hospital, Ridge Dr. Abdul-Samed Tanko Korle Bu Teaching Hospital Dr. Alexander Baafi Aqyekum Korle Bu Teaching Hospital Dr. Alfred Doku Korle Bu Teaching Hospital Dr. Collins Kokuro Komfo Anokye Teaching Hospital Dr. Desrie Delsol-Gyan Korle Bu Teaching Hospital Dr. Dzidzo Afi Anaglate Korle Bu Teaching Hospital Dr. Eugene Amable Korle Bu Teaching Hospital Dr. Fiifi Duodu Korle Bu Teaching Hospital Dr. Francis Agyekum La General Hospital Dr. Isaac Nana Ogyefo Komfo Anokye Teaching Hospital Prof. Isaac Owusu Komfo Anokye Teaching Hospital Dr. Jane Afriyie-Mensah Korle Bu Teaching Hospital Dr. Joseph Akamah Korle Bu Teaching Hospital Dr. Josephine Akpalu UGSMD/Korle-Bu Teaching Hospital Dr. Kwaku Obeng Amponsah Korle Bu Teaching Hospital Dr. Lambert Tetteh Appiah Komfo Anokye Teaching Hospital Dr. Martin Adu-Adadey Korle Bu Teaching Hospital Dr. Mary Commeh Non-Communicable Disease Control Programme, GHS Dr. Michael Adomako Korle Bu Teaching Hospital Dr. Nana Adjoa Moniku Coleman Korle Bu Teaching Hospital Dr. Nana-Akyaa Yao Korle Bu Teaching Hospital Dr. Patrick Adjei Korle Bu Teaching Hospital Dr. Patrick Opoku Berchie Komfo Anokye Teaching Hospital Dr. Prince Boahene Komfo Anokye Teaching Hospital Dr. Roberta Lamptey Korle Bu Teaching Hospital Dr. Vincent Boima Korle Bu Teaching Hospital Dr. Yaw Adu-Boakye Komfo Anokye Teaching Hospital

GUIDELINE REVIEWERS

Dr. Baffour Awuah Ministry of Health Prof. Bernard C. Nkum Komfo Anokye Teaching Hospital Prof. David Ofori-Adjei University of Ghana Medical School Dr. Dennis Laryea Non-Communicable Disease Control Programme, GHS Prof. Francis Ofei University of Cape Coast School of Medical Sciences Prof. Frank Edwin University of Health and Allied Sciences, Ho Dr. Franklin Acheampong Korle Bu Teaching Hospital Dr. Yaw Ofori-Adjei Korle Bu Teaching Hospital

CONTRIBUTORS

Dr. Aba Amoasiwah Ghansah Weija-Gbawe Municipal Hospital Dr. Abdul-Subulr Yakubu Tamale Teaching Hospital, Tamale Ms. Adwoa Addai-Acheampong Tuobodom Health Centre, Techiman North Mr. Alhassan Abdul Kadiri Pusiga Health Centre Dr. Amoasiwah Aba Ghansah Ga South Municipal Hospital Dr. Arnold Osei-Wusu St. Patrick's Hospital, Offinso-Ashanti Ms. Asabea Opare-Appiah Korle Bu Teaching Hospital Dr. Ato Yeboah Ada East District Hospital Mrs. Belinda Marian Mensah National Health Insurance Authority Mr. Benson A.K. Tseganu Dedeso CHPS, Eastern Mrs. Constance Addo-Quaye National Health Insurance Authority Dr. Dzifa Ahadzi Tamale Teaching Hospital, Tamale Ms. Edith Gavor Ghana National Drugs Programme, MOH Dr. Edmund Acquaye Korle Bu Teaching Hospital Ms. Emma Antwi GHS-Greater Accra Region Mr. Emmanuel Asare GHS-Greater Accra Region Ms. Ernestina N L Anderson La General Hospital Dr. Eszter Ami Momade Cape Coast Teaching Hospital Dr. F. Amah Nkansah Korle Bu Teaching Hospital Dr. Fathia Karim Korle-Bu Teaching Hospital Ms. Faustina Opoku Nyanyano Health Centre, Gomoa East Mr. Frank Quartey University of Ghana Dr. Fredrick Asomani Akoto St. Gregory Catholic Hospital, Gomoa Budumburam Dr. George Peprah Takoradi Regional Hospital, Takoradi Dr. Jacob Omari Appah Omari Health Centre Prof. Jacob Plange-Rhule Ghana College of Physicians and Surgeons Dr. James Duah Christian Health Association of Ghana Dr. Janice Acheampong Police Hospital Mr. Jerry Fiave Ghana Health Service -Health Promotion Mr. Joshua A. Akpilima Jirapa Health Centre Mr. Justice Kwesi Baah Ghana Coalition of NGOs in Health Ms. Lily Atakora Prampram Polyclinic Ms. Loretta M Donkor Afienya CHPS Prof. M.O. Mate-Kole Korle Bu Teaching Hospital Mama Aflo Vuiede II Queen of Mafi Aflokope, Volta Region Mr. Mark Amankwa Harrison Korle Bu Teaching Hospital Dr. Mavis Sakyi Legon Hospital, Accra Ms. Mercy Abekah Mensah Nyanso CHPS, Tarkwa Nsuaem Dr. Momodou Cham Faith Based Groups Dr. Naa Klotefo Clottey Ga West Municipal Authority Hospital Nana Obuobi I Traditional ruler, Queen mother, Mayera, Greater Accra Nana Tsetse Agyeman IV Queen mother, Nii Djanwe, Greater Accra

Mr. Ronald O. Adom Private Health Insurers Association
Ms. Ruth Ewuradjoa Panford Tema General Hospital
Dr. Sally-Ann Ohene World Health Organisation
Mr. Samuel Asamoah Nkrumah Princess Marie Louis Hospital
Dr. Seth Yao Nani Ga West Municipal Hospital, Amasaman
Dr. Sheila Attuquayefio Regional Hospital, Koforidua
Ms. Tina Asaa Gyimah Samsam Community Clinic
Mr. Wisdom Kwabena Gavor Central Aflao Hospital
Ms. Yvonne Yirenkyiwaa Esseku Pharmaceutical Society of Ghana

GHANA HEART INITIATIVE TEAM

Ms. Alberta E. Acquah Project Administrative Assistant, Ghana Dr. Alfred Doku Project Director, Ghana Dr. Brigitte Jordan-Harder Senior Technical Advisor, Germany Mr. Fionn Harnischfeger Project Manager, Germany Mr. Janosch Jerman Senior Project Manager, Germany Ms. Juliette Edzeame Project Coordinator, Ghana

CONTENT

3.2.11

3.2.12

Cardiac murmurs

Hepatomegaly and ascites

FC	IPRINT DREWORD REFACE		4 5 6
		DGEMENT	7
1	INTRODU	JCTION	16
2	risk fag	CTORS FOR CARDIOVASCULAR DISEASES	24
	2.1	Introduction	25
	2.2	Risk assessment	25
	2.2.1	Total risk assessment	25
	2.2.2	World Health Organization/International Society of Hypertension	26
		(WHO/ISH) risk prediction chart	
	2.2.3	Lifestyle modification for the prevention and management of CVDs	28
	2.2.4	Risk management through primary and secondary prevention	30
	2.2.5	Management of dyslipidaemias by level of care	31
3	SYMPTO	MS AND SIGNS OF CARDIOVASCULAR DISEASES	38
	3.1	Symptoms of CVDs	39
	3.1.1	Dyspnoea	39
	3.1.2	Chest pain	39
	3.1.3	Oedema	40
	3.1.4	Haemoptysis	41
	3.1.5	Syncope	41
	3.1.6	Palpitations	42
	3.2.1	General appearance	42
	3.2.2	Dyspnoea at rest (tachypnoea)	42
	3.2.3	Oedema	43
	3.2.4	Abnormal pulse	43
	3.2.5	Abnormal blood pressure	43
	3.2.6	Cyanosis	44
	3.2.7	Clubbing	44
	3.2.8	Apex beat	44
	3.2.9	Parasternal heaves (lift) and thrills	44
	3.2.10	Heart sounds	44

45

45

4 CARDIAC ARREST

4.1	Introduction	47
4.2	Clinical presentation of cardiac arrest	49
4.3	Management of cardiac arrest according to level of care	49

5 DISEASES

54

46

5.1	HYPERTENSION	54
5.1.1	Introduction	55
i.	Definition	55
ii.	Epidemiology	55
iii.	Classification	55
5.1.2	Aetiology	55
5.1.3	Clinical presentation	57
i.	Symptoms	57
ii.	Signs	57
5.1.4	Complications of hypertension	57
5.1.5	Management of hypertension relevant for all levels of care	58
i.	Investigation	58
ii.	Non-pharmacological treatment for all levels of care	59
5.1.6	Management of hypertension according to level of care	60
5.1.7	Resistant hypertension	66
5.1.8	Hypertensive emergency	
5.1.9	Patient Information/education at all levels	72
5.1.10	Prevention of hypertension	72

5.2	STROKE	74
5.2.1	Introduction	75
i.	Definition	75
ii.	Epidemiology	75
iii.	Classification of strokes	75
iv.	Aetiology	76
V.	Risk factors	76
5.2.2	Clinical presentation	77
5.2.3	Management according to level of care	78
5.2.4	Complications of stroke	86
5.2.5	Referral	86
5.2.6	Patient education and prevention	87

5.3	CHEST PAIN, CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION	92
5.3.1	Introduction	93
i.	Definition	93
ii.	Epidemiology	93
5.3.2	Stable coronary artery disease	93

i.	Clinical presentation	93
ii.	Symptoms	93
iii.	Signs	95
5.3.3	Management of stable CAD	95
i.	Treatment objectives	95
ii.	Management according to level of care	96
5.3.4	Patient education/information	101
5.3.5.	Prevention of stable CAD	101
5.3.6	Acute coronary syndromes (ACS)	101
i.	Introduction	101
ii.	Aetiology	102
iii.	Symptoms	102
iv.	Differential diagnoses of ACS	103
V.	Management	104
va.	Treatment objectives	105
vi.	Management according to level of care	106
5.4	HEART FAILURE	112
5.4.1	Introduction	113
i.	Definition	113
ii.	Epidemiology	113
iii.	Classification of heart failure	113
5.4.2	Aetiology	114
5.4.3	Clinical presentation	114
i.	Symptoms and signs	114
5.4.4	Aspects of management relevant for all levels of care	114
i.	Non-pharmacological treatment relevant for all levels	115
5.4.5	Management according to level of care	115
5.5	VENOUS THROMBOEMBOLISM	124
5.5.1	Introduction	125
i.	Definition	125
ii.	Epidemiology	125
iii.	Risk factors	125
5.5.2	Deep vein thrombosis	126
i.	Clinical presentation	126
ii.	Management according to level of care	127
5.5.3	Acute pulmonary embolism (PE)	130
i.	Classification of acute PE	130
ii.	Clinical presentation	130
iii.	Management according to level of care	132
5.5.4	Management of VTE in special populations (relevant for all levels of care)	136
5.5.5	Prevention of VTEs	136

5.6	ACUTE RHEUMATIC FEVER	138
5.6.1	Introduction	139
i.	Definition	139
ii.	Epidemiology	139
iii.	Aetiology	139
5.6.2	Clinical presentation	139
5.6.3	Management according to level of care	142
5.6.4	Secondary prevention (applies for health facilities with a doctor and a physician specialist)	144
5.7	RHEUMATIC HEART DISEASE	148
5.7.1	Introduction	149
i.	Definition	149
ii.	Epidemiology	149
iii.	Classification	149
5.7.2	Aetiology	149
5.7.3	Symptoms and signs	150
i.	Mitral regurgitation (MR)	150
ii.	Mitral stenosis	151
iii.	Aortic regurgitation (AR)	151
iv.	Aortic stenosis	152
V	Tricuspid regurgitation (TR)	152
vi.	Pulmonary valve	152
5.7.4	Management according to level of care	153
5.7.5	Patient information	158
5.8	INFECTIVE ENDOCARDITIS	160
5.8.1	Introduction	161
i.	Definition	161
ii.	Classification	161
iii.	Risk factors	161
5.8.2	Aetiology	161
5.8.3	Clinical presentation	162
5.8.4	Management according to level of care	164
5.8.5	Complications	168
5.8.6	Prevention	168
5.8.7	Patient information/education	170
5.9		
	CARDIAC ARRHYTHMIAS	172
5.9.1	CARDIAC ARRHYTHMIAS Introduction	172 173
5.9.1 i.		
	Introduction	173
i.	Introduction Definition	173 173
i. ii.	Introduction Definition Epidemiology	173 173 173
i. ii. iii.	Introduction Definition Epidemiology Classification of arrhythmias	173 173 173 173
i. ii. iii. 5.9.2	Introduction Definition Epidemiology Classification of arrhythmias Aetiology	173 173 173 173 173 173

5.9.4	Basic investigation according to level of care	174
5.9.5	Tachyarrythmias: general overview	175
i.	Management according to level of care	175
ii.	Atrial fibrillation	178
iii.	Atrial flutter	181
iv.	Management of paroxysmal supraventricular tachycardia	182
V.	Management of ventricular tachyarrhythmia in stable patients	183
vi.	Management of ventricular fibrillation health facility with a doctor/physician specialist	185
5.9.6	Bradyarrhythmias	186
i.	Sinus bradycardia	186
ii.	Atrioventricular block	186
iii.	Sick sinus syndrome (sinus node dysfunction)	188
5.9.7	Prevention	190
5.9.8	Patient information/education	190


LIST OF TABLES	192
LIST OF FIGURES	194
ANNEX 1	196
ANNEX 2	197

1 INTRODUCTION

1.1 CARDIOVASCULAR DISEASE BURDEN

Non-communicable diseases such as heart diseases, stroke, diabetes, cancers, respiratory diseases, injuries, etc accounts for 60% of the 58 million deaths worldwide; 80% of these deaths occur in low- and middle-income countries (LMIC). People in LMICs tend to get NCDs at younger ages, suffer longer, and die sooner than those in high income countries. Almost half of NCD deaths are attributable to cardiovascular diseases (hypertension, stroke, heart attack, heart failure, etc).

Globally, cardiovascular diseases (CVDs) are the number one cause of death. According to statistics from the World Health Organisation (WHO), CVDs were responsible for about 17.9 million (31%) deaths worldwide in 2016. Heart attack (myocardial infarction) and stroke contributed to 85% of these deaths¹. Modernisation in societies (fast foods, sedentary lifestyle, technologies, etc.) brings along changes in behaviour and lifestyle, and consequently changes in the health and disease patterns^{2,3}. The major population risk factors for CVDs include age, smoking, history of hypertension or diabetes mellitus, obesity, unhealthy diet, alcohol misuse, lack of physical activity, dyslipidaemia, family history of heart disease, ethnicity/race and psychosocial factors^{4,5}.



Worldwide NCD mortality: 2008 verse 2030

Figure 1: Projected NCD mortalities (WHO 2008), *2030 projected values

LMICs are the most affected by CVDs. Globally, about 80% of CVD-related deaths as well as 87% of CVD-related disabilities occur in LMICs⁵. Although high income countries have put in place measures that are working to decrease their CVD rates, the same cannot be said for LMICs⁴. Between 1990 and 2013, sub-saharan Africa remained the only part of the world that had an increase in the CVD-related deaths⁵.

CVD related deaths in sub-saharan Africa continue to increase with stroke being responsible for nearly half a million deaths in 2012⁵. Sub-saharan Africa is also known to record the world's highest prevalence of rheumatic heart disease (RHD) i.e. 15-20 per 1000 people⁶. Hypertension, the leading risk factor for CVDs, is rising rapidly and has been predicted to increase by 60% among adults by 2025⁴.

1.2 EFFORTS TO REDUCE CVD RELATED DEATHS

In sub-saharan Africa, individuals at high risk of CVDs are usually at the peak of their productive years⁴. There are local and international efforts to improve the control of NCDs through lifestyle modification coupled with early detection and management. The Sustainable Development Goals (SDGs) aim to ensure healthy lives and promote well-being for all⁷.

The Ghana NCD Policy 2011 has the following objectives:

- \rightarrow To reduce the incidence of chronic NCDs
- \rightarrow To reduce the unhealthy lifestyles that contribute to NCDs
- \rightarrow To reduce morbidity associated with NCDs
- \rightarrow To improve the overall quality of life of persons with NCDs

1.3 PURPOSE AND IMPORTANCE OF CVD GUIDELINES

About three quarters of the world's CVD-related deaths occur in LMIC like Ghana. This is mainly because the health facilities in these countries are not well equipped to detect CVDs early and properly manage them. High income countries have integrated primary health care programmes that aid in the early diagnosis and treatment of CVDs and other NCDs.

In Ghana, there are no standardised guidelines dedicated to the management of CVDs. Apart from improving health care through capacity building, provision of guidelines to health workers and its proper implementation can greatly reduce the morbidity and mortality associated with CVDs. The CVD guidelines will serve as an essential tool that assist the health workers to manage CVDs and streamline the referral process as it will give guidance on referrals as well.

1.4 PROCESSES IN THE DEVELOPMENT OF CVD GUIDELINES

These guidelines are developed by the relevant stakeholders: The Ministry of Health, the Ghana Health Service, the NCD Control Programme, the Korle-Bu Teaching Hospital, University of Ghana School of Medicine and Dentistry, the Ghanaian Society of Cardiology.

The processes involved in the development of these guidelines include:

- → Stakeholder planning workshop
- → Stakeholder selection of the relevant topics
- → Selection of writers, reviewers and editorial team
- → Development of draft CVD guideline
- → Stakeholder review and recommendation
- → Final version submission to Ministry of Health
- → Approval of the guidelines for use in Ghana

1.5 LEVEL OF EVIDENCE (LOE)

The recommendations made for the management of CVDs in these guidelines were based on data from studies or research. The weight of evidence is graded A to C as shown in *table 1* below.

Table 1: Level of evidence

Level of evidence	
Level of evidence A	Data derived from multiple randomized clinical trials or meta-analyses
Level of evidence B	Data derived from single randomized clinical trial or large non-randomized studies
Level of evidence C	Consensus of the experts and/or small studies, retrospective studies, registries

1.6 STRUCTURE/ORGANIZATION OF CVD GUIDELINES

The CVD guidelines begin with an introduction, which describes the burden of CVDs globally and narrows down to Ghana. It highlights the need for having national CVD guidelines as well as the importance of each level of healthcare in the management of CVDs. The document continues to describe CVD risk assessment and prevention, symptoms and signs of CVDs and details nine⁶ CVDs that are of high public health importance in Ghana. The structure is summarised below:

Structure of the CVD Guidelines:

- 1 Introduction
- 2 Cardiovascular diseases risk, assessment and prevention
- 3 Symptoms and signs of cardiovascular diseases
- 4 Cardiac arrest
- 5 Diseases
 - 5.1 Hypertension
 - 5.2 Stroke
 - 5.3 Chest pain, coronary artery disease and myocardial infarction
 - 5.4 Heart failure
 - 5.5 Venous thromboembolism
 - 5.6 Acute rheumatic fever
 - 5.7 Rheumatic heart disease
 - 5.8 Infective endocarditis
 - 5.9 Cardiac arrhythmias

1.6.1 LEVELS OF CARE

The levels of care and facilities available vary from region to region. The Essential Medicine List (EML) of Ghana has 7 categories of prescription to bring clarity to the medicine that can be prescribed at various levels. These categorizations include:

- Level A Community-based health planning and services (CHPS; the lowest level)
- Level M Midwifery
- Level B1 Health centre without doctor
- Level B2 Health centre with doctor
- Level C District hospital
- Level D Regional/teaching hospital
- Level SM Specialist medicines

To enhance ease of recommendation of therapy at various levels of care in Ghana, the stakeholders recommended the following levels for this CVD guideline:

Level 0 – For all levels		
Level 1 – Health facility without a doctor		
Level 2 – Health facility with a doctor		
Level 3 – Health facility with a physician specialist or family physician		
Health facility with cardiologists and high sophisticated equipment		
ightarrow Management of diseases for the different levels is clearly indicated by the respective colour for easy		

- use of the guidelines. → Medicines outside the scope of the essential medicines list (EML) are clearly indicated by the diamond
- → Medicines outside the scope of the essential medicines list (EML) are clearly indicated by the diamond symbol *.

1.7 RECOMMENDED RESOURCES NEEDED FOR CVD MANAGEMENT

The WHO's technical package for CVD management in primary health care recommends the following technologies/resources, tools and medications for primary health care facilities (for primary care facilities with only non-physician health workers, most of the medicines below are required for refill of prescriptions issued by physicians at a higher level of care).

Resources needed	Health facility without a doctor Level 1	Health facility with a doctor Level 2	Health facility with a specialist Level 3
Diagnostic equipment	 Blood pressure (BP) machine Stethoscope Glucometer and strips A weighing scale A tape measure A stadiometer (for height assessment) Waist/hip charts Body Mass Index (BMI) charts Thermometer CVD risk assessment tools Strips for urinalysis 	 Equipment in Level 1 Haematology equipment and reagents Biochemistry equipment and reagents Ophthalmoscope X-ray Electrocardiograph (ECG) machine 	 Equipment in levels 1 and 2 Echocardiogram machine (high specification) Blood analysis: fasting blood sugar, elec- trolytes, creatinine, choles- terol and lipoproteins Cardiac catheterisation lab Ambulatory BP Holter machine Treadmill Facilities for telemedicine A critical care unit
Medications	 Thiazide-like diuretic Calcium-channel blocker (eg. Nifedipine, Amlodipine) 	 Diuretics (including Spironolacto- ne and Furosemide) Beta-blockers (eg. Bisoprolol, Metoprolol) Digoxin Warfarin Clopidogrel Statins (eg. Atorvastatin) ACEI/ARB (eg. Lisinopril, Losartan) Furosemide Aspirin 	 CVD risk medications Heart failure medications Antiarrhythmic medications Antiplatelets Advanced cardiac life support medications

Table 2: Various levels of care and recommended resources

1.8 CARDIAC ARREST AND EMERGENCY RESPONSE CAPACITY

Cardiac arrest can occur at anytime and any place in seeming healthy individuals. The general public and the health system in Ghana should build capacity in manpower, infrastructure and system to manage cardiac arrest. The capacity building should include but not be limited to:

- 1. Training of pupils and students of primary, secondary and tertiary educational institutions in basic life support (BLS).
- 2. Training of commercial drivers and security agencies in first aid and basic life support (BLS).
- **3.** Provision of Automated External Defibrillators (AED) at large institutions such as banks, schools, churches, mosques, airports, ports/harbours and ministries.
- 4. Training of health professionals in basic and advance resuscitation:
 - Pre-service training of Community Health Workers (CHO), midwives and nurses in basic life support (BLS) and training of physician assistants and doctors in advance cardiac life support (ACLS)
 - In-service training (continuous professional development (CPD)) of CHO, midwives and nurses in basic life support (BLS), and training of physician assistants and doctors in advance cardiac life support (ACLS)

5. Formation of emergency response teams in health facilities.

Each health facility should have a dedicated team to respond to emergencies at various units. The team should be able to respond to emergencies within 5 minutes. This requires that for each day and shift, there would be a team with requisite skills, equipment and medications to respond to emergencies.

- 6. Paramedics should have requisite training and skills in resuscitation.
- **7.** Ambulances should have the requisite equipment and medicines necessary for resuscitation and care of the sick.
- **8.** Clear lines of communication between the referring and receiving health institutions to ensure continuity of care and to prevent unnecessary delays.

1.9 PRESCRIPTION WRITING

Medicine is to be prescribed only when they are necessary in the management of a patient following a clear or probable diagnosis. In all cases, the benefit of administering the medicine should be considered in relation to the risk involved. This is particularly important in special patient populations such as pregnant women when the risk of both mother and foetus must be considered.

Standard prescriptions should:

- Be written legibly in ink
- Be dated
- State the full name (and address if possible) of the patient
- Specify the age and weight of the patient (especially in the case of children)
- Bear the generic name of the medication and the required dosage.
- Be written completely by the prescriber (certified) and not left for another person to complete
- Be signed in ink by the certified prescriber
- Bear the contact details of the prescriber (e.g., name, facility name and telephone number)

The following should be noted when writing a prescription:

- Names of medicines and preparations should be written in full
- Generic names should always be used as advised by these guidelines
- Avoid the use of unnecessary decimal points (e.g. 5mg and not 5.0mg)
- Where decimals are unavoidable, use a zero in front of the decimal point where there is no other figure (0.5ml and not .5ml)
- Quantities of 1 gram or more should be written in grams (e.g. 1g, 4g)
- Quantities less than 1 gram should be written in miligrams (e.g. 500mg and not 0.5g)
- Quantities less than 1mg should be written in micrograms (e.g. 500micrograms and not 0.5mg)
- 'Micrograms' and 'nanograms' should not be abbreviated; similarly, 'units' should not be abbreviated
- Use the term millilitre and not cubic centimetre
- State the dose and dosing frequency clearly
- State the quantity to be supplied and/or indicate the number of days of treatment required.
- Clearly state the route of administration; avoid the use of the parenteral route of administration except where there are clear clinical indications for this route; use the oral route whenever possible

1.10 REFERRAL

Primum non nocere! First, do no harm!

To better serve patients, it is vital that healthcare professionals know when to refer appropriately for next level or specialized management. These guidelines make provision for referral of patients to other health facilities.

Patients should be referred if:

- 1. The health facility lacks the appropriate resources needed for the diagnosis and management of the patient in the form of:
 - Lack of expertise/qualified health workers
 - Lack of appropriate diagnostic tools
 - Lack of appropriate medication
- 2. The patient and family request for second opinion or different level of care

Patients should be referred in accordance with agreed arrangements to facilities where the necessary competence, diagnostic tools and support exist.

→ Notification and prior discussion of the case should be undertaken to ensure that the receiving health facility is adequately prepared for continuity of care.

The referral letter should consist of:

- Date
- Name and contact of physician/health worker and institution the patient is referred from
- Name of patient, age, sex, contact of relative
- Reason for referral
- The patient's history, clinical findings, test results and prior treatment
- The provisional diagnosis
- Initial treatment given
- Signature of the referring physician/health worker
- → The referral letter should be structured clearly with headings so that the receiving clinician will find the relevant information easily.
- \rightarrow See annex 1 (page 196) for a copy of the referral letter.
- → It is recommended that feedback is given to the referring clinician/health facility to help advice on future management of the patient and other patients.

Feedback should include:

- Final diagnosis
- Long term management plan including follow up instructions
- Name and contact of physician
- \rightarrow See annex 2 (page 197) for a copy of the feedback form.

1.10 CONFLICT OF INTEREST

Stakeholders (writers, reviewers and editors) declare that they have no personal interests or benefits in the development of these CVD guidelines.

EMERGENCY CONTACTS

Police: 191/18555 Fire Service: 192/999 Ambulance: 193

REFERENCES:

- 1 World Health Organization. Cardiovascular diseases (CVDs). 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
- 2 Agyei-Mensah S, de-Graft Aikins A. Epidemiological transition and the double burden of disease in Accra, Ghana. J Urban Heal. 2010 Sep; 87(5): 879–897.
- ³ Kodaman N, Aldrich MC, Sobota R, Asselbergs FW, Poku KA, Brown NJ, et al. Cardiovascular disease risk factors in Ghana during the rural-to-urban transition: A cross-sectional study. Tayo BO, editor. PLoS One. 2016 Oct; 11(10): 1-20.
- 4 Paolo F, Michelle C, Miller A. Cardiovascular disease and hypertension in sub-Saharan Africa: burden, risk and interventions. Intern Emerg Med. 2016; 11(3): 299–305.
- 5 Ofori-Asenso R, Garcia D. Cardiovascular diseases in Ghana within the context of globalisation. Cardiovasc Diagn Ther. 2016; 6(1): 67–77.
- 6 Mocumbi AO. Lack of focus on cardiovascular disease in sub-Saharan Africa. Cardiovasc Diagn Ther. 2012 Mar; 2(1): 74–77.
- 7 United Nations. Sustainable development knowledge platform. Available from: https://sustainabledevelopment.un.org/sdgs.

2 RISK FACTORS FOR CARDIOVASCULAR DISEASES

LIST OF ABBREVIATIONS AND ACRONYMS

ABI	Ankle Brachial Index	HDL	High-Density Lipoprotein
AFR	Africa	LDL	Low-Density Lipoprotein
ASCVD	Atherosclerotic	PAD	Peripheral Artery Disease
	Cardiovascular Disease	TG	Triglycerides
BMI	Body Mass Index	VLDL	Very Low-Density Lipoprotein
BP	Blood Pressure	WHO/ISH	World Health Organization/
CAD	Coronary Artery Disease		International Society of
CVD	Cardiovascular Disease		Hypertension
DM	Diabetes Mellitus	WHR	Waist Hip Ratio
FBS	Fasting Blood Sugar		

2.1 INTRODUCTION

Risk factors are conditions that, when present, put people at greater likelihood of developing atherosclerotic cardiovascular diseases (ASCVD). The term ASCVD comprises: coronary artery disease, peripheral artery disease, cerebral and carotid artery disease. Some of the risk factors such as hypertension can cause CVD directly without going through atherosclerosis. For instance, hypertension can cause heart failure from hypertensive heart disease, aortic dissection and hemorrhagic stroke.

Several CVD risk factors have been identified. Early detection and management of these CVD risk factors will help prevent and/or slow the progression of CVDs. Many of these CVD risk factors are controllable (modifiable risk factors) whereas a few cannot be controlled/modified and are not dependent on lifestyle (non-modifiable risk factors)¹.

Although much of the burden of CVDs can be explained by the well-established risk factors, several emerging risk factors have been identified. The emerging risk factors for CVD become significant when added to the traditional risk factors (accelerate the development of CVDs)².

Traditional cardiovascular risk factors		Emerging cardiovascular risk factors ³
Modifiable CVD risk factors	Non-modifiable CVD risk factors	
Hypertension	Age (>45 yrs in men; >55 yrs in women)	Arterial wall stiffness
Diabetes	Family history of premature coronary artery disease: males, age <55 yrs; females, age <65 yrs	Coronary artery calcification
Dyslipidemia (high LDL, low HDL, high Triglycerides)	Male sex	Lipoprotein A
Obesity (BMI >30)		Hyperfibrinogenemia
Excessive alcohol consumption		Raised inflammatory markers e.g. IL-6
Tobacco smoking		C-reactive protein
Physical inactivity		Chronic kidney disease Carotid intima media thickness
Obstructive sleep apnea		Hyperhomocysteinaemia
		Microalbuminuria
		Hyperuricemia

Table 3: Traditional and emerging cardiovascular risk factors

2.2 RISK ASSESSMENT

2.2.1 TOTAL RISK ASSESSMENT

Counting the number of risk factors present in an individual does not give accurate estimate of atherosclerotic cardiovascular disease (ASCVD) risk. It is more beneficial if the ASCVD risk is expressed as 10-year or 30-year (lifetime) risk or cardiovascular age. Several risk assessment models are available for estimating the risk of initial ASCVD events in asymptomatic individuals. However, no single risk assessment model will be best suited for all patients⁴. These guidelines adopt the World Health Organization (WHO) risk assessment tool⁵.

2.2.2 WORLD HEALTH ORGANIZATION/INTERNATIONAL SOCIETY OF HYPERTENSION (WHO/ISH) RISK PREDICTION CHART

Chart AFR D (Africa zone D) is appropriate for Ghana. AFR D covers the West African sub-region, which Ghana falls under. Before using the chart, make sure the following information is available: gender, age, presence or absence of diabetes, smoking status, systolic blood pressure (BP) and total blood cholesterol. For health facilities, which cannot check blood cholesterol, use the appropriate chart that does not have total cholesterol.

i. HOW TO USE THE WHO/ISH PREDICTION CHART

- Step 1: Select the appropriate chart depending on the presence or absence of diabetes.
- Step 2: Select male or female tables.
- Step 3: Select smoker or non-smoker boxes.
- Step 4: Select age group box (e.g. if age is 50-59 years select 50, if 60-69 years select 60 etc.).
- Step 5: Within this box or cell, find the nearest cell where the individuals' systolic blood pressure (mmHg) and total blood cholesterol level (mmol/l) cross or intercept. The colour of this cell determines the 10-year ASCVD risk of developing a stroke or heart attack which is expressed in percentages (from <10% to >40%).


ii. RECOMMENDED ACTION PER RISK CATEGORY

Table 4: Recommended action per risk category

Risk score	Recommended action	Evidence rating
Low 10-year risk (<10%)	Reassure and encourage to maintain a healthy lifestyle (e.g. regular exercise, healthy diet etc. see below)	В
Intermediate 10-year risk (10-30%)	Engage patient in discussions on lifestyle changes and treat for hypertension, diabetes and high blood cholesterol when indicated	В
High 10-year risk (>30%)	Recommend lifestyle changes and treat for hypertension, diabetes and high blood cholesterol when indicated. check for the presence of CVDs and treat appropriately	А

iii. PRACTICAL POINTS

- Individuals with already established atherosclerotic CVD do not require the use of risk assessment tools; they are already high risk and managed as such
- First degree relatives (parents and siblings) of individuals with high CVD risk should be advised to undergo CVD risk assessment
- The WHO/ISH risk score may underestimate the total CVD risk in certain individuals. Therefore, treatment decisions can be made in certain cases: e.g. persistently raised BP (>160/100mmHg), or blood cholesterol (>8mmol/l), or diabetes with renal disease⁵; the chart (*figure 2*) shows aggregated risk scores but for a very high level of one risk, treatment can be initiated to correct or reduce this individual risk



WHO/ISH CVD RISK CHART FOR AFRICA ZONE D




Figure 2: WHO/ISH CVD risk chart for Africa zone D (Adapted from WHO risk prediction chart for Africa zone D)⁵

2.2.3 LIFESTYLE MODIFICATION FOR THE PREVENTION AND MANAGEMENT OF CVDs

Lifestyle modification involves altering long term habits typically of eating or physical activity and maintaining the new behaviour. This is important in the prevention and management of CVDs.

It requires long term commitment on the part of the health worker and patient. The specific lifestyle recommendation will depend on existing co-morbidities (other relevant medical conditions).

Lifestyle modification includes:

i. BEHAVIOURAL CHANGES

- Lifestyle modifications require a change in mindset; making small changes at a time
- Successful initiation and maintenance of lifestyle changes require commitment to the process of change
- The family and caregivers can influence the patients' lifestyle choices and should be involved in the care process
- Lifestyle recommendations must be tailored to the individual's socioeconomic status and the patient's own assessment of his self-competencies
- Patients must be guided to set realistic goals

ii. STRESS MANAGEMENT

- Elevated levels of stress particularly chronic stress are associated with CVDs⁶⁻⁸
- Behavioural interventions for dealing with stress include having a positive outlook, healthy coping and relaxation techniques^{9,10}
- Patients needing professional help must be referred to the clinical psychologist

iii. EATING PATTERNS

- Food composition must be individualized as "one size does not fit all" (Evidence Rating A)^{11,12}
- In making lifestyle recommendations, the focus is not on individual nutrients (like carbohydrates, proteins, etc) but rather on meal patterns because meals are eaten in patterns rather than specific components (Evidence rating C)
- The meals recommended must take into consideration the cultural preferences of the patient
- Creating a caloric deficit is to be added for managing patients with obesity; the average adult requires about 25 to 30 kcal/kg body weight per day to maintain the current body weight; creating a deficit of about 500 kcal/day will result in gradual weight loss
- The energy requirement is activity dependent i.e. a sedentary job may require less energy than field workers or those in the construction industry
- Obesity in children is on the increase, reaching epidemic proportions; eating patterns are a learned behaviour; it is important that children are introduced to healthy options at an early age
- Where available, a diet therapist should be involved

Table 5: General nutritional recommendations

Recommendations	Evidence rating
 Consume whole grains with high fiber content to avoid glucose surges (refined carbohydrates are absorbed faster) e.g. unpolished rice, wheat, maize¹³ 	В
 Consume foods high in polyunsaturated fat e.g. salmon, herrings, tuna, mackerel, etc. and mono-unsaturated fat e.g. groundnuts, cashew nuts, olive oil, avocado, pear^{14,18,19} Avoid trans-fat e.g margarine Limit intake of saturated fats from both plant and animal sources e.g butter¹⁵ 	A
 Reduce total daily salt intake (dietary salt should not exceed 1 teaspoon full per day)¹⁶ 	А
 Daily intake of fruits and vegetables (consume ≥5 portions of fresh fruit and vegetables/day)¹⁷ 	В

iv. PHYSICAL ACTIVITY

Specific recommendations must be individualized based on the presence of co-morbidities (other relevant medical conditions). Supervised physical activity is more encouraged than unsupervised activity.

Table 6: Recommendations for physical activity		
Recommendations		
Type of activity	 Outdoor (e.g. walking, cycling) Indoor (strength training, swimming, aerobics, etc.) Use the staircase instead of lift where possible 	
Frequency	 Most days of the week for outdoor activities 2-3 times weekly for indoor activities 	
Duration	• At least 150 minutes a week but not less than 10 minutes a stretch; depends on level of intensity and tolerance	
Intensity	 High: 80% of maximum heart rate e.g. running, skipping Moderate: 60% of maximum heart rate e.g. brisk walking, household cleaning Low-intensity: 40% of maximum heart rate e.g. strolling on level ground 	

Та

v. SEDENTARY TIME

Prolonged sedentary time adversely affects cardiovascular risk^{20–22} (Evidence Rating A). Patients must therefore consciously track the amount of time they spend being sedentary.

Table 7: Sedentary time

Recommendations	Evidence rating
Patients are encouraged to break periods of prolonged sitting with brief periods of activity; 3-5 minutes for every hour of sitting	с

vl. USE OF SUBSTANCES

Table 8: Substance use and abuse

Recommendations	Evidence rating
Avoid or stop smoking; patients must be assisted to quit using tobacco and shisha	С
Reduce alcohol consumption (limit alcohol to ≤ 2 units per day men and ≤ 1 unit per day women)	В

A unit of alcohol is equivalent to:

- 1 standard glass of beer (375 ml)
- 1 small glass of wine (100 ml)
- I tot of spirit (30 ml)

2.2.4 RISK MANAGEMENT THROUGH PRIMARY AND SECONDARY PREVENTION

The goal of the preventive approach is to target the modifiable risk factors by implementing measures to control them to levels where they are less likely to pose a danger for the development of ASCVD. ASCVD risk assessment has become the norm in shared-decision making with patients²³. Non-modifiable risk factors should be documented and factored into clinical decisions. Risk estimation is useful in assessing a patient's risk of developing ASCVD. (Refer to *figure 2*)

Modifiable risk factor	Target
Hypertension	<140/90 mmHg
Diabetes	HbA1c <7% or FBS <6 mmol/l
LDL	Very high-risk: <1.8 mmol/l, or a reduction of at least 50% High-risk: <2.6 mmol/l, or a reduction of at least 50% Low to moderate risk: <3.0 mmol/l
HDL	>1.0 mmol/l in men and >1.2 mmol/l in women indicate lower risk
Triglycerides	<1.7 mmol/l indicates lower risk and higher levels indicate a need to look for other risk factors
Obesity	BMI 20–25 kg/m² Waist circumference <94 cm (men) or <80 cm (women)
Physical inactivity (PA)	At least 150 minutes a week of moderate aerobic physical activity and not less than 10 minutes a stretch
Diet	Low in saturated fat with a focus on wholegrain products, vegetables, fruit and fish
Smoking	No exposure to tobacco in any form

PRIMARY PREVENTION

MANAGEMENT OF ELEVATED LIPID LEVELS

High blood cholesterol levels increase the risk of clinical ASCVD²⁵. Among the lipoprotein carriers of serum cholesterol, low-density lipoprotein (LDL) is the primary atherogenic (bad) cholesterol. Thus, it is important to target low levels of LDL. It must be noted that there are other forms of cholesterol abnormalities, which can also lead to ASCVD such as low levels of high-density lipoprotein (HDL) and high levels of triglycerides (TG) or very low-density lipoprotein (VLDL). The use of lifestyle (non-pharmacological) and pharmacological interventions/treatment are recommended to reduce blood levels of cholesterol^{23, 26-28}.

Statins are the first line pharmacological agents used for reducing LDL cholesterol and are categorised by their potency (*table 10*) in reducing LDL levels usually in 8 to 12 weeks of taking the medications daily. Other medications such as Ezetimibe[•], Niacin[•] and Evolocumab[•] can be added to statins to enhance reduction of LDL to target levels.

Table 10: **Categories of statin based on potency** (*Adapted from Guideline on the Management of Blood Cholesterol*²⁹)

Intensity	LDL-C lowering effect (goal)	Statins (oral)
High intensity	≥50%	Atorvastatin 40–80mg Rosuvastatin 20-40mg
Moderate intensity	30%-49%	Atorvastatin 10-20mg Rosuvastatin 5-10mg Simvastatin 20–40mg
Low intensity	<30%	Simvastatin 10mg

Table 11: Risk category and pharmacological intervention

Adult patient risk category	Recommendation/goals
20 to 39 years old with family history of premature ASCVD	 Estimate lifetime risk and manage If LDL >4.1 mmol/l, consider statin therapy
40 to 75 years without diabetes with LDL between 1.8 and 4.9 mmol/l (3 categories)	
1. High risk	Start statin therapy with goal to reduce LDL by ${>}50\%$
2. Intermediate risk	Start statin with goal to reduce LDL by 30%-49%
3. Low risk	Educate patient and encourage lifestyle changes
Adults with LDL above 4.9 mmol/l	Irrespective of the risk score, start high intensity statin therapy
Diabetes mellitus and aged 40 to 75 years (2 categories)	
1. High risk	High intensity statin otherwise use moderate intensity statin
2. Intermediate risk	Start moderate intensity statins
Age >75 years	Individualized clinical assessment, risk discussion and encourage shared-decision making

In patients with established ASCVD, the recommendation is that the "lower the better" when it comes to cholesterol management. The goals of treatment are LDL-C below 1.8 mmol/l or >50% LDL-C reduction, when target level cannot be reached²³.

Control of high blood pressure is a very important measure of secondary prevention (see *chapter 5* on management of hypertension).

2.2.5 MANAGEMENT OF DYSLIPIDAEMIAS BY LEVEL OF CARE

i. HEALTH FACILITY WITHOUT A DOCTOR

MANAGEMENT (EVIDENCE LEVEL A)

Educate patients about:

- Risk factors for CVDs
- Lifestyle modification review lifestyle habits with regards to diet, physical activity, weight/BMI, tobacco use

Emphasise the importance of a healthy lifestyle:

- Diet modification: a low calorie, low saturated fat (animal fat), high polyunsaturated fat diet is recommended under the supervision of a dietician
- Weight reduction for overweight and obese patients
- Reduction of alcohol consumption in patients who drink excessively
- Regular physical activity or exercise tailored to the individual patient
- → Emphasise the importance of a normal blood pressure and regular blood pressure measurement (Refer to chapter 5 in case BP is too high).

ii. HEALTH FACILITY WITH A DOCTOR

iia. INVESTIGATION

- Fasting blood lipid profile
- Thyroid function test (if lipid levels very high)
- Plasma protein (if lipid levels very high, to exclude nephrotic syndrome)
- Urine protein (if lipid levels very high, to exclude nephrotic syndrome)
- Fasting glucose level
- Blood pressure measurement

iib. MANAGEMENT

NON-PHARMACOLOGIC MANAGEMENT (EVIDENCE LEVEL A)

Educate patients about:

- Risk factors for CVDs
- Lifestyle modification review lifestyle habits with regards to diet, physical activity, weight/BMI, tobacco use
- Potential ASCVD risk reduction from lipid-lowering therapy
- The potential adverse effects of lipid-lowering therapy

Emphasise the importance of a healthy lifestyle:

- Diet modification: a low calorie, low saturated fat (animal fat), high polyunsaturated fat diet is recommended under the supervision of a dietician
- Weight reduction in overweight and obese patients
- Reduction of alcohol consumption in patients who drink excessively
- Regular physical activity of exercise tailored to the individual patient

PHARMACOLOGIC MANAGEMENT

Low CVD risk

• Simvastatin, oral 10-20mg at night

Moderate CVD risk - diabetes and CVD risk equivalents

- Atorvastatin, oral 10-20mg daily or
- Rosuvastatin, oral 5-10mg daily or
- Simvastatin, oral 20-40mg at night

High CVD risk

- Atorvastatin, oral 40-80mg daily
- Rosuvastatin, oral 20-40mg daily
- → NOTE: In all cases, assess adherence and percentage LDL reduction and lifestyle changes with repeated lipid measurement 4 to 12 weeks after statin initiation or dose adjustment, repeated every 3 to 12 months as needed¹.

Referral criteria:

- → All patients who remain outside the target values beyond 6 months should be referred to a health facility with a specialist.
- \rightarrow For control of an elevated BP please refer to *chapter 5.1* of these guidelines.
- → For the management of diabetes please refer appropriate diabetes guidelines.

iii. HEALTH FACILITY WITH A PHYSICIAN SPECIALIST OR TERTIARY HOSPITAL

iiia. INVESTIGATION

- Fasting blood lipid profile
- Thyroid function test (if lipid levels very high)
- Plasma protein (if lipid levels very high, to exclude nephrotic syndrome)
- Urine protein (if lipid levels very high, to exclude nephrotic syndrome)
- Fasting blood sugar
- Blood pressure measurement

iiib. MANAGEMENT (EVIDENCE LEVEL A/B)

NON-PHARMACOLOGIC MANAGEMENT (EVIDENCE LEVEL A)

Educate patients about:

- Risk factors for CVDs
- Lifestyle modification: review lifestyle habits with regards to diet, physical activity, weight/BMI, tobacco use
- Potential ASCVD risk reduction from lipid-lowering therapy
- The potential adverse effects of lipid-lowering therapy

Emphasise the importance of a healthy lifestyle:

- Diet modification: a low calorie, low saturated fat (animal fat), high polyunsaturated fat diet is recommended under the supervision of a dietician
- Weight reduction in overweight and obese patients
- Reduction of alcohol consumption in patients who drink excessively
- Regular physical activity of exercise tailored to the individual patient

PHARMACOLOGIC MANAGEMENT

Low CVD risk

• Simvastatin, oral 10-20mg at night

Moderate CVD risk - diabetes and CVD risk equivalents

- Atorvastatin, oral 10-20mg daily or
- Rosuvastatin, oral 5-10mg daily or
- Simvastatin, oral 20-40mg at night

High CVD risk

- Atorvastatin, oral 40-80mg daily or
- Rosuvastatin, oral 20-40mg daily
- → NOTE: In all cases, assess adherence and percentage LDL reduction and lifestyle changes with repeated lipid measurement 4 to 12 weeks after statin initiation or dose adjustment, repeated every 3 to 12 months as needed¹.

In very high-risk ASCVD patients

- Add Ezetimibe⁺ to the patient's maximally tolerated statin therapy if the LDL-C level remains ≥ 1.8 mmol/l
- If the LDL-C level on maximally tolerated statin and Ezetimibe⁺ remains ≥ 1.8 mmol/l, a PCSK9 inhibitor can be added
- → NOTE: Very high-risk patients include patients with a history of multiple major ASCVD events or one major ASCVD event and multiple high-risk conditions.

In patients with severe hypercholesterolaemia (LDL-C level \geq 4.9 mmol/l) (Evidence level B)

- Add Ezetimibe if the LDL-C level remains \geq 2.6 mmol
- Add a PCSK9 inhibitor if the LDL-C level on statin and **Ezetimibe**[•] remains >(2.6mmol/l) and the patient has multiple factors that increase subsequent risk of ASCVD events
- \rightarrow For management of hypertension please refer to *chapter 5.1* of these guidelines.
- \rightarrow For the management of diabetes please refer to the appropriate guideline.

REFERENCES:

- 1 Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors assciated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438): 937–952.
- 2 McClelland RL, Jorgensen NW, Budoff M, Blaha MJ, Post WS, Kronmal RA, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Stu.) J Am Coll Cardiol. 2015; 66(15): 1643–1653.
- 3 Akhabue E, Thiboutot J, Cheng JW, Vittorio TJ, Christodoulidis G, Grady KM et al. New and emerging risk factors for coronary heart disease. Am J Med Sci 2014; 347(2): 151–158.
- 4 Collins DRJ, Tompson AC, Onakpoya IJ, Roberts N, Ward AM, Heneghan CJ. Global cardiovascular risk assessment in the primary prevention of cardiovascular disease in adults: systematic review of systematic reviews. BMJ Open [Internet]. 2017; 7(3): 1–13. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28341688.
- Mendis S, Lindholm LH, Mancia G, Whitworth J, Alderman M, Lim S, et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens [Internet]. 2007;25(8):1578–1582. Available from: https://journals.lww.com/jhypertension/Abstract/2007/08000/World_Health_Organization_WHO_and_International.9.aspx.
- 6 Ginty AT, Kraynak TE, Fisher JP, Gianaros PJ. Cardiovascular and autonomic reactivity to psychological stress: Neurophysiological substrates and links to cardiovascular disease. Aut Neurosci [Internet]. 2017 Nov; 207: 2–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28391987.
- Zagraauw HM, Kuiper J, Bot I. Acute and chronic psychological stress as risk factors for cardiovascular disease: Insights gained from epidemiological, clinical and experimental studies. Brain Behav Immun [Internet]. 2015 Nov; 50: 18–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26256574.
- 8 Wirtz PH, von Kanel R. Psychological stress, inflammation, and coronary heart disease. Curr Cardiol Rep [Internet]. 2017 20; 19–111. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28932967.
- 9 Klainin-Yobas P, Ng SH, Stephen PDM, Lau Y. Efficacy of psychosocial interventions on psychological outcomes among people with cardiovascular diseases: a systematic review and meta-analysis. Patient Educ Couns [Internet]. 2016; 99(4): 512–521. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27045976.
- 10 Tan MP, Morgan K. Psychological interventions in cardiovascular disease: an update. Curr Opin Psychiatry [Internet]. 2015; 28(5): 371–377. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26181666.
- 11 Laddu D, Hauser M. Addressing the nutritional phenotype through personalized nutrition for chronic disease prevention and management. Prog Cardiovasc Dis [Internet]. 2019; 62(1): 9–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30553801.
- 12 Thushara RM, Gangadaran S, Solati Z, Moghadasian MH. Cardiovascular benefits of probiotics: a review of experimental and clinical studies. Food Funct [Internet]. 2016; 7(2): 632–642. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26786971.
- 13 Meija L, Havensone G, Lejnieks A. Postprandial glycaemic and insulinaemic responses after consumption of activated wheat and triticale grain flakes. J Nutr Metab [Internet]. 2019; 2019: 6594896. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30755803.
- 14 Garshick M, Mochari-Greenberger H, Mosca L. Reduction in dietary trans fat intake is associated with decreased LDL particle number in a primary prevention population. Nutr Metab Cardiovasc Dis [Internet]. 2014; 24(1): 100–106. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24099723.
- 15 Scholl J., Traditional dietary recommendations for the prevention of cardiovascular disease: do they meet the needs of our patients? Cholesterol [Internet]. 2012; 2012: 367898. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22482040.
- 16 Malta D, Petersen KS, Johnson C, Trieu K, Rae S, Jefferson K, et al. High sodium intake increases blood pressure and risk of kidney disease. From the Science of Salt: A regularly updated systematic review of salt and health outcomes (August 2016 to March 2017). J Clin Hypertens [Internet]. 2018; 20(12): 1654–1665. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30402970.
- 17 Rees K, Takeda A, Martin N, Ellis L, Wijesekara D, Vepa A, et al. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev [Internet]. 2019 13; 3: CD009825. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30864165.

- 18 Hall WL. The future for long chain n-3 PUFA in the prevention of coronary heart disease: do we need to target non-fisheaters? Proc Nutr Soc [Internet]. 2017; 76(3): 408–418. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28508737.
- 19 Watanabe Y, Tatsuno I. Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future. Expert Rev Clin Pharmacol [Internet]. 2017; 10(8): 865–873. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28531360.
- 20 Barker AR, Gracia-Marco L, Ruiz JR, Castillo MJ, Aparicio-Ugarriza R, Gonzalez-Gross M, et al. Physical activity, sedentary time, TV viewing, physical fitness and cardiovascular disease risk in adolescents: The HELENA study. Int J Cardiol [Internet]. 2018 01; 254: 303–309. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29221862.
- 21 Dohrn IM, Sjostrom M, Kwak L, Oja P, Hagstromer M. Accelerometer-measured sedentary time and physical activity A 15 year follow-up of mortality in a Swedish population-based cohort. J Sci Med Sport [Internet]. 2018; 21(7): 702–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29128418.
- 22 Patterson R, McNamara E, Tainio M, de Sa TH, Smith AD, Sharp SJ, et al. Sedentary behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis. Eur J Epidemiol [Internet]. 2018; 33(9): 811–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29589226.
- 23 Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary. Circulation. 2019 Mar 17; 1–74.
- 24 Prevention and Control of Noncommunicable Diseases: Guidelines for primary health care in low-resource settings. World Health Organization; 2012.
- 25 World Health Organization. Cardiovascular disease. 2018. Available from: https://www.who.int/cardiovascular_diseases/en/.
- 26 Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2014 Nov 4; 64(18): 1749–1767.
- 27 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/ AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol. Executive Summary. Circulation. 2018 Nov 10; 1–120
- 28 Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016 14; 37(39): 2999–3058.
- 29 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/ AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 Nov 3; 735–1035
- **30** American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018 Jan 1; 41(Supplement 1): S13–27.
- 31 Alsheikh-Ali AA, Omar MI, Raal FJ, Rashed W, Hamoui O, Kane A, et al. Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study. PLoS ONE. 2014; 9(8): e102830.
- 32 Asamoah-Boaheng M, Sarfo-Kantanka O, Tuffour AB, Eghan B, Mbanya JC. Prevalence and risk factors for diabetes mellitus among adults in Ghana : a systematic review and meta-analysis. 2018; 1–10.
- International Diabetes Federation. IDF Diabetes Atlas 2017.
 Available from: https://www.diabetesatlas.org/.
- 34 Roglic G, World Health Organization, editors. Global report on diabetes. Geneva, Switzerland: World Health Organization; 2016. 86 p.

3 SYMPTOMS AND SIGNS OF CARDIOVASCULAR DISEASES

LIST OF ABBREVIATIONS AND ACRONYMS

AR	Aortic Regurgitation	PND	Paroxysmal Nocturnal
AV	Arterio-venous		Dyspnoea
COPD	Chronic Obstructive	PUD	Peptic Ulcer Disease
	Pulmonary Disease	RA	Right Atrium
DIC	Disseminated Intravascular	RVF	Right Ventricular Failure
	Coagulopathy	SAAG	Serum-Ascites Albumin
JVP	Jugular Venous Pressure		Gradient
MAO	Monoamine Oxidase	SLE	Systemic Lupus Erythematosus
PDA	Patent Ductus Arteriosus	ТВ	Tuberculosis

3.1 SYMPTOMS OF CVDs

3.1.1 DYSPNOEA

- Dyspnoea is a subjective experience of breathing discomfort; also referred to as breathlessness.
- Orthopnoea dyspnoea on lying flat.
- Paroxysmal nocturnal dyspnoea dyspnoea that usually occurs during sleep; wakes patient up and may be relieved by standing or sitting.
- Dyspnoea of sudden onset should be treated as a medical emergency.

CAUSES

Table 12: Causes of dyspnoea

Causes of dyspnoea		
Cardiovascular	Respiratory	Others
 Heart failure Constrictive pericarditis Arrhythmias Pericardial effusion Pulmonary emboli 	 Bronchial obstruction Bronchospasm/asthma Chronic obstructive pulmonary disease (COPD) Infection e.g. pneumonia, pulmonary tuberculosis Interstitial fibrosis Tumour infiltration into lungs Pleural effusion 	 Massive ascites Anaemia Hyperviscosity syndrome Muscular atrophy

Table 13: Differentiating features of cardiac vs. respiratory dyspnoea

Differentiating features of cardiac vs. respiratory dyspnoea		
Cardiac	Respiratory	
 Cough comes after the onset of dyspnoea 	 Cough prominent and precedes dyspnoea 	
 Orthopnoea 	 Sputum production 	
 Paroxysmal nocturnal dyspnoea (PND) common 	 Wheezing (more common) 	
 Oedema 	 No PND; patient may have midnight awakening with 	
 Raised jugular venous pressure (JVP) 	cough and sputum	
 Reduced urine output 	 No orthopnoea 	
 Improves with diuretics 	 Normal urine output 	
	 No change with diuretics 	

3.1.2 CHEST PAIN

Chest pain is discomfort or pain, pressure or tightness that is felt anywhere along the front of the body between the neck and upper abdomen.

Pain in the chest is a symptom that should not be ignored and can result from any of the following causes (see *table 14*). *Table 15* shows the clinical classification of angina.

CAUSES

Table 14: Causes of chest pain

Causes	
Cardiac	Non-cardiac
 Myocardial infarction (heart attack) Unstable angina Stable angina (chest pain on exertion) Prinzmetal angina (variant angina) Pericarditis Aortic valve stenosis Mitral valve prolapse Pericardial effusion Congenital cardiac anomalies 	 Pulmonary origin (pneumonia, pulmonary embolism, pleuritis, pneumothorax, asthma, COPD, acute bronchitis, lung abscess) Musculoskeletal (costochondritis, trauma, muscle pain, referred pain from spine, cancer induced pain) Mediastinal (aortic dissection, mediastinitis) Gastrointestinal (oesophagitis, gastritis, peptic ulcer disease (PUD), oesophageal spasm, cholecystitis, pancreatitis) Others (herpes zoster, post herpetic neuralgia) Psychogenic (panic attacks, psychiatric disorders, anxious state)

Table 15: Clinical classification of angina

Clinical classification of angina		
Typical angina (definite)	 Meets all three of the following characteristics Substernal chest discomfort of characteristic quality and duration Provoked by exertion or emotional stress Relieved by rest and/or nitrates within minutes 	
Atypical angina (probable)	Meets any two of the above characteristics	
Non-anginal chest pain	Meets one or none of the above characteristics	

3.1.3 OEDEMA

This is due to an increase in interstitial fluid volume.

It typically begins in dependent body parts (legs, sacrum). Anasarca is defined as gross, generalised swelling.

CAUSES

Table 16: Causes of body swelling

Causes of body swelling		
Cardiac	Heart failureConstrictive pericarditis	
Venous	Venous insufficiencyDeep vein thrombosis	
Renal	Nephrotic syndromeRenal failure	
Pulmonary	 Pulmonary hypertension 	
Liver	Liver cirrhosisLiver failure	
Medication	Calcium channel blockers, e.g. nifedipine	 Non steroidal anti inflammatory drugs (NSAIDs)
Others	 Hypoproteinemic states Lymphoedema Pregnancy Malnutrition 	

3.1.4 HAEMOPTYSIS

- Haemoptysis, or the coughing up of blood, can range from blood-streaking of sputum, to the presence of frank blood.
- Haemoptysis has a variety of causes, but the cause can be determined in most patients. It is important to identify the cause and location of the bleeding in order to guide treatment.

CAUSES

The usual causes of haemoptysis to look out for are listed in table 17:

Table 17: Causes of haemoptysis

Causes of haemoptysis		
Cardiovascular Left ventricular failure Mitral stenosis AV malformation	 Pulmonary Pulmonary embolism/infarction Bronchiectasis Cystic fibrosis Bullous emphysema 	 Hematologic Disseminate intravascular coagulopathy (DIC) Bleeding disorder Thrombocytopenia
Infections Pulmonary TB Lung abscess Pneumonia 	Systemic diseases Vasculitis Goodpasture syndrome Systemic Lupus Erythematodus (SLE)	Neoplastic Lung cancer Metastatic cancer
Drugs/toxins Anticoagulants Aspirin Thrombolytics	Traumatic Chest injuries	latrogenicBronchoscopyTranstracheal aspiration

3.1.5 SYNCOPE

It is a temporary loss of consciousness usually related to insufficient blood flow to the brain or cerebral hypoperfusion characterised by rapid onset, short duration, and spontaneous complete recovery.

It does not only carry the potential of harm to the patient but frequently carries a poorer prognosis when it is due to an underlying heart disease.

This presentation should be distinguished from causes of transient loss of consciousness that are not due to global hypoperfusion such as seizure or hypoglycaemia and from presentations that may resemble transient loss of consciousness such as falls.

Syncope should be differentiated from dizziness, presyncope, near-fainting and vertigo.

i. CAUSES

Table 18: Causes of syncope

Non-cardiac	Cardiac
Reflex/neurogenic:	 Arrhythmias:
Vasovagal 20-33% of all cases of syncope	tachyarrhythmias and bradyarrhythmias
 Carotid sinus hypersensitivity 	 Myocardial infarction or heart attack
 Situational (e.g. micturition, defecation, cough, 	Structural:
swallowing)	aortic stenosis, hypertrophic obstructive cardiomyopathy
 Orthostatic hypotension (volume depletion, medicine, 	 Pulmonary embolism
autonomic dysfunction)	 Aortic dissection
 Vertebrobasilar disease 	Cardiac tamponade
	 Atrial myxoma

ii. FEATURES DISTINGUISHING SYNCOPE FROM SEIZURES²

Table 19: Symptoms of syncope and seizure

Favours syncope	Favors seizure
 Presyncope or preceded by dizziness 	 Waking with tongue bite
 Loss of consciousness after prolonged standing or sitting 	 Postictal confusion or sleep
 Sweating before the fall 	 Prodromal déjà vu or jamais vu
 Short duration with spontaneous recovery 	

3.1.6 PALPITATIONS

Palpitations are defined as an unpleasant awareness of the forceful, rapid, or irregular beating of the heart. Below are some causes of palpitations (*table 20*).

Table 20: Causes of palpitation

Cardiac	Non-cardiac
 Atrial fibrillation/flutter 	 Anaemia
 Atrial myxoma 	 Alcohol
 Atrial premature contractions 	 Anxiety/stress
 Atrioventricular re-entry 	Coffeine
 Cardiomyopathy 	Cocaine
 Multifocal atrial tachycardia 	Exercise
 Sick sinus syndrome 	Fever
 Supraventricular tachycardia 	 Hypoglycemia
 Valvular heart disease 	Nicotine
 Ventricular premature contractions 	Phaeochromocytoma
 Ventricular tachycardia 	Pregnancy
	 Hyperthyroidism
	 Withdrawal of medications, e.g. Beta-blockers

3.2 SIGNS OF CVDs

3.2.1 GENERAL APPEARANCE

Although cardiac patients may appear healthy and comfortable at rest, patients with underlying CVD may have any or some of the following:

Table 21: General signs of CVD

Signs	Some associated conditions
Anxiety and restlessness	MI, hyperthyroidism
Diaphoresis/sweating	Tachyarrhythmias, MI, hyperthyroidism, cardiac tamponade
Cold clammy extremities and pallor	Low cardiac output states e.g. heart failure (HF), anaemia, shock
Cardiac cachexia	Severe chronic heart failure and other long-standing low cardiac output states.

3.2.2 DYSPNOEA AT REST (TACHYPNOEA)

This is increased respiratory rate or laboured breathing. It may be due to a heart disease or a respiratory disease (refer to *table 12*).

The patient may be dyspnoeic on lying flat, and comfortable when he/she sits up.

3.2.3 OEDEMA

• May be present and pitting in nature and extent quantified

• Severe right heart failure may also be present with ascites and scrotal/vulvar oedema Anasarca is defined as gross, generalized oedema.

3.2.4 ABNORMAL PULSE

Abnormal pulse may be a sign of cardiac disease.

- It may be rapid (>120bpm) or slow (<40bpm)</p>
- It may be weak or thread
- It may be irregular
- It may be strong and bounding

Jugular venous pulse provides insight into the right heart pressure and function.

Pulse	Associated condition
Diminished peripheral pulse	Peripheral vascular disease
Asymmetric pulse	Coarctation of aorta/aortic dissection Subclavian steel syndrome
Delayed upstroke in the carotid pulse (anacrotic pulse)	Aortic stenosis
Biphasic pulse/pulsus bisferiens	Aortic stenosis and aortic regurgitation, as well as hypertrophic cardio- myopathy causing subaortic stenosis
Pulsus paradoxus	Asthma, chronic obstructive pulmonary disease (COPD), pericardial tamponade
Pulsus alternans	Left ventricular failure
Collapsing pulse (water-hammer pulse/Corrigan's pulse)	Aortic regurgitation (AR), hyperdynamic circulation, patent ductus arte- riosus (PDA), peripheral artero-venous fistula, arteriosclerotic aorta
Raised jugular venous pressure	Tricuspidal stenosis/regurgitation, hyperdynamic circulation, pericardial effusion, constrictive pericarditis, fluid overload, superior vena cava obstruction




Figure 3: Measurement of jugular venous pressure (Adapted from: Maxine A. Papadakis, Stephen J. McPhee, Michael W. Rabow; Current Medical Diagnosis & Treatment 2019)

3.2.5 ABNORMAL BLOOD PRESSURE

Abnormal blood pressure may be low or high.

 \rightarrow For blood pressure classification refer to *chapter 5.1* on hypertension.

3.2.6 CYANOSIS

- Cyanosis is defined as the bluish discoloration of the skin and mucous membranes due to hypoxia. It may be central or peripheral
- Central due to arterial desaturation or hypoxia from pulmonary disease, left heart failure, or rightto-left intracardiac or intrapulmonary shunting; the latter will not be improved by increasing the inspired oxygen concentration
- Peripheral cyanosis reflects impaired tissue delivery of adequately oxygenated blood e.g. in low-output states, polycythaemia or peripheral vasoconstriction

3.2.7 CLUBBING

- Occurs in chronic cyanotic states; it may be due to congenital heart diseases; other causes include non-cardiac conditions such as respiratory diseases and gastrointestinal diseases
- Differential clubbing of the toes but not the fingers suggest pulmonary hypertension related to a patent ductus arteriosus and a right to left shunt through the ductus

3.2.8 APEX BEAT

It is the most inferior, most lateral point on the precordium (anterior area of the chest covering the heart) at which the cardiac impulse can be felt. A displaced apex beat usually implies enlargement of the heart, called cardiomegaly.

3.2.9 PARASTERNAL HEAVES (LIFT) AND THRILLS

A parasternal heave (or lift) is a precordial impulse that may be felt (palpated) in patients with cardiac or respiratory disease. It usually suggests the presence of dilatation, as in right ventricular dilatation of severe pulmonary hypertension. A thrill is a vibratory sensation on the hand, frequently in the auscultatory areas of the valves. A thrill therefore is a palpable murmur.

3.2.10 HEART SOUNDS

Table 23: Heart sounds

Normal heart sounds	S1	S2	
Event	Closure of atrioventricular valves	Closure of semilunar valves	
Pitch	lower	higher	
Duration	longer	shorter	
Point of maximum intensity	Apex/mitral area	Base of heart	
Pathological heart sounds	S3	S4	
Event	Caused by turbulent flow into ventricles (rapid ventricular filling)	Atrial contraction against a stiff (non-compliant) ventricle	
Pitch	Low	Low	
Significance	Ventricular dilation May be heard in children and young adults (<40 years), but usually pathological in old age which may signify heart failure	Atrial dilatation in conditions like hyper- tensive heart disease and aortic stenosis	

3.2.11 CARDIAC MURMURS

Cardiac or valvular dysfunction may lead to turbulent or abnormal flow called murmurs which are heard using the stethoscope. *Table 24* shows some cardiac diseases that give rise to murmurs and where they can best be heard.

Table 24: Cardiac murmurs

Valve	Side best auscultated	Location		
Mitral	Left	5th intercostal space, midclavicular line		
Aortic	Right	2nd intercostal, right sternal border		
Tricuspid	Left	4th intercostal space, left sternal border		
Pulmonary	Left	2nd intercostal space, left sternal border		
Cardiac lesion	Murmur	Location		
Mitral incompetence	Pansystolic murmur	Apex radiating to the axilla		
Mitral stenosis	Mid-late diastolic rumbling murmur	Apex		
Aortic incompetence	Early diastolic murmur	Left sternal edge		
Aortic stenosis	Ejection systolic	Aortic area radiating to the neck/carotid artery		
Tricuspid incompetence	Pansystolic murmur	Left sternal edge		
Tricuspid stenosis	Mid-late diastolic murmur	Left sternal edge		
Pulmonary incompetence	Early diastolic murmur	Left sternal edge		
Pulmonary stenosis	Ejection systolic murmur	Left sternal edge		

3.2.12 HEPATOMEGALY AND ASCITES

These signs could point to an underlying cardiac disease such as:

- Congestive heart failure
- Right-sided heart failure
- Constrictive pericarditis
- Endomyocardial fibrosis

REFERENCES

- 1 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013 Oct 7; 34 (38): 2949–3003.
- 2 Brignole M, Moya A, de Lange FJ, Deharo J-C, Elliott PM, Fanciulli A, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018 Jun 1; 39 (21): 1883–948.

4 CARDIAC ARREST

LIST OF ABBREVIATIONS AND ACRONYMS

ACS	Acute coronary syndrome	ICD	Implantable cardioverter
ACLS	Advanced Cardiac Life		defibrillator
	Support	MI	Myocardial infarction
BLS	Basic Life Support	SCD	Sudden cardiac death
CAD	Coronary artery disease	VT	Ventricular tachycardia
CPR	Cardiopulmonary	VF	Ventricular fibrillation
	resuscitation		

4.1 INTRODUCTION

Sudden cardiac death (SCD) from cardiac arrest is the largest cause of natural death worldwide and is responsible for half of all heart disease deaths. Although resuscitation rates are improving throughout the world, the majority of individuals who suffer a sudden cardiac arrest will not survive¹. Such rapid deaths are often due to lethal ventricular arrhythmias in the setting of underlying coronary artery disease². In Africa, the hypertensive heart disease, cardiomyopathies and rheumatic heart disease account for most cardiac arrest³.

i. **DEFINITION**

Cardiac arrest is the abrupt loss of heart function from the failure of the heart to pump effectively. Sudden cardiac arrest occurs when the heart develops an abnormal rhythm and can't pump blood. Cardiac arrest is often fatal if appropriate steps are not taken immediately⁴.

ii. EPIDEMIOLOGY

Cardiac arrest is a major international public health problem accounting for an estimated 15-20% of all deaths.¹ Cardiac arrest resulting in sudden death is most common in adults with acquired structural heart disease, but it also rarely occurs in younger individuals with inherited disorders. Coronary artery disease is known to be the most common underlying pathology.

iii. CLASSIFICATIONS

Cardiac arrest is often classified into "shockable" versus "non-shockable", as determined by the ECG rhythm to refer to whether the cardiac dysrhythmia is treatable using defibrillation. The two "shockable" rhythms are ventricular fibrillation and pulseless ventricular tachycardia while asystole and pulseless electrical activity are "non-shockable".

iv. AETIOLOGY

Coronary artery disease (CAD) is responsible for more than half of all SCDs resulting from cardiac arrest. Other structural heart disease (not related to CAD) account for 10% of all SCDs. Congestive heart failure, from whatever cause, increases the risk of SCD fivefold. Inherited arrhythmia syndromes in the setting of a structurally normal heart accounts for 5 to 10% of sudden cardiac arrests. These are usually caused by genetic mutations of ion channels (channelopathies) that lead to a predisposition to fatal arrhythmias. Examples of these inherited arrhythmia syndromes include Long QT syndrome, Brugada syndrome, Catecholaminergic polymorphic ventricular tachycardia, and Short QT syndrome.

In Africa, hypertensive heart disease, cardiomyopathies (peripartum cardiomyopathy, idiopathic dilated cardiomyopathy and endomyocardial fibrosis), pericardial disease and rheumatic valvular heart disease account for most cases of cardiac arrest³. The most common reversible causes of cardiac arrest are summarized below (5Ts and 5Hs): 5Hs: 5Ts:

- Hypovolaemia
- Hypoxia
- Hydrogen ions (acidosis)
- Hypo-/Hyperkalaemia
- Hypo-/Hyperglycaemia
- Tension pneumothoraxTamponade (cardiac)
- Toxins (including drugs)
- Thrombosis (pulmonary embolism)
- Thrombosis (ACS or MI)

Sudden cardiac death

- Most common cause of death
- \sim 50% of all cardiovascular death
- \blacksquare In \sim 25% the first symptom of CV diseases




Figure 4: Causes of cardiac arrest and sudden cardiac death

v. PHASES OF CARDIAC ARREST

Cardiac arrest needs prompt intervention to prevent death because the window of opportunity for survival is very short. *Figure 5* shows the phases of cardiac arrest which is commonly caused by VF. Best chance of survival occurs at the electrical phase.




Figure 5: The three phases of cardiac arrest by Westfeldt and Becker (Adapted from JAMA 2002)

4.2 CLINICAL PRESENTATION OF CARDIAC ARREST

Cardiac arrest is not preceded by any warning symptoms in approximately half of victims. For those who do experience symptoms, they may include a new or worsening chest pain, fatigue, blackouts, dizziness, shortness of breath, weakness or vomiting.

Cardiac arrest will be accompanied by a lack of palpable pulses in the victim. As a result of loss of cerebral perfusion, the victim will rapidly lose consciousness and breathing will stop.

4.3 MANAGEMENT OF CARDIAC ARREST ACCORDING TO LEVEL OF CARE

Sudden cardiac arrest is an emergency. Cardiopulmonary resuscitation (CPR) beginning with chest compressions should commence immediately after securing scene safety and calling for help. Defibrillation should be attempted as soon as it is available, and the rhythm is "shockable" (see AHA adult cardiac arrest algorithm: *figure 6 and 7*).

i. HEALTH FACILITY WITHOUT A DOCTOR

\rightarrow Refer to BLS healthcare provider adult cardiac arrest algorithm.

LABORATORY INVESTIGATIONS

- Random blood sugar
- Full blood count
- → NB: Laboratory investigations should not delay patient referral after Return of Spontaneous Circulation (ROSC).

PHARMACOLOGICAL TREATMENT

→ Refer patient to a facility with a doctor as soon as patient develops a pulse (ROSC). Give oxygen if hypoxaemic (SPO2 < 90%)

ii. HEALTH FACILITY WITH A DOCTOR

 \rightarrow Refer to adult cardiac arrest algorithms (BLS and ACLS see figure 6 and 7).

LABORATORY AND OTHER INVESTIGATIONS

- Full blood count
- Random blood sugar
- Blood urea and electrolytes
- Arterial blood gases (ABGs)
- Thyroid function
- Liver function
- Lipid profile
- Electrocardiogram
- Chest X-ray

PHARMACOLOGICAL TREATMENT

Identify reversible causes (H's and T's as above) and treat accordingly after Return of Spontaneous Circulation (ROSC).

 \rightarrow Refer to facility with a physician specialist after ROSC.

iii. HEALTH FACILITY WITH PHYSICIAN SPECIALIST


 \rightarrow Refer to adult cardiac arrest algorithms (BLS and ACLS see figure 6 and 7).

LABORATORY AND OTHER INVESTIGATIONS

- Full blood count
- Random blood sugar
- Blood urea and electrolytes
- Arterial blood gases (ABGs)
- Thyroid function
- Liver function
- Lipid profile
- Cardiac enzymes
- Electrocardiogram
- Chest X-ray
- Echocardiogram

PHARMACOLOGICAL TREATMENT AND DEVICE THERAPY

- Identify and treat reversible causes (H's and T's)
- Consider targeted temperature management
- Treat underlying structural and coronary heart disease
- Consider secondary prevention strategies in consultation with cardiologist (e.g. Beta-blockers and Implantable cardioverter defibrillator (ICDs))





Basic Life Support (BLS) Algorithm (Adapted from American Heart Association 2, 2015)




Figure 7: Advance Cardiac Life Support (ACLS) Algorithm (Adapted from American Heart Association 2, 2015)

 \rightarrow Further explanations for *figure 7* can be found in the table on the *next page*.

CPR quality

- Push hard (at least 2 inches (5 cm) and fast (100-120/min) and allow complete chest recoil
- Minimize interruptions in compressions
- Avoid excessive ventilation.
- Change compressor every 2 minutes, or sooner if fatigued
- If no advanced airway, 30:2 compression-ventilation ratio
- Quantitative waveform capnography
- If PETCO2 <10 mmHg, attempt to improve CPR quality</p>
- Intra-arterial pressure
- If relaxation phase (diastolic) pressure <20 mmHg, attempt to improve CPR quality</p>

Shock energy of defibrillation

- Biphasic: Manufacturer recommendation (eg, initial dose of 120-200 J); if unknown, use maximum available
- Second and subsequent doses should be equivalent, higher doses may be considered
- Monophasic: 360 J

Drug therapy

- Epinephrine iv/io dose: 1mg every 3-5 minutes
- Amiodarone iv/io: first dose: 300mg bolus; second dose: 150mg

Advanced airway

- Endotracheal intubation or supraglottic advanced airway
- Waveform capnography or capnometry to confirm and monitor ET tube placement
- Once advanced airway in place, give 1 breath every 6 seconds (10 breaths/min) with continuous chest compressions

Return of spontaneous circulation (ROSC)

- Pulse and blood pressure
- Abrupt sustained increase in PETCO2 (typically ≥ 40 mmHg)
- Spontaneous arterial pressure waves with intra-arterial

monitoring

Reversible Causes

- Hypovolemia
- Hypoxia
- Hydrogen ion (acidosis)
- Hypo-/hyperkalemia
- Hypothermia

- Tension pneumothorax
- Tamponade, cardiac
- Toxins
- Thrombosis, pulmonary
- Thrombosis, coronary

REFERENCES

- Hayashi M, Shimizu W, Albert CM. The Spectrum of Epidemiology Underlying Sudden Cardiac Death. Circ Res. 2015 Jun; 116(12): 1887–906.
- 2 Lopshire JC, Zipes DP. Sudden cardiac death: better understanding of risks, mechanisms, and treatment. Circulation. 2006 Sep; 114(11): 1134–6.
- 3 Chin A. Sudden cardiac death in Africa. Cardiovasc J Afr [Internet]. 2014 [cited 2019 Nov 8]; 25(4): 151–2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25192296
- 4 Kleinman ME, Brennan EE, Goldberger ZD, Swor RA, Terry M, Bobrow BJ, et al. Part 5: Adult basic life support and cardiopulmonary resuscitation quality: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015.

5 **DISEASES**

5.1 HYPERTENSION

LIST OF ABBREVIATIONS AND ACRONYMS

ABPM	Ambulatory Blood Pressure	FBS	Fasting Blood Sugar
	Monitoring	HF	Heart Failure
ACEI	Angiotensin Converting Enzyme	HPT	Hypertension
	Inhibitor	LVH	Left Ventricular Hypertrophy
ACS	Acute Coronary Syndrome	MI	Myocardial Infarction
ARB	Angiotensin Receptor Blocker	NSAIDS	Nonsteroidal Anti-Inflammatory
BB	Beta-Blocker		Drug
BP	Blood Pressure	OPD	Outpatients' Department
CCB	Calcium Channel Blocker	PRN	As Needed/Required
CKD	Chronic Kidney Disease	SBP	Systolic Blood Pressure
CVD	Cardiovascular Disease	TSH	Thyroid Stimulating Hormone
DBP	Diastolic Blood Pressure		

5.1.1 INTRODUCTION

i. **DEFINITION**

"Hypertension is defined as systolic blood pressure (SBP) values \geq 140 mmHg and/or diastolic blood pressure (DBP) values \geq 90 mmHg"¹. This definition applies to those, who are 18 years and above. For children and teenagers, BP centiles are preferred in diagnosing hypertension^{1,2}.

- White coat office (clinic or OPD) hypertension is a form of hypertension in untreated patients where the BP is persistently elevated when measured in the clinic but normal when measured outside the clinic using ambulatory blood pressure monitoring (ABPM) and/or home blood pressure monitoring (HBPM)^{1,2}.
- Masked ambulatory hypertension is a form of hypertension in untreated patients where the BP is normal in the office/clinic but elevated when measured outside the office using ABPM and/or HBPM^{1,2}.

ii. EPIDEMIOLOGY

In Ghana, the number of new cases of hypertension reporting to clinics increased by more than tenfold between 1988 and 2007. Not many hypertensive patients are aware of their status especially in Africa. In 2006, 33-34% of people in a rural-urban setting in Ghana were aware of their hypertension status. Out of these, only 16.7-28% were on treatment and only 6.2% attained target (BP is controlled)^{5,6}.

iii. CLASSIFICATION

Table 25: Classification of hypertension¹

(Adapted from the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension)

Category	Systolic (mmHg)	and/or	Diastolic (mmHg)
Optimal	<120	and	<80
Normal	120-129	and/or	80-84
High normal	130-139	and/or	85-89
Grade 1 hypertension	140-159	and/or	90-99
Grade 2 hypertension	160-179	and/or	100-109
Grade 3 hypertension	≥180	and/or	100-109
Isolated systolic hypertension	≥140	and	<90

5.1.2 AETIOLOGY

The causes of hypertension are classified into two main groups: primary and secondary hypertension.

i. PRIMARY OR ESSENTIAL HYPERTENSION

The cause of this form of hypertension is unknown. It is however the most common form of hypertension and contributes to about 95% of cases in adults.

RISK FACTORS FOR ESSENTIAL HYPERTENSION

Table 26: Risk factors of primary or essential hypertension

Non-modifiable risk factors	Modifiable risk factors	
1. Age (above 45 in men and 55 years in women)	1. Overweight/central obesity	5. Low potassium consumption
2. Race (more in black population)	2. Sedentary lifestyle	6. Low vitamin D
3. Family history	3. Smoking	7. Stress
	4. High salt intake	8. Alcohol abuse

ii. SECONDARY HYPERTENSION

This form is due to an underlying cause that can be diagnosed and treated. It contributes to about 5% of people with hypertension. Common causes are listed in the *table 27 below*.

Aetiology	Clinical features
Endocrine	
Cushing's syndrome	Obesity, increased abdominal girth, purple striae, moon face
Acromegaly	Coarse facial appearance, headache, visual impairment, large hands and feet
Thyroid disease	Hypothyroidism: weight loss despite increased appetite, excessive sweating, heat intolerance Hypothyroidism: weight gain, cold intolerance, constipation, lethargy, fatigue, hair loss
Hyperparathyroid disease	Bone and joint pains, abdominal pain, fatigue, nausea, vomiting, polyuria, kidney stones
Conn's syndrome	Muscle weakness or spasms, hypokalaemia, metabolic alkalosis
Adrenal hyperplasia	Muscle weakness or spasms, hypokalaemia, metabolic alkalosis
Phaeochromocytoma	Sweating, tremors, palpitations, headaches
Renal	
Renal parenchymal disease:Chronic glomerulonephritisAdult polycystic diseaseChronic tubulointerstitial nephritis	Periorbital oedema, nocturia, generalized body swelling, anaemia
Cardiovascular	
Aortic coarctation	Radio-femoral delay, bruit
Medication	
Oral contraceptives, steroids, vaso- pressin, non steroidal anti-inflamma- tory drugs (NSAIDs), psychoactive/ recreational drugs (amphetamines, cocaine)	Look out for these medicines in patient's history
Others	
Obstructive sleep apnoea	Apnoeic during sleep, daytime sleepiness, snoring

5.1.3 CLINICAL PRESENTATION

i. SYMPTOMS^{7,18}

Hypertension is the leading cause of death in Sub-Saharan Africa yet hypertension is generally asymptomatic. Onset of symptoms generally heralds onset of complications such as eye, heart and kidney disease.

Occasionally hypertensives may have the following symptoms:

- Palpitation
- Easy fatigability
- Headache
- Transient loss of consciousness
- Breathlessness
- Visual disturbance
- Chest pain
- Seizure

ii. SIGNS^{1,9}

The signs seen are usually due to the underlying pathology or complication of the hypertension.

- Displaced apex due to enlarged heart
- Renal bruit (renovascular hypertension)
- Radio-femoral delay (coarctation of aorta)
- S3 heart sound (heart failure)
- S4 heart sound (hypertensive heart disease)
- Flame-shaped haemorrhages, cotton wool spots and papilloedema in the eye
- \rightarrow Refer to *chapter 3* on symptoms and signs for further information.

ADDITIONAL INDICES AND SIGNS TO LOOK OUT FOR ON PHYSICAL EXAMINATION^{1,9}

- Body Mass Index (BMI)
 Ideal BMI <25 kg/m², overweight 25–30 kg/m², obese >30 kg/m²
- Waist circumference (WC)

Ideal WC <94 cm in men and <80 cm in women; in the obese, WC in men >102 cm; women >88 cm

- Peripheral pulses:
 - Absent (peripheral artery disease)
 - Weak (peripheral artery disease, cardiac disease)
 - Irregular (cardiac arrhythmias)
- Unilateral weakness (hemiparesis or hemiplegia)

5.1.4 COMPLICATIONS OF HYPERTENSION

Hypertension is associated with multiple organ damage involving the heart, brain, kidneys, eyes and blood vessels¹⁰. Early detection and management of end-organ-damage will improve the outcome of management of hypertension. Hypertension combined with unhealthy diet (high salt intake and alcohol abuse), obesity, smo-king, dyslipidaemia, reduced physical activity and diabetes, is associated with increased mortality⁴.

The complications of hypertension:

- Stroke
- Subarachnoid haemorrhage
- Hypertensive encephalopathy
- Atherosclerosis
- Aortic dissection
- Arrhythmias
- Chronic kidney disease

- Retinopathy
- Heart attack or myocardial infarction
- Left ventricular hypertrophy
- Heart failure (systolic and diastolic)
- Pre-eclampsia/eclampsia

5.1.5 MANAGEMENT OF HYPERTENSION RELEVANT FOR ALL LEVELS OF CARE

The overall goal of managing hypertension is to adequately control the BP and maintain it at target levels as well as control risk factors and promote a healthy life style in order to reduce associated morbidity and mortality.

The recommended BP levels are^{1,8}:

- BP <140/90 mmHg in all patients
- Provided treatment is well tolerated, BP target can be lowered to 130/80 mmHg or less in most patients
- Patients <65 years: the recommended target SBP ranges between 120-129 mmHg
- Patients ≥65 years: the recommended target SBP ranges between 130-139 mmHg
- Patients ≥80 years: the recommended SBP target ranges between 130–139 mmHg if tolerated
- The recommended DBP target is <90 mmHg irrespective of age and level of risk or comorbidities
- → NB: Tight blood pressure control or low targets in the elderly put them at risk of syncope and kidney disease.

i. INVESTIGATION

BLOOD PRESSURE (BP) MEASUREMENT

ia. BP MEASUREMENT IN THE HEALTH FACILITY

Proper measurement of BP is very vital to accurately diagnose hypertension. The current standard of care for blood pressure measurement is the automated sphygmomanometer for use both in hospitals and at home. Other available BP measuring tools that can be used are the anaeroid and the mercury sphygmomanometers. The use of the mercury sphygmomanometer is currently discouraged because of the mercury content. Below is the recommended way of taking BP measurements at the health facility.

Recommended method for BP measurement in the health facility setting^{1,2}:

- Patient should sit comfortably for 3–5 minutes before BP measurement.
- The systolic blood pressure should be initially measured by palpating the radial pulse.
- Take three BP measurements 1–2 minutes apart. Additional measurements should be performed if the first two readings differ by >10 mmHg. The patient's BP is the average of the last two BP readings.
- At patient's first visit, measure the BP in both arms, and if >10mmHg difference, the arm with the higher reading is used for future BP measurement.
- The patient should be comfortably seated, the arm should be exposed and supported at the level of the heart.
- Ensure that the patient has not smoked or ingested caffeine-containing foods or drinks in the previous 30 minutes before the BP measurement (Advise patient to avoid these substances on subsequent visits).
- The appropriate cuff size should be selected for the patient. A large cuff (15 cm) is preferred for patients with a mid-upper arm circumference (MUAC) >33 cm. Those with MUAC <33 cm require the standard cuff (12 cm). The bladder within the cuff should encircle 80% of the arm during the BP measurement.
- In patients with suspected orthostatic hypotension (low BP on standing) such as the elderly and diabetics, measure BP after 1 and 3 minutes of standing at their first consultation.
- Use Korotkoff I and V (disappearance) to identify SBP and DBP respectively during auscultatory BP measurement.
- In patients with atrial fibrillation (irregular pulse) and other arrhythmias, take repeated BP measurements to improve accuracy.

(Adapted From The Kenyan National Guidelines for Cardiovascular Diseases Management, 2018 & the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension)

ib. OUT-OF-OFFICE/CLINIC BP MEASUREMENT

BP measurement outside the health facility can be done in two ways: ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM). These two remove the effect of white coat hypertension and also give BP measurements that are more reflective of the patient's BP.

 \rightarrow Refer to the *introduction section under hypertension* for definition of white coat hypertension.

AMBULATORY BP MONITORING (ABPM)

ABPM involves the use of a device that records and provides the average BP measurements over a given period, usually 24 hours. The device is usually set to take the BP measurements every 15-30 minutes and provides the average BP readings for daytime, night time and at the end of the 24 hours¹. Compared to the office BP measurement, the ABPM is a better predictor of cardiovascular events like myocardial infarction (MI) and stroke².

HOME BP MONITORING (HBPM)

HBPM is self-blood pressure monitoring that involves the use of validated, semi-automated BP monitors to record BP for at least 3 days before each clinic visit. At each BP measurement, the patient should be well relaxed, (at least 3-5 minutes rest), comfortable and should take two measurements 1-2 minutes apart. The average of all the BP readings will be used in assessing the patient's BP¹. HBPM is also a better predictor of CVDs than office BP measurement².

Category	Systolic (mmHg)	and/or	Diastolic (mmHg)
Office BP	≥140	and/or	≥90
Ambulatory BP			
Daytime (or awake) mean	≥135	and/or	≥85
Night-time (or asleep) mean	≥120	and/or	≥70
24-hour mean	≥130	and/or	≥80
Home BP mean	≥135	and/or	≥85

Table 28: Hypertension cutoff values for office and out-of-office BP measurements¹ (Adapted from The 2018 ESC/ESH Guidelines For The Management Of Arterial Hypertension)

ii. NON-PHARMACOLOGICAL TREATMENT FOR ALL LEVELS OF CARE

Table 29: Non-pharmacological treatment for all levels^{1,2}

(Adapted from The Kenyan National Guidelines For Cardiovascular Diseases Management, 2018 & The 2018 ESC/ESH Guidelines For The Management Of Arterial Hypertension)

Lifestyle modification	Level of evidence
Reduce salt intake/avoid adding salt to food at table (dietary salt should be restricted to <5 g per day)	А
Regular intake of fruits, vegetables, fish, and unsaturated fatty acids (e.g. olive oil); consume low-fat dairy products and reduce intake of red meat	А
Weight reduction among hypertensive patients who are either obese or overweight, aim at BMI range of 20-25 kg/m ² and waist circumference of <94 cm in men and <80 cm in women	А
Regular exercise (30 minutes of moderate-intensity aerobic exercise such as walking, jogging, cycling, swimming, skipping, etc. 5 to 7 days per week)	Α
Reduce or avoid alcohol consumption (Limit alcohol to <14 units per week for men and <8 units per week for women)	Α
Avoid or stop smoking; refer patient to support groups to help in their cessation of smoking	В

5.1.6 MANAGEMENT OF HYPERTENSION ACCORDING TO LEVEL OF CARE

i. HEALTH FACILITY WITHOUT A DOCTOR

ia. LABORATORY INVESTIGATION

- Urinanalysis (urine dipstick)
- Random blood sugar
- \rightarrow If not available or results are abnormal, refer to a facility with a doctor.

ib. PHARMACOLOGICAL TREATMENT (FOR PHYSICIAN ASSISTANTS)

GRADE 1 HYPERTENSION (SBP 140-159 mmHg, DBP 90-99 mmHg) with inadequate control after 3 months of lifestyle modification **or** if patient has more than 3 risk factors:

- Male
- Age (men >55 years, women >65 years)
- Smoking
- Obesity (including abdominal obesity)
- Dyslipidaemia (high blood cholesterol)
- Impaired fasting glucose
- Family history of early coronary artery disease¹¹

Recommended therapy for PHYSICIAN ASSISTANTS (LOE A) (Refer to table 32 for doses)

- Monotherapy: thiazide-like diuretic or calcium channel blockers (CCB)
- If after 2-4 weeks of treatment response is not adequate, add second drug (dual therapy):
 CCB + Thiazide-like diuretic
- → If BP remains uncontrolled (refer to *treatment objectives for target BP values*), refer patient to the next level of care: health facility with a doctor.

GRADE 2 HYPERTENSION (SBP 160-179 mmHg, DBP 100-109 mmHg)

Recommended therapy (LOE A)

- Dual therapy preferred: CCB + thiazide-like diuretic
- → If BP remains uncontrolled (refer to *treatment objectives for target BP values*), refer patient to the next level of care (health facility with a doctor).

Criteria for referring a hypertensive patient to a health facility with a doctor:

- Patients who have SBP >180 mmHg and/or DBP > 110 mmHg
- Patients who have not attained target BP despite 4 weeks of adequate antihypertensive treatment
- Patients with pre-existing diabetes mellitus or blood sugar suggestive of diabetes mellitus
- Patients with HIV/AIDS
- Hypertensives with complications such as heart disease, stroke and kidney disease

ii. HEALTH FACILITY WITH A DOCTOR

iia. LABORATORY INVESTIGATION

- Full blood cell count
- Urinalysis
- Blood glucose
- Blood urea, electrolytes and creatinine (including eGFR)
- Serum lipids
- Serum uric acid
- Chest X-ray
- 12-lead Electrocardiogram (ECG)

iib. PHARMACOLOGICAL TREATMENT

GRADE 1 HYPERTENSION (SBP 140-159 mmHg, DBP 90-99 mmHg) with inadequate control after 3 months of lifestyle modification **or** if patient has more. than 3 risk factors:

- Male
- Age (men >55 years, women >65 years)
- Smoking
- Obesity (including abdominal obesity)
- Dyslipidaemia (high blood cholesterol)
- Impaired fasting glucose
- Family history of early coronary artery disease¹¹

Recommended therapy (Level of evidence A)

- Monotherapy: thiazide-like diuretic or calcium channel blockers (CCB)
- → If after 2-4 weeks of treatment response is not adequate, add second drug (dual therapy): CCB + Thiazide-like diuretic.

GRADE 2 HYPERTENSION (SBP 160-179 mmHg, DBP 100-109 mmHg) **Recommended therapy** (Level of evidence A)

- Dual therapy preferred: CCB + Thiazide-like diuretic or
- ACE Inhibitor + Thiazide-like diuretic or
- ACE Inhibitor + CCB
- → Add third drug (multi-therapy) if response is not adequate after 2-4 weeks of treatment: ACE Inhibitor + CCB + thiazide-like diuretic.

GRADE 3 HYPERTENSION (SBP ≥180 mmHg, DBP ≥110 mmHg)¹⁴

Recommended therapy (Level of evidence A)

- Use dual therapy at the beginning:
 ACE Inhibitor + CCB or CCB + thiazide-like diuretic or ACE inhibitor + thiazide-like diuretic
- → If response is not adequate within 2-4 weeks, add a third drug: ACE Inhibitor + CCB + thiazide-like diuretic.
- ACE inhibitors are preferred in facilities that can monitor the potassium levels of patients
- Elderly patients may require lower doses of medication (e.g. half the dose of Beta-blockers; Amlodipine: give 2.5mg instead of 5mg)
- Add on therapy should be at lower doses for Beta-blockers and reduced for ACE1 if patient is elderly or is on diuretics

- Replace ACE1 with ARBs, if patient cannot tolerate ACE1
- → If BP remains uncontrolled (refer to *treatment objectives for target BP values*), refer patient to the next level of care: health facility with a physician specialist.

Criteria for referring a hypertensive patient to a specialist

- All pregnant women with hypertension (refer to an obstetrician)
- Patients with abnormal results on urine dipstick or blood tests i.e. full blood cell count (anaemia), abnormal blood urea nitrogen (BUN)/blood urea, electrolytes and creatinine (BUE-Cr)
- Adolescents and children diagnosed with hypertension (refer to a paediatrician)
- Patients with suspected secondary cause of hypertension
- Patients with chronic heart disease, heart failure and coronary artery disease (refer to a cardiologist)
- Patients with renal insufficiency or chronic kidney disease (refer to a nephrologist)
- Patients with stroke or transient ischaemic attack, intracerebral haemorrhage, vascular dementia and lacunar infarction (refer to a neurologist)
- Patients with peripheral arterial disease (refer to a cardiologist or a vascular surgeon)
- Geriatric patients (≥80 years) being diagnosed with hypertension for the first time

iii. HEALTH FACILITY WITH A PHYSICIAN SPECIALIST OR FAMILY PHYSICIAN MANAGEMENT OF HYPERTENSION FOR A HEALTH FACILITY WITH A PHYSICIAN SPECIALIST Investigation for a health facility with a physician specialist⁷:

- All investigation under levels 1 and 2:
- Echocardiogram for those with symptoms and signs of hypertensive heart disease
- Phaeochromocytoma –resting plasma catecholamines, urinary catecholamines and metabolites (metanephrines), CT scan of abdomen
- Cushing's syndrome dexamethasone suppression test (overnight, low dose and high dose), 24 hour urinary free cortisol, plasma Adrenocorticotropin hormone levels, Corticotropin releasing hormone test, adrenal CT scan, pituitary MRI
- Acromegaly growth hormone level, glucose tolerance test, insulin-like growth factor-1 levels, MRI scan of head (pituitary tumour)
- Hyperparathyroid disease serum parathyroid hormone, serum calcium, 24 hour urinary calcium, serum alkaline phosphatase
- Thyroid disease serum TSH, free T3, free T4
- Renal parenchymal diseases urinalysis, renal ultrasound, renal biopsy
- Renal artery stenosis doppler of renal arteries, CT angiogram of kidneys

Pharmacological treatment:

\rightarrow Elevated BP without evidence of target organ damage (TOD)

In hypertensive patients with no target-organ injury (preclinical CVD or a history of CVD), modestly lowering the target BP to <140/90 mmHg is recommended.

\rightarrow Elevated BP with target organ damage, preclinical CVD, or CVD (secondary prevention)

For hypertensives with evidence of target-organ damage, BP levels should be consistently maintained below the target level of 130/80 mmHg. Physicians should look out for the following when managing patients with evidence of target organ damage:

- Albuminuria; spot urine albumin: creatinine ratio >200mg/g
- Abnormal renal function (with estimated glomerular filtration rate [eGFR] <60 ml/min/1.73m²)
- ECG with evidence of LVH

- Metabolic syndrome
- Framingham risk score corresponding to >20% 10-year CHD risk
- Glucose intolerance [2-hour post- prandial glucose ≥7.8 mmol/l]
- Impaired fasting glucose [5.6-6.9 mmol/l]
- Diabetes mellitus, and/or overt clinical CVD
- → Most of the patients with TOD require multiple antihypertensives in order to maintain BP levels below the target level of 130/80 mmHg.
- → Gradually reducing the BP over several weeks (or more) to the recommended target BP level is preferable.
- → Caution must be taken to avoid rapidly lowering BP since rapid drop in BP can increase the risk of target-organ ischemia/dysfunction, particularly in hypertensives with widespread vascular disease and/or chronic kidney disease¹².

iiia. LABORATORY INVESTIGATION7

- Full blood cell count
- Urinalysis
- Blood glucose
- Blood urea, electrolytes and creatinine (including eGFR)
- Serum lipids
- Serum uric acid
- Chest X-ray
- 12-lead electrocardiogram (ECG)

iiib. SPECIAL INVESTIGATION FOR PATIENTS WITH SECONDARY HYPERTENSION Phaeochromocytoma

- Resting plasma catecholamines
- Urinary catecholamines and metabolites (metanephrines)
- CT scan of abdomen

Cushing's syndrome

- Dexamethasone suppression test (overnight, low dose and high dose)
- 24h urinary free cortisol
- Plasma adrenocorticotropin hormone levels
- Corticotropin releasing hormone test
- Adrenal CT scan, pituitary MRI

Acromegaly

- Growth hormone level
- Glucose tolerance test
- Insulin-like growth factor 1 levels, MRI scan of head (pituitary tumour)

Hyperparathyroid disease

- Serum parathyroid hormone
- Serum calcium
- 24-hour urinary calcium
- Serum alkaline phosphatase

Thyroid disease

- Serum thyroid stimulating hormone
- Free T3
- Free T4

Renal parenchymal diseases

- Urinalysis
- Renal ultrasound

Renal artery stenosis

- Doppler of renal arteries
- CT angiogram of kidneys

iiic. PHARMACOLOGICAL TREATMENT

ELEVATED BP WITHOUT EVIDENCE OF TARGET ORGAN DAMAGE (TOD)

In hypertensive patients with no target-organ injury (preclinical CVD or a history of CVD), modestly lowering the target BP to <140/90 mmHg is recommended.

ELEVATED BP WITH TARGET ORGAN DAMAGE, PRECLINICAL CVD, OR CVD (SECONDARY PREVENTION)

For hypertensive patients with evidence of target organ damage, BP levels should be consistently maintained below the target level of 130/80 mmHg. Physicians should look out for the following when managing patients with evidence of target organ damage:

- Albuminuria; spot urine albumin: creatinine ratio >200mg/g
- Abnormal renal function (with estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m²)
- ECG evidence of LVH
- Metabolic syndrome
- Framingham risk score corresponding to >20% 10-year CHD risk
- Glucose intolerance [2-hour post-load glucose ≥7.8 mmol/l]
- Impaired fasting glucose [5.6-6.9 mmol/l]
- Diabetes mellitus, and/or overt clinical CVD
- Most of the patients with TOD require multiple antihypertensives in order to maintain BP levels below the target level of 130/80 mmHg
- Gradually reducing the BP over several weeks (or more) to the recommended target BP level is preferable
- Caution must be taken to avoid rapidly lowering BP since rapid drop in BP can increase the risk of target-organ ischemia/dysfunction, particularly in hypertensives with widespread vascular disease and/or chronic kidney disease¹²

Co-morbidity	ACEI	ARB	Aldosterone antagonist	Beta-blocker	ССВ	Diuretic
Diabetes/Pre-Diabetes						
СКD			Х			
HF				•	Х	
CHD/angina						
Post-MI						
Vascular disease risk						
Recurrent stroke						

Table 30: Preferences for antihypertensive drugs by comorbidity for health facility with a physician specialist³

indicates compelling indication (proven benefit);

likely benefit or safety proven;

X contraindication; ACEI, ACE inhibitor; ARB, Angiotensin receptor blocker; CCB, Calcium channel blocker; CKD, chronic kidney disease; CHD, coronary heart disease; MI, myocardial infarction.

Caution:

- If eGFR is <50 ml/min per 1.73 m², Eplerenone⁺ only; use spironolactone with caution; periodically check serum potassium
- Non-dihydropyridine CCBs (Diltiazem* and Verapamil) are contraindicated in systolic HF

Single pill combination therapy

With advancement in medicine, the need for patients to swallow several pills or tablets of medication has decreased. Medications now come in combinations that are contained in a single pill or tablet. The European Society of Cardiology currently recommend that these combination medicine can be used as first line management for patients with hypertension¹. The benefits of these combination medication cannot be underestimated. These combination medication reduce pill burden, increase compliance. The benefits are derived from the synergistic effects of the combinations.

Some common combinations that can be found on the market include:

- ACE-1 + calcium channel blocker: **Perindopril** + **Amlodipine**
- ACE-1 + diuretic: Lisinopril + Hydrochlorothiazide
- ACE-1 + calcium channel blocker + diuretic: Perindopril* + Amlodipine + Indapamide*
- Calcium channel blocker + Beta-blocker: Nifedipine + Atenolol
- ARB + calcium channel blocker: Irbesartan⁺ + Amlodipine
- ARB + diuretic: Candesartan + Hydrochlorothiazide
- ARB + calcium channel blocker + diuretic: Valsartan + Amlodipine + Hydrochlorothiazide
- Beta-blocker + diuretic: Atenolol + Hydrochlorothiazide
- \rightarrow N.B. \bullet = drugs not in the Essential Medicines List (EML)

5.1.7 RESISTANT HYPERTENSION

Resistant hypertension is defined as the failure to control BP on ≥ 3 antihypertensive medications (including a diuretic) despite giving adequate doses, or controlling BP but on ≥ 4 antihypertensives including a diuretic. Co-morbidities such as obesity, type 2 diabetes mellitus, and CKD have been associated with the rapidly increasing prevalence of resistant hypertension in Africa^{13,14}. Inadequate control of BP is confirmed by ABPM or HBPM in patients whose adherence to therapy has been confirmed¹.

Practical tips for lowering BP in resistant hypertension

Treatable causes of resistant hypertension should be sought for and managed as much as possible. These causes include obstructive sleep apnoea (OSA), high-salt/low-potassium diet, alcohol abuse, NSAIDS, nasal decongestants, cocaine¹². Below is the recommendation for BP control in resistant hypertension:

Therapeutic recommendations for lowering BP in resistant hypertension


Scrutinize patient's current drug regimen:


- Stop medications (e.g. NSAIDs) that can affect BP lowering
- Look out for risk factors such as alcohol abuse and high salt intake which undermine pharmacological BP lowering

Review current antihypertensive drug regimen:

Avoid undesirable therapeutic combinations that are poorly tolerated and/or minimally effective (see recommended combinations on *page 65*)

- Include ≥1 diuretic that is appropriate for the level of kidney function
- Consider adding a second diuretic with a complementary mechanism of action (e.g. Chlorthalidone* & spironolactone)
- → If systolic heart function is normal (ejection fraction ≥50%), consider the simultaneous use of a dihydropyridine (DHP) and a non-DHP CCB
- \rightarrow If available, use noninvasively measured vascular function to guide therapeutic selections
- → Consider referral to a hypertension specialist





Drug	Conditions favouring use	Contraindications		
		Compelling	Possible	
Diuretics (thiazide-like; thiazide) <i>Indapamide</i> •, <i>Bendrofluazide</i> (Bendroflumethiazide)	 Heart failure (HF) Elderly hypertensives Isolated systolic HTN (ISH) Hypertensives of african origin 	• Gout	 Pregnancy Beta-blockers (especially <i>Atenolol</i>) 	
Diuretics (loop) Frusemide, Torasemide*	Renal insufficiencyHF		 Pregnancy 	
Diuretics (anti-aldosterone) <i>Spironolactone</i>	HFPost-myocardial infarctionResistant hypertension	Renal failureHyperkalaemia		
CCB (dihydropyridine) Amlodipine, Nifedipine	 Elderly patients Isolated systolic hyper- tension Angina pectoris Peripheral vascular disease Carotid atherosclerosis Pregnancy 		 Tachyarrhythmias HF especially with reduced ejection fraction 	
CCB non-dihydropyridine Verapamil, Diltiazem*	 Angina pectoris Carotid atherosclerosis Supraventricular tachycardia 	AV block (grade 2 or 3)HF	 Constipation (Verapamil) 	
ACEI Lisinopril, Perindopril*	 HF LV dysfunction Post-myocardial infarction Non-diabetic nephropathy Type 1 diabetic nephropathy Prevention of diabetic microalbuminuria Proteinuria 	 Pregnancy Hyperkalaemia Bilateral renal artery stenosis Angioneurotic oedema (more common in Blacks than in Caucasians) 		
ARB Valsartan, Losartan	 Type 2 diabetic nephropathy Type 2 diabetic micro- albuminuria Proteinuria LVH ACEI cough or intolerance 	 Pregnancy Hyperkalaemia Bilateral renal artery stenosis 		
Beta-blockers Bisoprolol, Carvedilol	 Angina pectoris Post-myocardial infarction HF (<i>Carvedilol</i>, <i>Meto-prololol</i>, <i>Bisoprolol</i>) Tachyarrhythmias 	 Asthma Chronic obstructive pulmonary disease AV block (grade 2 or 3) Pregnancy (<i>Atenolol</i>) 	 Peripheral vascular disease Bradycardia Glucose intolerance Metabolic syndrome Athletes and physically active patients Non-dihydropyridine CCBs (Verapamil, Diltiazem*) 	

Table 31: Antihypertensive medications, indications and contraindications⁹

Class	Example	Usual monotherapy (per os)	Maximum daily dose (per os)	Possible side effects	
Long-acting CCB	Amlodipine	5mg OD	10mg OD	OedemaHeadache	
	<i>Felodipine</i> •	5mg OD	10mg OD		
	Nifedipine	Retard tabs: 10-20mg BD	Retard tabs: 30mg BD	 Palpitations 	
Thiazide	Bendrofluazide	2.5mg OD	5mg OD	HypokalaemiaHyperuricaemia	
diuretic	Hydrochlorothiazide (HCTZ)	12.5mg OD	2.5mg OD 25mg OD		
Thiazide-like	Indapamide*	2.5mg OD	5mg OD	HyperglycaemiaRashDyslipidaemia	
diuretics	Chlorthalidone•	25mg OD	50mg OD		
ACE inhibitor	Captopril [•]	25-50 BD or TDS	50mg TDS	 Cough (ACEI) Hyperkalaemia Increased serum creatinine Angioedema 	
	Enalapril	5-20mg daily in 1 or 2 divided doses	20mg daily in 1 or 2 divided doses		
	Lisinopril	10mg OD	40mg OD		
	Perindopril◆	4mg OD or 5mg OD	8mg OD or 10mg OD		
	Ramipril	2.5mg OD	10mg OD		
Beta-	Atenolol	25mg OD	100mg		
blockers	Bisoprolol	2.5mg OD	20mg OD		
	Carvedilol	6.25mg BD	25mg BD		
	Labetalol	100mg BD	400mg BD		
	Metoprolol succinate	25mg OD	100mg OD		
	Nebivolol*	5mg OD	20mg OD		
ARB	Candesartan	8mg OD	32mg OD		
	Irbesartan [◆]	150mg OD	300mg OD		
	Losartan	50mg OD	100mg OD		
	Telmisartan [◆]	40mg OD	80mg OD		
	Valsartan	80mg OD	160mg OD		
	Les	s commonly used Antihyperten	sive medications		
Class	Example	Usual monotherap	Maximum daily dose	Possible side effect	
Centrally	Methyldopa	250mg BD or TDS	1000mg/day	 Angina Orthostatic Hypotension Gynaecomastia Rash Erectile dys- function 	
acting agents	Clonidine	0.1mg BD	2.4mg/day		
	Phenoxybenzamine*	10mg BD	40mg TDS		
Potassium- sparing diuretics	Amiloride*	5mg OD/ divided	10mg OD or divided dose	 Hyperkalaemia 	
	Triametrene	25mg OD or divided dose	100mg OD or divided dose		
	Spironolactone	25-50mg OD	50-100mg daily in divided dose		
Loop	Torasemide*	5mg OD	20mg OD	 Hyperuricaemia 	
diuretics	Furosemide	20mg OD	80mg OD or divided dose	 Hypokalaemia 	
Vasodilators	Hydralazine	25mg BD or TDS	150mg/day	HypotensionPalpitations	
Alpha 1	Prazosin	1mg BD-TDS	20mg/day	HypotensionDiarrhoeaTachycardia	
receptor blocker	Terazosin	1mg OD	20mg/day		

Table 32: Antihypertensive medications and the common side effects²

(Adapted from Kenyan National Guidelines For Cardiovascular Diseases Management, 2018)

ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; CCB: Calcium channel blocker; OD: administer once daily; BD: administer twice daily; TDS: administer 3 times daily. • = Drugs not on the EML

5.1.8 HYPERTENSIVE EMERGENCY

This refers to severely elevated BP (SBP >180 mmHg and/or DBP >120 mmHg) associated with progressive organ dysfunction. Patients with hypertensive emergencies require immediate BP reduction in order to avoid or limit target end organ damage and therefore require in-patient management with close monitoring².

Examples of hypertensive emergencies include:

- Hypertensive encephalopathy
- Acute left ventricular failure
- Acute myocardial infarction
- Acute kidney injury
- Aortic dissection
- Subarachnoid haemorrhage
- Acute retinal haemorrhage or papilloedema

i. CLINICAL PRESENTATION

Patients present with the following acute symptoms and severe hypertension:

- A = Altered consciousness
- B = Breathlessness
- C = Chest pain (in ischaemia)
- D = Deficit (weakness in one or more limbs) or decreased urinary output
- E = Oedema
- F = Fundus if feasible haemorrhages, exudates, papilloedema
- G = Generalized seizures

ii. MANAGEMENT OF HYPERTENSIVE EMERGENCY PER LEVEL OF CARE

iia. HEALTH FACILITY WITHOUT A DOCTOR

 \rightarrow This is a medical emergency. Delay in the care will lead to increased mortality. Refer to the next level of care or to a specialist as soon as possible.

INVESTIGATION

Refer to investigation for hypertension stated above for each level.

TREATMENT

- Resuscitate patient
- Give oxygen if available to patients who require oxygen
- Secure intravenous access
- Start oral antihypertensive (thiazides or calcium channel blockers)
- \rightarrow Refer to a health facility with a doctor/physician specialist for further management.
- → If patient is unconscious, pass nasogastric (NG) tube (if expertise is available), refer immediately.

iib. HEALTH FACILITY WITH A DOCTOR OR WITH A PHYSICIAN SPECIALIST

INVESTIGATION

Refer to investigation for hypertension stated above for each level.

Table 33: Hypertensive emergency management options²

Head CT scan should be performed for hypertensive emergencies involving the central nervous system (CNS) (e.g. stroke, intracerebral haemorrhage, subarachnoid haemorrhage).

TREATMENT

\rightarrow Initiate iv antihypertensives (refer to *table 32*) and institute rigorous monitoring of patient's vital signs.

Condition	Management option		
Acute ischaemic stroke	Antihypertensive therapy is not routinely recommended for patients with acute stroke and hypertension (refer to stroke chapter for details)		
Acute intracerebral haemorrhage	Lower BP when the SBP is >200 mmHg or the DBP is >110 mmHg If there are signs of raised ICP, maintain mean arterial pressure (MAP) just below 130 mmHg (or SBP <180 mmHg) for first 24 hours after onset; maintain MAP below 110mmHg (or SBP <160 mmHg) for first 24 hours after symptoms onset for patients without raised ICP		
Subarachnoid haemorrhage	Maintain SBP <160 mmHg until the aneurysm is treated or cerebral vasospasm occurs. Oral Nimodipine* is used to prevent delayed ischaemic neurological deficits, but it is NOT indicated for treating acute hypertension		
Aortic dissection	 Immediately reduce the SBP < 110 mmHg and maintain it at this level unless signs of end organ hypoperfusion are present; preferred treatment includes a combination of Opioid analgesics (morphine sulphate) Beta blockers (e.g. Labetalol, Esmolol*) or CCBs (e.g. Verapamil, Diltiazem*) Avoid Beta-blockers, if there is aortic valvular regurgitation or suspected cardiac tamponade 		
Acute myocardial infarction or heart attack	 Treat if SBP >160 mmHg and/or DBP >100 mmHg, reduce BP by 20-30% of baseline Thrombolytics are contraindicated if BP is >185/100 mmHg; preferred medications include Beta-blockers & Nitroglycerin* 		
Acute heart failure	Treat with vasodilators (in addition to diuretics) for SBP \geq 140 mmHg, iv or sublingual <i>Nitroglycerin</i> [•] is the preferred agent		
Pre-eclampsia/ eclampsia	 Prepartum and intrapartum: SBP should be <160 mmHg and DBP <110 mmHg If the platelet count is <100,000 cells/mm, SBP should be maintained below 150/100 mmHg Patients with eclampsia or pre-eclampsia should also be loaded with iv magnesium sulphate 4g diluted in 100ml normal saline given over 15 minutes then with an infusion of 2g/hour to avoid seizures Preferred medication: <i>Hydralazine, Labetalol, Nifedipine</i> Medication to avoid: <i>Nitroprusside</i>⁺, ACEIs, <i>Esmolol</i>⁺ 		
Acute kidney injury (AKI)	 Slowly decrease BP by 20-25% within 24 hours using oral antihypertensives Do not aggressively drop the BP 		

(Adapted from Kenyan National Guidelines For Cardiovascular Diseases Management, 2018)

HPT

Drug	Dose	Onset of action	Adverse effects	Comments
iv Furosemide	20-40mg in 1-2 minutes	5-15 minutes	HypovolemiaHypokalemia	May be used in combination with other drugs to maintain their efficacy; indicated in acute left ventricular failure
iv Labetalol	20-80mg iv	5-10 minutes	 Scalp tingling Dizziness Nausea Heart block 	Can be used in many hypertensive emergencies; avoid in acute heart failure
iv Nicardipine*	5-15mg per hour as iv	5-10 minutes	TachycardiaHeadacheNausea	Can be used in many hypertensive emergencie, avoid in acute heart failure
iv Nitroglycerine*	5-100µg/min	2-5 minutes	 Headache Vomiting Methemo globi- naemia tolerance 	Useful in myocardial ischemia with hypertension
iv or im Hydralazine	20-40mg (repeat PRN)	5-20 minutes	HeadachePalpitationOedemaHypotension	Useful in pregnancy related hypertension

Table 34: Intravenous medications used in hypertensive emergencies¹¹

* = Drugs not on the EML PRN = as needed/required

(Adapted from the Indian Standard Treatment Guidelines on Hypertension, 2016)

5.1.9 PATIENT INFORMATION/EDUCATION AT ALL LEVELS

- Inform the patients that the antihypertensive medicine will not cure their hypertension rather reduce BP level thereby reduce their risk of complications.
- Educate patients on how to take the antihypertensive medications and on the importance of follow-up.
- Educate patients on the complications of uncontrolled hypertension such as stroke, heart failure, acute myocardial infarction or heart attack, aortic dissection, cardiac arrest etc. and also on the importance of following their recommended treatment regimen.
- Patients should be advised on the usefulness of home blood pressure monitoring as it has been shown to improve cardiovascular outcomes compared to clinic/office BP measurements.
- Educate patients on the importance of maintaining a healthy lifestyle.

5.1.10 PREVENTION OF HYPERTENSION

Primary hypertension prevention is hinged mainly on avoiding and controlling modifiable risk factors. This can be achieved through lifestyle modification.

→ Refer to non-pharmacological management of hypertension for lifestyle modifications, that can help prevent primary hypertension (paragraph 5.1.2 and chapter 2: risk factors).

REFERENCES

- 1 Williams B, Masera G, Spiering W, Rosei EA, Azizi M, Burnier M. 2018 ESC / ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018; 39(33): 3021–3104.
- 2 Kibachio J, Maree E, Gathecha G, Mwangi M. Ministry of Health Kenya. National Guidelines for Cardiovascular Diseases Management. Ministry of Health Kenya; 2018.
- World Health Organization. A global brief on Hypertension. 2013.
 Available from: https://www.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf?ua=1.
- 4 Cappuccio FP, Miller MA. Cardiovascular disease and hypertension in sub-Saharan Africa: burden, risk and interventions. Internal and Emergency Medicine. 2016; 11(3): 299–305.
- 5 Bosu WK. Epidemic of hypertension in Ghana: a systematic review. BMC Public Health. 2010 Jul 14; 10: 418.
- 6 Kayima J, Wanyenze RK, Katamba A, Leontsini E, Nuwaha F. Hypertension awareness, treatment and control in Africa: a systematic review. BMC Cardiovasc Disord. 2013 Aug 2; 13: 54.
- 7 Kumar P, Clark Mi. Clinical Medicine. 8th ed. Elsevier; 2012.
- 8 Ministry of Health in Ghana. Standard Treatment Guidelines Ghana 2017. Available from: http://apps.who.int/medicinedocs/documents/s16434e/s16434e.pdf.
- Seedat YK, Rayner BL, Veriava Y. South African hypertension practice guideline 2014: review article. Cardiovascular Journal of Africa. 2014; 25(6): 288–294.
- 10 Schmieder RE. End Organ Damage. Deutsches Ärzteblatt International. 2010; 107(49): 866–874.
- 11 Ministry of Health & Family Welfare. Government of India. Hypertension: Screening, Diagnosis, Assessment, and Management of Primary Hypertension in Adults in India. 2016. Available from: http://nrhm.gov.in/images/pdf/guidelines/nrhm-guidelines/stg/Hypertension_QRG.pdf.
- 12 Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RHJ, et al. Management of High Blood Pressure in Blacks. An Update of the International Society on Hypertension in Blacks Consensus Statement. Hypertension. 2010; 56(5): 780–800.
- 13 Mokdad A, Ford E, Bowman B, Dietz W, Vinicor F, Bales V, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. The Journal of the American Medical Association. 2003; 289(1): 76–79.
- 14 Ford E, Giles W, Mokdad A. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004; 27(10): 2444–2449.
- 15 The Kenya Association of Physicians, The Kenya Cardiac Association TKRS. Protocol for the identification and management of hypertension in adults in primary care. 2015. Available from: http://www.jkuat.ac.ke/departments/hospital/wp-content/uploads/2015/08/Hypretension-Protocol.pdf.

5 DISEASES 5.2 STROKE

LIST OF ABBREVIATIONS AND ACRONYMS

re
nalized
eam
ion
ce
e Plasmi-
norrhage
ropriate
one
Attack
echo-
Activator
tion
nbolism
nisation

5.2.1 INTRODUCTION

i. **DEFINITION**

Stroke is defined by WHO as 'a clinical syndrome consisting of rapidly developing clinical signs of focal (or global in case of coma) disturbance of cerebral function lasting more than 24 hours or leading to death with no apparent cause other than a vascular origin².

Stroke is typically associated with a neurological deficit caused by an acute focal injury of the central nervous system by a vascular cause, including cerebral infarction, intracerebral haemorrhage, and subarachnoid haemorrhage². A more accurate definition stems from the definitions of the various classification of strokes in *table 35*.

ii. EPIDEMIOLOGY

Stroke is the leading cause of long-term disability and the second most common cause of death worldwide^{3,4}. About 71% of all stroke deaths are in lower and middle income countries⁵. Whereas high-income countries show significant reductions in stroke incidence of about 42% over the last 40 years, a 100% increase in stroke incidences occurred in lower and middle income countries over the same period⁶. Sub-Saharan Africa has the highest burden of stroke with age-adjusted incidence of 316 per 100,000 people per year⁷, age-adjusted prevalence of up to 14.6 per 1000 people⁸, and case fatality of up to 43% at 1 month and 84% at 3 years^{9,10}.

Ghana and most other African countries have witnessed the epidemiological transition in disease morbidity and mortality¹¹. In the last few years, the leading causes of death have shifted from communicable diseases to a combination of both communicable and chronic NCDs¹². The rising incidence of mortality associated with cardiovascular disease (CVD) especially stroke have been unmatched. For instance, in Accra, CVD moved from being the seventh and tenth cause of death in 1953 and 1966 respectively to number one cause of death in 1991 to date¹³. In Komfo Anokye Teaching Hospital, stroke constituted 9.1% of total medical adult admissions and 13.2% of all medical adult deaths from January 2006 to December 2007¹¹.

In 2003, data collected showed that stroke was the fourth leading cause of death among in-patients in 32 sentinel hospitals in the 10 regions of Ghana¹². The rising incidence and prevalence of hypertension in Ghana¹⁴⁻¹⁷ especially in the urban communities implies that the burden of stroke will continue to increase until immediate action is taken to stop this trend¹¹.

iii. CLASSIFICATION OF STROKES

Based on the stroke definition in the ICD-11 of WHO, cerebrovascular disease has been categorized and defined as in *table 35*, next page.

Table 35: Classification of strokes²

Cerebrovascular disease categories and define	itions (selected) in the ICD-11
Stroke	
Cerebral ischaemic stroke	 Intracerebral haemorrhage Definition: Acute focal neurological dysfunction caused by focal infarction at single or multiple sites of the brain or retina; evidence of acute infarction may come either from: symptom duration lasting more than 24 hrs neuroimaging or other technique in the clinically relevant area of the brain
Intracerebral haemorrhage	Definition: Acute neurological dysfunction caused by haemorrhage within the brain parenchyma or in the ventricular system
Subarachnoid haemorrhage	Definition: Acute neurological dysfunction caused by subarachnoid haemorrhage
Transient ischaemic attack ⁺	Definition: A transient episode of focal neurological dysfunction caused by focal brain or retinal ischaemia without acute infarction in the clinically relevant area of the brain or retina; symptoms should resolve completely within 24 hours
Cerebrovascular disease with no acute cerebral symptom ⁺	 Silent cerebral infarct (defined as an infarct demonstrated on neuroimaging or at autopsy that has not caused acute dysfunction of the brain) Silent cerebral microbleed Silent cerebral macrobleed Silent white matter abnormalities associated with vascular disease (defined as abnormalities in the cerebral white matter of proven or assumed vascular origin)

⁺Categories not classified as "stroke"

iv. AETIOLOGY

Identifying the underlying cause of stroke helps in evaluating patients, choosing purposeful diagnostic tests, predicting prognosis, and planning secondary preventive measures of stroke in daily clinical practice.

Table 36: Aetiology of stroke

Aetiology of stroke	
Infarcts	Haemorrhage/bleeds
A – Atherosclerosis	S - Structural lesion (e.g. cerebral aneurysms)
S – Small-vessel disease	M - Medications (anticoagulants, antiplatelets)
C – Cardiac pathology (embolic stroke)	A – Amyloid angiopathy
0 - Other causes	S - Systemic disease/e.g. bleeding disorders
D - Dissection	H – Hypertension
	U – Unknown

v. **RISK FACTORS**

The risk factors of stroke can be grouped **under modifiable and non-modifiable risk factors**. The top 11 potential **modifiable risk factors** associated with stroke occurrence according to the SIREN (the largest study done on stroke in Africa) has been arranged in decreasing order of magnitude in *table 37*. These 11 identified risk factors account for 98.2% of population attributable risk with stroke among people from Ghana and Nigeria¹⁸.

Table 37: Risk factors of stroke

Risk factors of stroke	
Non-modifiable	Modifiable
 Age Sex Ethnicity Family history 	 Hypertension Dyslipidaemia Regular meat consumption Elevated waist to hip ratio Diabetes mellitus Low intake of green leafy vegetables Psychological stress Added salt at the table Cardiac disease Physical inactivity Current use of cigarettes

5.2.2 CLINICAL PRESENTATION

i. SYMPTOMS AND SIGNS

The sudden onset of the symptoms is an important clue in the diagnosis of stroke. The time of symptom onset is crucial as it determines the mode of treatment. If the actual time is not known, the last time the patient was seen well should be used. A brief neurological examination should commence from the very moment the patient is seen.

Symptoms

- Weakness of the limbs (usually one sided)
- Slurred speech
- Facial droop on one side
- Difficulty swallowing
- Confusion
- Loss of consciousness
- Loss of sensation
- Severe headaches that are usually unlike headaches in the past
- Loss of balance or coordination
- Vision changes in one eye or both
- Seizures
- Bladder and bowel incontinence
- Nausea and vomiting
- Behavioural changes

Signs

- Hemiplegia or hemiparesis (complete or incomplete weakness of one side respectively)
- Dysarthria (difficulty in articulation)
- Aphasia/dysphasia (difficulty in forming speech)
- Reduced level of consciousness
- Cranial nerve palsies commonly facial nerve palsy/weakness
- Nystagmus
- Quadriparesis (weakness in all limbs) in brain stem strokes
- Unilateral loss of sensation

 \rightarrow Refer to chapter 3 of these guidelines for more detailed information.

5.2.3 MANAGEMENT ACCORDING TO LEVEL OF CARE

Management of acute stroke relies on brief but accurate history before any imaging or laboratory investigation is done. A quick non-contrast head CT scan is the most reasonable investigation to help identify the stroke type and appropriate management. Blood investigation may be carried out while waiting for image studies.

i. HEALTH FACILITY WITHOUT A DOCTOR

ia. LABORATORY INVESTIGATION

- Full blood cell count
- Blood sugar (instant finger stick glucose testing is acceptable in the emergency setting)
- → Laboratory investigation should not delay the referral.

ib. TREATMENT

- Assess ABC (airway, breathing and circulation) and correct any abnormalities if possible
- Perform a swallowing test, if patient fails do not give anything by mouth, pass an NG tube an NG tube
- Avoid lifting the patient on the affected limb to avoid shoulder subluxation
- Avoid putting objects into the patients mouth during a seizure episode; place patient on the lateral strong side, clear the area of sharp objects or obstacles and remove dentures or eyeglasses if present
- Elevate the head of the bed at 20-30 degrees
- Check vitals (blood pressure, pulse rate, respiratory rate, temperature) and random blood sugar
- Give suppository Paracetamol 1g if axillary temperatures are more than 37.2°
- → Do not give Aspirin when there is no CT scan to rule out a bleed
- Give suppository Diazepam 10mg if seizures do not self-abort in less than 5 minutes
- → Refer the patient after less than 30 minutes to a health facility with a physician specialist and the capacity to perform a head CT. Provide pre-hospital notification to the referring health facility that a suspected stroke is en route so that appropriate resources will be mobilised before arrival of the patient.

ii. HEALTH FACILITY WITH A DOCTOR

iia. LABORATORY INVESTIGATION

- Full blood cell count
- Blood sugar (instant finger stick glucose testing is acceptable in the emergency setting)
- Liver function test
- Lipid profile
- BUE & Cr
- HBA1C

iib. NON-LABORATORY INVESTIGATION

- Non-contrast head CT scan
- ECG

iic. TREATMENT

- Assess ABC (airway, breathing and circulation) and to correct any abnormalities abnormalities if possible
- Perform a swallowing test, pass NG tube if patient fails and never give anything by mouth
- Avoid lifting the patient on the affected limb to avoid shoulder subluxation
- Avoid putting objects into the patient's mouth during a seizure episode, place patient on the lateral strong side, clear the area of sharp objects or obstacles and remove dentures or eyeglasses if present
- Elevate the head of the bed at 20-30 degrees
- Check vitals (blood pressure, pulse rate, respiratory rate, temperature, RBS)
- Give suppository Paracetamol 1g if axillary temperatures are more than 37.2°
- \rightarrow Do not give Aspirin when there is no CT scan to rule out a bleed
- Give suppository Diazepam 10mg if seizures do not self-abort in less than 5 minutes
- → If patient has no CT scan:
- Patient showing signs of raised Intracranial Pressure (ICP), i.e. Cushing's triad (high BP, low pulse and irregular respiration), dilated pupils, increasing somnolence or decreasing level of consciousness start management as outlined below and refer to a teaching hospital.
 - iv Mannitol 20% concentrated solution in a dose of range of 0.5-2g/kg body weigh every 6-8 hours over 48 hours; each dose should run over 15-30 minutes; if Mannitol is not available iv Furosemide is a good option (next step)
 - Use iv Furosemide if patient is a known CKD or has renal impairment
 - Oral Acetazolamide 250mg bd can be added if CT scan shows acute hydrocephalu
- Oral statin can be added (e.g. Atorvastatin 20mg)
- Monitor for seizures. If patient has a seizure give oral antiseizure medications (e.g. Carbamazepine 200mg daily or Levetiracetam 250mg daily, refer all recurrent seizures in a day or seizures lasting more than 30 minutes
- \rightarrow For BP management see *chapter 5.1* on hypertension.

iii. HEALTH FACILITY WITH A PHYSICIAN SPECIALIST/FAMILY PHYSICIAN

iiia. LABORATORY INVESTIGATION

- Full blood cell count
- Blood sugar (instant finger stick glucose testing is acceptable in the emergency setting)
- Liver function test
- Lipid profile
- BUE & Cr
- HBA1C
- Thrombophilia screen for patients with no apparent cause of the stroke:
 - Antithrombin deficiency
 - Protein C deficiency
 - Protein S deficiency
 - Factor V Leiden
 - Prothrombin 20210 mutation
 - Antiphospholipid antibody
 - Homocysteine levels

iiib. NON-LABORATORY INVESTIGATION

- Non-contrast head CT scan
- MRI if available
 - If available:
 - Carotid artery doppler for anterior circulation ischaemia
 - Vertebral artery doppler for posterior circulation ischaemia
 - Holter ECG
 - Echocardiogram

N.B.

- Non-contrast head CT is a rapidly obtained, highly sensitive, and relatively more available investigation method.
- Rapid brain MRI offers the additional advantage of being both highly sensitive and specific for ischaemic stroke, particularly in cases of suspected stroke mimics¹⁹. In brain MRI, at least two sequences need to be done; diffusion weighted images (DWI) and apparent diffusion co-efficient (ADC). However, the availability and cost of MRI in Ghana limits its use in acute stroke.
- Holter ECG in suspected cardio-embolic stroke. A longer duration of this investigation is recommended (at least 72 hours) to diagnose atrial fibrillation. In some instances, insertable cardiac rhythm monitor (ICM) may be required in cryptogenic strokes²⁰.
- Echocardiogram, preferable trans-oesophageal echocardiogram (TOE) in suspected cases of cardio-embolic strokes.




Figure 10: Non-contrast CT scan showing haemorrhagic stroke




Figure 11: Non-Contrast CT scan showing ischaemic stroke




Figure 12: Echocardiogram showing an intracardiac embolus at the apex of the left ventricle

iiic. TREATMENT

1. HEAD CT SCAN CONFIRMED INFARCT

If possible, refer to a stroke unit within 4.5 hours after start of symptom for acute treatment of infarctive stroke. The three main principles of acute stroke care are:

- \rightarrow Achieve timely recanalisation of the occluded artery and reperfusion of the ischaemic tissue
- \rightarrow Optimise collateral flow
- → Avoid secondary brain injury

Acute reperfusion treatment (table 39)

There is enough evidence that iv thrombolysis with rtPA and endovascular thrombectomy with a retrievable stent improves neurologic outcomes in patients with acute ischaemic stroke. Both treatments should be administered as quickly as possible after stroke onset, can be combined, and are safe in appropriately selected candidates.

 \rightarrow NB: currently this is not widely available in Ghana.

The standard dose of iv rtPA, if available for acute ischaemic stroke, is 0.9mg/kg, with 10% administered as a bolus and the remainder infused over 1 hour. The total dose should not exceed 90mg. See *table 38* for inclusion and exclusion criteria for iv thrombolysis.

Table 38: Indications and contraindications for iv thrombolysis³³

Indications and contraindications for iv thrombolysis

Eligibility criteria for tPA

- Diagnosis of ischaemic stroke causing measurable neurologic deficit
- Time from onset of stroke symptoms less than 4.5 hours before tPA administration

Exclusion criteria for tPA

History

- History of intracranial haemorrhage in the preceding 6 months
- Stroke or serious head or spinal trauma in the preceding 3 months
- Major surgery (e.g., cardiac, thoracic, abdominal, orthopaedic) in the previous 14 days
- Arterial puncture at a non-compressible site in the preceding 7 days
- Any other condition that could increase the risk of haemorrhage after tPA administration

Clinical

- Symptoms suggestive of subarachnoid haemorrhage (e.g., sudden onset of severe headache, stiff neck, photophobia, blurred/double vision)
- Stroke symptoms due to another non-ischaemic acute neurological condition (e.g., seizure with post-ictal Todd's paralysis, or focal neurological signs due to severe hypo- or hyperglycaemia)
- Severe hypertension refractory to antihypertensives such that target blood pressure <185/110 mmHg cannot be achieved

Laboratory

- Blood glucose concentration < 2.7 mmol/l or > 22.2 mmol/l
- Elevated activated partial thromboplastin time (aPTT)
- International Normalized Ratio (INR) >1.7
- Platelet count below 100,000 per cubic millimetre
- Current use of direct thrombin inhibitors or direct factor Xa inhibitors with elevated insensitive global coagulation tests or a quantitative test of drug activity (i.e., Hemoclot for Dabigatran*, specific factor Xa activity assays for Rivaroxaban* and Apixaban*)

CT or MRI findings

- Any haemorrhage on brain CT or MRI
- CT showing early signs of extensive infarction, or MRI showing an infarct volume > 150 ml on diffusion-weighted imaging

If patient is not a candidate for thrombolysis, then the following should be instituted:

- Start oral Aspirin 50-325mg (LOE A) daily in acute state
 - Clopidogrel is a better option after the acute phase in secondary prevention (LOE B)
 - Other options are available (see pages 87/88 on secondary prevention of stroke)
- Oral Atorvastatin 40-80mg nocte or Rosuvastatin 20-40mg nocte
- → Do not crash the BPs with iv antihypertensives (use iv only in hypertensive emergency, see pages 71-72)
- Manage blood sugars and maintain sugars between 6-10 mmol/l

- Manage pyrexia with preferably iv paracetamol and tepid sponging
- SC Enoxaparin 40mg or Dalteparin 5000 IU daily as thrombo-prophylaxis
- Start physiotherapy as soon as possible
- Patients with carotid artery stenosis of more than 50% and symptomatic can be considered for carotid endarterectomy or stenting

2. TRANSIENT ISCHAEMIC ATTACK

The risk stratification tool, the ABCD2 score has been developed to help identify patients at high risk of recurrent events with the aim of determining the need for urgent hospitalisation and investigation²¹. The total ABCD2 score ranges from 0 to 7. A score of 4 or more or 2 or more TIAs in 24 hours is an indication for admission.

Clinical features	Points
Age is 60 years or older	1
Blood pressure >140/90 mmHg	1
Clinical features: Unilateral weakness Speech disturbance without weakness	2
Duration: • >60 minutes • 10-60 minutes • <10 minutes	2 1 0
Diabetes	1

ABCD² score points (Total score 0-7)

There is about 80% reduction in the risk of stroke after TIA with the early implementation of secondary stroke prevention strategies²³, these include:

- Anticoagulation of patients with atrial fibrillation
- Treatment with antiplatelet agent(s)
- Treatment with statins for most patients
- Management of hypertension
- Revascularisation of patients with symptomatic carotid artery stenosis
- Lifestyle modification

3. HEAD CT SCAN CONFIRMED HAEMORRHAGE

Intracerebral haemorrhage remains a significant cause of morbidity and mortality. It contributes to severe longterm disability. Treatment includes both medical and surgical options depending on the severity of the clinical state and availability of medical resources.

Medical treatment centres on:

- → Reducing intracranial pressure
- → Preventing haematoma expansion
- → BP control

a. Raised intracranial pressure

Non-pharmacological management

- Elevate the head of the bed by 20-30°
- Hyperventilation for those on ventilatory support

Pharmacological management

- iv Mannitol 20% solution in a dose range of 0.2-2.0g/kg body weight every 6-8 hours over 48 hours; each dose should run over 15-30 minutes; (if Mannitol is not available or contraindicated such as impaired renal function, iv Furosemide is a good option)
- Use iv Furosemide 40mg 12 hourly, if patient is known to have CKD or renal impairment
- Oral Acetazolamide 250mg bd can be added if CT scan shows acute hydrocephalus or if there is a refractive oedema to any of the above medications
- Corticosteroids such as Dexamethasone do not have demonstrated efficacy in the treatment of cytotoxic oedema as seen in stroke; routine use of Dexamethasone should be avoided²⁴

b. Haematoma expansion

Controlling BPs prevent haematoma expansion. For patients with primary or secondary problems with haemostasis or taking oral anti-coagulants such as **Warfarin**, replacement of vitamin K (iv vitamin K 10mg daily for 3 days) is recommended. There is an additional benefit in adding prothrombin to correct INR as it is superior to FFPs²⁵.

c. Hypertension

When BP is more than 180/110 mmHg, it can lead to re-bleed, haematoma expansion and worsening of the oedema. BP control should aim at maintaining the BP between 140/80 mmHg and 180/110 mmHg. Mean arterial pressure however should not drop more than 25% within 24 hours.

iv antihypertensives such as continuous iv **Labetalol** infusion at 5-20mg per hour can be used in the acute control of BP above 180/110 mmHg; iv **Hydralazine** should be avoided as it causes rebound hypertension.

d. Statins

Early introduction of statins have significantly improved 30 day survival rate following bleeding events. Patients who received statins are more likely to be discharged home than those who did not²⁶.

e. Seizures

Monitor for seizures: if patient has a seizure give oral antiseizure medications (e.g. **Carbamazepine** 200mg daily or **Levetiracetam** 250mg daily).

→ Refer all recurrent seizures in a day or seizures lasting more than 30 minutes to the next level of care

f. Anticoagulation and DVT prophylaxis

Prophylactic anticoagulation against venous thromboembolism can be initiated 48 hours after an acute bleed. There is also added benefit to the use of intermittent pneumatic compressions²⁷.

4. SUBARACHNOID HAEMORRHAGE (SAH)

SAH is a neurosurgical emergency. The emergency management of SAH should involve ABC of basic resuscitation. Patients who cannot maintain their airway should be immediately intubated. This includes patients who are in coma, in stupor from hydrocephalus and patients who need to be sedated on account of agitation. Until patient can have endovascular coiling or surgical clipping, medical management should be instituted to prevent complications of SAH. General management include headache management, BP control, management of hydrocephalus, prevention of cerebral vasospasms and delayed cerebral infarct.

a. Headache

Use of opioids, e.g. **Morphine** (iv Morphine 4mg 6 hourly), is preferred. **Dexamethasone** (iv Dexamethasone 4mg 8 hourly) may also be used.

b. Blood pressure control

When BPs are above 160 mmHg systolic, iv antihypertensive, e.g. **Labetalol** should be used. Continuous iv infusion is preferred at 5-20mg per hour. iv **Hydralazine** should be avoided as it causes rebound hypertension.

c. Hydrocephalus

In the event of hydrocephalus, Tab Acetazolamide 250mg three times daily can be used. An external ventricular drainage (EVD), is also a surgical option even though there is increased risk of infection. In the case of communicating hydrocephalus however, lumbar drainage can be used in place of EVD. For prophylaxis against raised ICP, straining should be reduced with the use of stool softeners such as lactulose.

d. Delayed cerebral ischemia

Tab Nimodipine[•] 60mg 4 hourly is used in the prevention of delayed cerebral ischemia. Duration of this treatment is on average 21 days. Adequate maintenance of normal blood volume with fluids is recommended. Prophylactic anticoagulation should be avoided. Pneumatic stocking compression can be used instead.

e. Hyponatremia

Hyponatremia is a known complication of SAH due to the syndrome of inappropriate ADH secretion (SIADH), or cerebral salt wasting syndrome. Serum sodium should therefore be monitored and replaced appropriately.

f. Seizures

Use of antiepileptic medications is mainly limited to the period before surgical treatment of the aneurysm and is not needed after surgical treatment except in cases of ongoing seizures. Levetiracetam and Carbamazepine are preferred. Phenytoin is generally not recommended as it causes neurocognitive decline²⁸.

g. Prevention of rebleed

iv **Tranexamic** acid, 1g 8 hourly for 72 hours, can be used to avoid rebleeding pending endovascular or surgical intervention. Prolonged use however increases the risk of VTEs, strokes and MI.

→ After stabilisation, all SAH patients should be referred for clipping or coiling.

NB: Coiling however is the preferred choice as it has a better outcome.

 \rightarrow Patients with SAH should be on admission for at least two weeks.

5.2.4 COMPLICATIONS OF STROKE

Medical complications following stroke are common and are associated with poor clinical outcomes, increased length of stay and higher rates of readmission, increased cost of care, delayed time to rehabilitation, and increased mortality²⁹. While the majority of deaths that occur in the first week of stroke are attributable to ischaemic stroke, mortality beyond the first week is attributable to the complications of stroke^{30,31}.

Early complications

- Malignant cerebral oedema
- Haemorrhagic transformation of ischaemic brain tissue
- Infections, eg aspiration pneumonia/lobar pneumonia and urinary tract infection (UTI)
- Venous thromboembolism
- Bed sores
- Seizures


Late complications


- Seizures/epilepsy
- Depression
- Falls

5.2.5 REFERRAL

Ideally all stroke cases should be referred to a Stroke Unit immediately for optimal care from a multidisciplinary team (MDT = the medical, neurosurgical, nursing, physiotherapy, clinical psychologist, occupational therapist, dietician, speech and language therapist).

→ All stroke cases should be referred to a facility with a physician specialist. The physician specialist will have to follow the algorithm *below* to refer to a stroke unit.





Discharge plan

Discharge plan should be initiated from day one of admission with the MDT. *Below is a table* for the scoring system for ROSIER scale:

Table 40: The recognition of stroke in the emergency room (ROSIER) scale³²

ROSIER Scale				
Stroke Assessment				
The aim of this assessmen stroke and stroke mimics.	t tool is to enable med	dical and nurs	ng staff to differer	ntiate patients with
Assessment	Date	Time		
Symptom onset	Date	Time		
GCS E = M = V = \rightarrow ⁺ If blood sugar < 3.5	-		s once blood gluc	ose is normal
Has there been loss of consciousness or syncope? Y (-1) N (0)			N (0)	
Has there been seizure activity?		Y (-1)	N (0)	
Is there a NEW ACUTE or	iset (or on awakening	g from sleep))	
I. Asymmetric facial we	eaknes s		Y (+1)	N (0)
II. Asymmetric arm wea	kness		Y (+1)	N (0)
III. Asymmetric leg weak	iness		Y (+1)	N (0)
IV. Speech disturbance			Y (+1)	N (0)
V. Visual field defect			Y (+1)	N (0)
			*Total score	_ (-2 to +5)
Provisional diagnosis: 🗌	stroke 🗌 Non-stroke	(specify)		
*Stroke is likely if total s	cores are >0			

Scores of </= 0 have a low possibility of stroke but not completely excluded

5.2.6 PATIENT EDUCATION AND PREVENTION

Some medical conditions and lifestyle choices can predispose anyone to stroke. Persons at risk must therefore be educated about their existing health conditions, the need for healthy lifestyle modification plans and to report for management when they feel unwell.

 \rightarrow Refer to *chapter 2* of these guidelines.

i. PREVENTION OF RECURRENT INFARCTIVE STROKE

About 80% of recurrent ischaemic strokes can be prevented using a combined approach of lifestyle and intensive medical therapy³⁴. However, only about 30% of patients who have ischaemic stroke receive all the appropriate recurrent stroke prevention measures.

In secondary prevention of stroke, the ABCDE approach can be adopted:

- A Antiplatelet/anticoagulation
- B Blood pressure control/blood glucose control
- **C** Cholesterol medication
- D Diet
- E Exercise and lifestyle modification

A Antiplatelet/anticoagulation

In the general prevention of recurrent ischaemic stroke, it is recommended to maintain patients on antiplatelet medications. Three options are available when deciding on antiplatelet therapy:

- Aspirin 50-325mg daily (LOE A)
- Aspirin + extended release Dipyridamole* 25mg/200mg twice daily (LOE B)
- Clopidogrel 75mg daily (LOE B)

Aspirin plus extended release Dipyridamole⁺ or Clopidogrel is a better secondary prevention option than Aspirin alone^{35,36}.

Long term Aspirin use with Clopidogrel is not recommended as it increases the risk of haemorrhage^{37,38}.

The choice of anti-platelets medications may however be dependent on:

- Patient preference
- Cost
- Comorbidities

For cardioembolic strokes such as atrial fibrillation, the use of anticoagulation is based on the risk stratification scores (e.g. CHA2DS2-VASc) and the bleeding risk scores (e.g. HASBLED).

 \rightarrow Refer to *chapter 5.9* on arrhythmia.

B Blood pressure control

 \rightarrow Refer to *chapter 5.1* on hypertension.

B Blood glucose control

 \rightarrow Refer to appropriate guidelines.

C Cholesterol medications

High intensity statin use is recommended in the prevention of recurrent ischaemic stroke. The two medications indicated are

- Atorvastatin 80mg daily⁴³
- Rosuvastatin 20-40mg daily⁴⁴

D Diet control

 \rightarrow Refer to *chapter 2* of these guidelines.

E Exercise and lifestyle modification

 \rightarrow Refer to *chapter 2* of these guidelines.

REFERENCES

- 1 Hatano S. Experience from a multicentre stroke register: A preliminary report. Bull World Health Organ. 1976; 54(5): 541–553.
- 2 Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ (Buddy), Culebras A, et al. An Updated Definition of Stroke for the 21st Century. Stroke. 2013; 44(7): 2064–2089.
- 3 Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation. 2015; 131(4): 29–322.
- 4 World Health Organization (WHO). The top ten leading causes of death by broad income group. Fact sheet. 2011. Available from: https://www.premierheart.com/webapp/downloads/who_stats.pdf.
- 5 Daniels M, Donilon T, Bollyky TJ. The Emerging Global Health Crisis: Noncommunicable Diseases in Low- and Middle-Income Countries. Council on Foreign Relations Independent Task Force Report No. 72. 2016. Available from: https://ssrn.com/abstract=2685111.
- 6 Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: A systematic review. The Lancet Neurology. 2009; 8(4): 355–369.
- 7 Walker R, Gray WK, Whiting D, Unwin N, Alberti G, Walker R, et al. Stroke incidence in rural and urban Tanzania: a prospective, community-based study. The Lancet Neurology. 2010; 9(8), 786–792.
- Ezejimofor MC, Uthman OA, Maduka O, Ezeabasili AC, Onwuchekwa AC, Ezejimofor BC, et al. Stroke survivors in Nigeria: A door-to-door prevalence survey from the Niger Delta region. Journal of the Neurological Sciences. 2017 Jan 15; 372: 262–269.
- 9 Walker RW, Jusabani A, Aris E, Gray WK, Whiting D, Kabadi G, et al. Post-stroke case fatality within an incident population in rural Tanzania. Journal of Neurology, Neurosurgery, and Psychiatry. 2011; 82(9): 1001–1005.
- 10 Sarfo FS, Awuah DO, Nkyi C, Akassia J, Opare-Sem OK, Ovbiagele B. Recent patterns and predictors of neurological mortality among hospitalized patients in Central Ghana. Journal of the Neurological Sciences. 2016; 363: 217–224.
- 11 Agyemang C, Attah-Adjepong G, Owusu-Dabo E, De-Graft Aikins A, Addo J, Edusei AK, et al. Stroke in Ashanti region of Ghana. Ghana Medical Journal. 2012; 46 (2 Suppl): 12–17.
- 12 De-Graft Aikins A. Ghana's neglected chronic disease epidemic: a developmental challenge. Ghana Medical Journal. 2007; 41 (4): 154–159.
- 13 Agyei-Mensah S, De-Graft Aikins A. Epidemiological transition and the double burden of disease in Accra, Ghana. Journal of Urban Health. 2010; 87 (5): 879–97.
- 14 Cappuccio FP, Micah FB, Emmett L, Kerry SM, Antwi S, Martin-Peprah R, et al. Prevalence, Detection, Management and Control of Hypertension in Ashanti, West Africa. Hypertension. 2004; 43 (5): 1017–1022.
- 15 Agyemang C, Owusu-Dabo E. Prehypertension in the Ashanti region of Ghana, West Africa: An opportunity for early prevention of clinical hypertension. Public Health. 2008; 122 (1): 19–24.
- Agyemang C. Rural and urban differences in blood pressure and hypertension in Ghana, West Africa. Public Health. 2006; 120 (6): 525–533.
- 17 Addo J, Smeeth L, Leon DA. Prevalence, detection, management, and control of hypertension in Ghanaian civil servants. Ethnicity & Disease. 2008; 18 (4): 505–511.
- 18 Owolabi MO, Sarfo F, Akinyemi R, Gebregziabher M, Akpa O, Akpalu A, et al. Dominant modifiable risk factors for stroke in Ghana and Nigeria (SIREN): A case-control study. The Lancet Global Health. 2018; 6 (4): 436–446.
- 19 Goyal MS, Hoff BG, Williams J, Khoury N, Wiesehan R, Heitsch L, et al. Streamlined hyperacute magnetic resonance imaging protocol identifies tissue-type plasminogen activator-eligible stroke patients when clinical impression is stroke mimic. Stroke. 2016; 47: 1012–1017.
- 20 Sinha AM, Diener HC, Morillo CA, Sanna T, Bernstein RA, Di Lazzaro V, et al. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): Design and rationale. American Heart Journal. 2010; 160 (1): 36–41.
- 21 Rothwell PM, Giles MF, Flossmann E, Lovelock CE, Redgrave JNE, Warlow CP, et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet. 2005; 366 (9479): 29–36.
- 22 Quinn TJ, Cameron AC, Dawson J, Lees KR, Walters MR. ABCD2 scores and prediction of noncerebrovascular diagnoses in an outpatient population: A case-control study. Stroke. 2009; 40 (3): 749–53.
- 23 Lavallée PC, Meseguer E, Abboud H, Cabrejo L, Olivot JM, Simon O, et al. A transient ischaemic attack clinic with round-theclock access (SOS-TIA): feasibility and effects. The Lancet Neurology. 2007; 6 (11): 953–960.
- 24 Wijdicks EFM, Sheth KN, Carter BS, Greer DM, Kasner SE, Kimberly WT, et al. Recommendations for the management of cerebral and cerebellar infarction with swelling: A statement for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2014; 45 (4): 1222–1238.

- 25 Moussouttas M, Malhotra R, Fernandez L, Maltenfort M, Holowecki M, Delgado J, et al. Role of antiplatelet agents in hematoma expansion during the acute period of intracerebral hemorrhage. Neurocritical Care. 2010; 12 (1),24–29.
- ²⁶ Flint AC, Conell C, Rao VA, Klingman JG, Sidney S, Johnston SC, et al. Effect of statin use during hospitalization for intracerebral hemorrhage on mortality and discharge disposition. JAMA Neurology. 2014; 71 (11): 1364–71.
- 27 Dennis M, Sandercock P, Graham C, Forbes J. The Clots in Legs or stockings after Stroke (CLOTS) 3 trial: A randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness. Health Technology Assessment. 2015; No. 19. 76.
- 28 Naidech AM, Kreiter KT, Janjua N, Ostapkovich N, Parra A, Commichau C, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke. 2005; 36 (3): 583–587.
- 29 Ingeman A, Andersen G, Hundborg HH, Svendsen ML, Johnsen SP. In-hospital medical complications, length of stay, and mortality among stroke unit patients. Stroke. 2011 ;42 (11): 3214–3218.
- 30 Silver FL, Norris JW, Lewis AJ, Hachinski VC. Early mortality following stroke: A prospective review. Stroke. 1984; 15 (3): 492–496.
- 31 Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ, et al. Medical and neurological complications of ischemic stroke: Experience from the RANTTAS trial. Stroke. 1998; 29 (2): 447–453.
- 32 Nor AM, Davis J, Sen B, Shipsey D, Louw SJ, Dyker AG, et al. The Recognition of Stroke in the Emergency Room (ROSIER) scale: Development and validation of a stroke recognition instrument. The Lancet Neurology. 2005; 4 (11): 727–734.
- 33 British Columbia Ministry of Health. Stroke and Transient Ischemic Attack Acute and Long-Term Management Risk Factors and Primary Prevention. 2015.
 - Available from: https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/stroketia_2015_full.pdf.
- Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: A quantitative modeling study. Stroke. 2007; 38 (6): 1881–1885.
- 35 Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. The Lancet. 2006: 367 (9523): 1665–1673.
- 36 Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal. 2005 Sep; 150 (3): 401.
- 37 Diener PHC, Bogousslavsky PJ, Brass PLM, Cimminiello PC, Csiba PL, Kaste PM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. The Lancet. 2004; 364 (9431): 331–337.
- 38 Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA (POINT). New England Journal of Medicine. 2018; 379: 215–225.
- 39 Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45 (7): 160–236.
- 40 Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. The Lancet. 2010; 375 (9718): 895–905.
- 41 Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective pioglitazone Clinical Trial in macrovascular Events): A randomised controlled trial. The Lancet. 2005; 366 (9493): 1279–1289.
- 42 Viscoli CM, Brass LM, Carolei A, Conwit R, Ford GA, Furie KL, et al. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke Trial. American Heart Journal. 2014; 168 (6): 823–829.
- 43 Goldstein LB, Amarenco P, Zivin J, Messig M, Altafullah I, Callahan A, et al. Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke. 2009; 40 (11): 3526–3531.
- 44 De Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: A critical reappraisal. JAMA Internal Medicine. 2010; 170 (12): 1032–1036.

STROKE

5 DISEASES

5.3 CHEST PAIN, CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION

LIST OF ABBREVIATIONS AND ACRONYMS

ACS	Acute Coronary Syndromes	IHD	Ischemic Heart Disease
ASCVD	Atherosclerotic Cardiovascular	LOE	Level of Evidence
	Disease	MI	Myocardial Infarction
CABG	Coronary Artery Bypass Graft	NSTEMI	Non-ST Elevation Myocardial
COPD	Chronic Obstructive Pulmonary		Infarction
	Disease	PAD	Peripheral Artery Disease
CAD	Coronary Artery Disease	PCI	Percutaneous Coronary
ECG	Electrocardiogram		Intervention
FBC	Full Blood Count	STEMI	ST Elevation Myocardial
GERD	Gastro-Oesophageal Reflux		Infarction
	Disease	UA	Unstable Angina

5.3.1 INTRODUCTION

i. **DEFINITION**

Atherosclerosis of the coronary arteries leads to clinical conditions, which usually come with varying degrees of chest pain or symptoms equivalent to chest pain due to myocardial ischaemia, injury or infarction. Worldwide, atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality¹. Coronary artery atherosclerosis results in plaque formation starting with fatty streaks and gradually leading to overt obstructive plaque. Thus, atherosclerosis of coronary arteries, also referred to as coronary artery disease (CAD), may lead to fixed obstruction of the coronary arteries or dynamic obstruction when there is plaque rupture or erosion resulting in thrombus formation and coronary vasospasm. Fixed severe obstructions usually result in myocardial ischaemia due to reduced blood supply, which if prolonged and severe gives rise to stable ischaemic heart disease. On the other hand, acute coronary vasospasm or dynamic obstructions would usually lead to myocardial injury and if prolonged and severe, results in myocardial infarction infarction or cell death.

ii. EPIDEMIOLOGY

There are many causes of imbalance between myocardial blood supply and demand, however, CAD is notably the most common. Many preventive and risk factor modifications are geared towards reducing the incidence of CAD. Worldwide, heart attacks accounted for 7.2 million deaths in 2005¹. Although data on CAD in Ghana is scanty, the consensus among many cardiologists and internists in Ghana is that the prevalence is increasing.

Pathological changes in coronary arteries	Clinical presentation
Fixed stenosis	Angina or stable angina
Acute or subacute thrombus formation/spasm	Unstable angina (UA)
	Non-ST Elevation Myocardial Infarction (NSTEMI)
	ST Elevation Myocardial Infarction (STEMI)

Table 41: Pathological changes affecting myocardial blood supply and demand

5.3.2 STABLE CORONARY ARTERY DISEASE

i. CLINICAL PRESENTATION

Stable CAD is characterized by angina pectoris, a clinical presentation of myocardial ischaemia brought on by exertion or stress and relieved by rest or Nitroglycerin[•]. There is usually no cardiomyocyte necrosis. Myocardial ischaemia in patients with stable CAD is a result of a mismatch between blood supply and metabolic demand. Reduced blood supply to the heart will result in abnormal myocardial function including regional wall motion abnormalities, ST-T wave changes on the 12-lead ECG (electrocardiogram) and cardiac ischaemic pain (angina)^{2,3}.

ii. SYMPTOMS

Angina pectoris - a sensation of "strangling in the chest"², is associated with chest pain:

- which is 'squeezing', 'tight' or 'gripping' or 'choking' in character (patient may place clenched fist over precordium to describe the pain – Levine's sign)
- may radiate to the left arm, neck or jaw

Angina equivalent symptoms (cardiac symptoms other than chest pain)

- dyspnoea on exertion
- exertional nausea
- syncope
- palpitations
- mid-epigastric discomfort or sharp chest pain in women, diabetics and the elderly^{4, 5, 3}

Definition	Characteristics
Typical angina or definite angina	 Must meet all three criteria below: Substernal chest pain or discomfort with characteristic duration usually less than 10 minutes (2 to 5 minutes) Brought on by exertion or emotional stress Relieved by rest or Nitroglycerin*/Glyceryl trinitrate
Atypical angina or probable angina	Meets 2 of the above characteristics
Non-anginal chest pain	Meets 1 or none of the typical anginal characteristics

Table 42: Characteristics of angina versus other forms of chest pain

iia. FUNCTIONAL CLASSIFICATION OF ANGINA

The severity of angina is based on the severity of chest pain due to the myocardial ischaemia. One way of documenting the severity of angina is by using the functional classification of angina by the Canadian Cardiovascular Society.

Functional Class	Description of levels of activity that bring on chest pain/angina
Class I	Ordinary activity such as walking or climbing stairs does not cause angina; angina occurs with strenu- ous, rapid or prolonged exertion at work or recreation
Class II	Slight limitation of ordinary activity; angina occurs on walking or climbing stairs rapidly, walking or stair climbing after meals, in cold wind or under emotional stress
Class III	Marked limitation of ordinary physical activity; walking one or two blocks (e.g. walking 50-300) metres on the flat on the level and climbing one flight of stairs in normal conditions and at normal pace
Class IV	Inability to carry on any physical activity without discomfort, anginal syndrome may be present at rest

iib. PRE-TEST RISK ASSESSMENT OF PATIENTS PRESENTING WITH CHEST PAIN

There are three variables important in predicting risk of presence of CAD in a patient presenting with symptoms of chest pain/angina, angina or angina equivalents:

- 1. Age: The older the patient, the more likely the patient has significant coronary artery disease
- 2. Type of Pain: Typical angina presentation is more likely to be due to CAD. Non anginal chest pain, fleeting chest pain, pins and needles are less likely due to CAD
- 3. Gender: Males are more likely to have coronary artery disease compared to females below menopausal age

Table 44 below should be used to assess a patient's pretest probability of having coronary artery disease should they present with chest pain⁷.

Table 44: CAD pretest proba	bilities (%) in patients v	with stable chest pain sympto	oms

	Typical angina		Atypical angina		Non-anginal pain	
Age	Men	Women	Men	Women	Men	Women
30-39	59	28	29	10	18	5
40-49	69	59	38	14	25	8
50-59	77	69	49	20	34	12
60-69	84	77	59	28	44	17
70–79	89	84	69	37	54	24
>80	93	76	78	47	65	32

(>85%) - Very high-risk patients

(66-85%) - High-risk patients (15-65%) - Medium-risk patients

iic. COMMON CAUSES OF CHEST PAIN

Chest pain can have several causes. As opposed to chronic recurrent chest pain, all patients with new onset chest pain should be evaluated under the differential diagnosis of myocardial infarction/heart attack as discussed below⁸.

Table 45: Mimics	of	angina	other	causes	of	chest	pain
------------------	----	--------	-------	--------	----	-------	------

Causes of chest pain	Features
Angina	 Substernal chest pain or discomfort with characteristic duration usually less than 10 minutes (2 to 5 minutes) Brought on by exertion or emotional stress Relieved by rest or Nitroglycerin*/Glyceryl trinitrate
GERD (Gastro-eesophageal reflux disease)	 Symptoms worse at night, early morning, may have chronic nocturnal cough Symptoms usually abate with avoidance of certain foods and late eating
Cholelithiasis	Worse after eating. especially fatty food
Peptic ulcer disease	May be worse with hunger and relived with antacids
Musculoskeletal	Worse with movement and reproducible with palpation
Radiculopathy/cervical spondylosis	Associated with numbness, neuropathic pain and neck pain
Herpes zoster	Very painful superficial blisters along dermatome; may not have rash
Psychiatric	Usually there is a precipitant and exaggerated description of detailed symptoms
Mild chronic heart failure	Patients may have exertional dyspnea due to heart failure and may present as angina equivalent; usually, they will have leg swelling and nocturnal symptoms of congestion
Pneumonia	Associated with pleurisy, cough and fever

iii. SIGNS

- Most patients may have no signs
- Diaphoresis (excessive sweating)
- Pulse rate may be increased or decreased
- Blood pressure may be increased or decreased
- Skin signs of hyperlipidaemia such as the presence of xanthelasma may be a pointer to atherosclerosis


5.3.3 MANAGEMENT OF STABLE CAD

i. TREATMENT OBJECTIVES

- Relieve chest pain and any other symptoms
- Improve quality of life
- Prevent complications of CAD such as acute myocardial infarction or heart failure
- Identify and manage modifiable risk factors
- Prevent cardiovascular related death

ia. STRATEGIES FOR ACHIEVING TREATMENT OBJECTIVES

- Educate patients about the aetiology, clinical manifestations, treatment options and prognosis of ischaemic heart disease (IHD); encourage active participation of patients in their treatment decisions
- Identify and treat conditions that contribute to, worsen, or complicate IHD
- Effectively modify risk factors for IHD by both pharmacological and nonpharmacological methods
- Use evidence-based pharmacological treatments to improve patients' health status and survival, with attention to avoiding drug interactions and side effects



ii. MANAGEMENT ACCORDING TO LEVEL OF CARE^{10,4}

iia. HEALTH FACILITY WITHOUT A DOCTOR

NON-LABORATORY INVESTIGATION

Blood Pressure

LABORATORY INVESTIGATION

- Full blood cell count
- Oxygen saturation
- Blood sugar

NON-PHARMACOLOGICAL TREATMENT

 \rightarrow Educate the patient by the patient education/information guide below.

Healthy lifestyle modifications:

- Weight control maintenance of a BMI of 18.5 to 24.9 kg/m², maintenance of a waist circumference less than 102 cm (40 inches) in men and less than 88 cm (35 inches) in women
- Lipid management
- Ensure compliance with BP control
- Smoking cessation and avoidance of exposure to second-hand smoke
- \rightarrow Refer patient to a health facility with a doctor.

iib. HEALTH FACILITY WITH A DOCTOR

NON-LABORATORY INVESTIGATION

- Blood pressure
- ECG
- Chest X-ray

LABORATORY INVESTIGATION

- Full blood cell count
- Oxygen saturation
- Blood sugar
- Lipid profile
- BUE/creatinine

NON-PHARMACOLOGICAL TREATMENT

\rightarrow Educate the patient by the patient education/information guide below.

Healthy lifestyle modifications:

- Weight control maintenance of a BMI of 18.5 to 24.9 kg/m², maintenance of a waist circumference less than 102 cm (40 inches) in men and less than 88 cm (35 inches) in women (less for certain racial groups)
- Lipid management
- BP control: ensure compliance with BP control
- Smoking cessation and avoidance of exposure to second-hand smoke

Risk factor management (LOE A)

Identify and manage risk factors such as hypertension, diabetes and hyperlipidaemias

- Optimise or initiate treatment for hypertension (refer to chapter 5.1 of these guidelines)
- Optimise or initiate treatment for diabetes mellitus
- Optimise cholesterol treatment (refer to *chapter 2* of these guidelines)
- Identify heart failure (refer to chapter 5.4 of these guidelines)

PHARMACOLOGICAL TREATMENT

ANTI-ANGINAL THERAPY (LOE A)

- Glyceryl trinitrate, sublingual 500mg then as required for the relief of chest pain; instruct patient to report if pain is not resolving
 - and
- Bisoprolol, oral 2.5-10mg daily depending on BP and response or
- Carvedilol, oral 3.125-25mg 12 hourly depending on BP and response or
- Metoprolol, oral 50-100mg 8-12 hourly depending on BP and response or
- Metoprolol XL, oral 25-50mg daily

- or
- Atenolol, oral 50-100mg daily depending on BP and response or
- Propranolol, oral 20-80mg 12 hourly depending on BP and response
- → NOTE: Avoid Beta-blockers in bronchial asthma, bradycardia and hypotension; avoid Atenolol in heart failure.

If patient is asthmatic or requires further antianginal medication, consider Verapamil and Diltiazem* (LOE A)

- Diltiazem*, oral 60-120mg 12 hourly or extended release preparations. or
- Verapamil, oral 80mg to 160mg 8hrly or extended release preparations. or
- Amlodipine, oral 5-10mg daily or
- Nifedipine XL, oral 30-60mg daily or
- Nifedipine, oral 10-40mg 12 hourly or
- Felodipine*, oral 5-10mg daily
- → Avoid in bradycardia, hypotension and in patients with heart failure; for Verapamil and Diltiazem⁺, avoid if patient is already on Beta-blockers.

ANTIPLATELET THERAPY (LOE A)

- Aspirin, oral 75mg daily
- or
- Clopidogrel, oral 75mg daily if allergic to Aspirin or GI intolerance
- \rightarrow Dual antiplatelet is not indicated unless high risk patient (new onset, severe angina).
- If further antianginal therapy is needed, or if Beta-blockers or Verapamil are contraindicated, then use:
- Isosorbide Dinitrate, oral 10mg 8-12 hourly or
- Isosorbide Mononitrate, oral 30-120mg daily
- → Patients on Sildenafil or other phosphodiesterase 5 inhibitors should not be placed on nitrates.
- Consider: Trimetazidine*, oral 35mg 8hrly or
- Consider: Ranolazine⁺, oral 500mg 12hrly
- → Refer patient to a health facility with a physician specialist, if there is no significant improvement in symptoms after the initial treatment above or the patient has worsening signs.

iic. HEALTH FACILITY WITH A PHYSICIAN SPECIALIST/FAMILY PHYSICIAN

NON-LABORATORY INVESTIGATION

- Blood pressure
- ECG
- Stress ECG
- Echocardiography
- Chest X-ray

LABORATORY INVESTIGATION

- Full blood count
- Oxygen saturation
- Blood sugar
- Lipid profile
- BUE/creatinine

NON-PHARMACOLOGICAL TREATMENT

\rightarrow Educate the patient by the patient education/information guide below.

Healthy lifestyle modifications:

- Weight control maintenance of a BMI of 18.5 to 24.9 kg/m², maintenance of a waist circumference less than 102 cm (40 inches) in men and less than 88 cm (35 inches) in women
- Lipid management
- BP control: Ensure compliance
- Smoking cessation and avoidance of exposure to second-hand smoke

Risk factor management (LOE A)

Identify and manage risk factors such as hypertension, diabetes and hyperlipidaemias.

- Optimise or initiate treatment for hypertension (refer to chapter 5.1 of these guidelines)
- Optimise or initiate treatment for diabetes mellitus
- Optimize cholesterol treatment (refer to chapter 2 of these guidelines)
- Identify heart failure (refer to chapter 5.4 of these guidelines)

PHARMACOLOGICAL TREATMENT

ANTI-ANGINAL THERAPY (LOE A)

- Glyceryl trinitrate, sublingual 500micrograms, then as required for the relief of chest pain; instruct patient to report if pain is not resolving and
- Bisoprolol, oral 2.5-10mg daily depending on BP and response or
- Carvedilol, oral 3.125-25mg 12 hourly depending on BP and response or
- Metoprolol, oral 50-100mg 8-12 hourly depending on BP and response or
- Metoprolol XL, oral 25-50mg daily

- or
- Atenolol, oral 50-100mg daily depending on BP and response or
- Propranolol, oral 20-80mg BD depending on BP and response
- → NOTE: Avoid Beta-blockers in bronchial asthma, bradycardia and hypotension; avoid Atenolol in heart failure.

If patient is asthmatic or requires further antianginal medications consider Verapamil and Diltiazem* (LOE A)

- Diltiazem⁺, oral 60-120mg 12 hrly or extended release preparations or
- Verapamil, oral 80-160mg 8 hrly or extended release preparations or
- Amlodipine, oral 5-10mg daily or
- Nifedipine XL, oral 30-60mg daily or
- Nifedipine, oral 10-40mg 12hourly or
- Felodipine*, oral 5-10mg daily
- → Avoid in bradycardia, hypotension and in patients with heart failure; for Verapamil and Diltiazem⁺, avoid if patient is already on Beta-blockers.

ANTIPLATELET THERAPY (LOE A)

- Aspirin, oral, 75mg daily or
- Clopidogrel, oral 75mg daily if allergic to Aspirin or GI intolerance
- \rightarrow Dual antiplatelet is not indicated except high risk patient (new onset, severe angina).

If further antianginal therapy needed or if beta-blockers or Verapamil are contraindicated:

- Isosorbide Dinitrate, oral 10mg 8-12 hourly
- or
- Isosorbide Mononitrate, oral 30-120mg daily
- → Patients on Sildenafil or other phosphodiesterase 5 inhibitors should not be placed on nitrates.
- Consider: Trimetazidine*, oral 35mg 8hourly or
- Consider: Ranolazine⁺, oral 500mg 12hourly
- → Refer patient to a specialised centre or a cardiologist, if there is no significant improvement in symptoms after the initial treatment above or the patient has worsening signs.
- → After initial stabilization, patient should be referred to cardiologist for further investigation and management. Thereafter, patient should be referred back to primary physician for continuation of care.

iid. SPECIALISED CENTRE WITH A CARDIOLOGIST

NON-LABORATORY INVESTIGATION

Additional to investigation undertaken at the level of care with a physician specialist: Coronary angiogram with

- Fractional flow reserve if available
- Intravascular ultrasound if available

LABORATORY INVESTIGATION

 \rightarrow Same as in a healthy facility with a physician specialist.

TREATMENT

- Confirm diagnosis
- Ensure guideline medical therapy/optimal medical therapy with adequate doses
- Coronary angioplasty with or without stent for severe obstructive CAD with moderate to severe symptoms or ischaemia while on optimal medical therapy
- CAD is significant if stenosis is >70% (>50% left main CAD) or there is significant functional testing (Fractional Flow Reserve (FFR)<0.80)
- Consider CABG for multiple vessel disease and SYNTAX score >22, left main disease and young diabetic with multivessel disease

5.3.4 PATIENT EDUCATION/INFORMATION

- The importance of medication adherence for managing symptoms and retarding disease progression
- How to recognize worsening cardiovascular symptoms and the need to rush to a medical facility once such symptoms occur
- How to recognise worsening cardiovascular symptoms
- Adherence to a diet that is low in saturated fat, cholesterol, and trans-fat; high in fresh fruits, whole grains, and vegetables
- Importance of healthy lifestyle modification

5.3.5. PREVENTION OF STABLE CAD

Stable CAD is prevented by the modification of its risk factors (refer to chapter 2 of these guidelines).

5.3.6 ACUTE CORONARY SYNDROMES (ACS)

i. INTRODUCTION

Acute coronary syndromes (ACS) are caused by acute to subacute lack of myocardial blood supply and/or increased myocardial demand leading to cardiomyocyte injury and necrosis. There are three clinical entities making up the acute coronary syndromes based on the pathophysiology and electrocardiographic (ECG) features at presentation². The three types of ACS include:

- Unstable Angina (UA)
- Non-ST Segment Elevation Myocardial Infarction (NSTEMI)
- ST Segment Elevation Myocardial Infarction (STEMI)

ECG changes during severe myocardial ischaemia and/or injury is used as an initial screening and diagnostic tool for all patients presenting with acute to subacute chest pain. Unlike the pain of of stable angina (fixed chronic stenosis), acute coronary syndromes usually present acutely with severe chest pain, which may wax and

Acute coronary syndrome (STEMI, NSTEMI and unstable angina) ST-segment elevation Nonspecific ECG changes Normal Troponin ST-segment depression T-wave inversion Normal CK-MB Figure 15: Acute coronary syndromes: Troponin Troponin STEMI, NSTEMI and UA CK-MB CK-MB **STEMI** NSTEMI Unstable angina

wane depending on the severity of coronary occlusion. Aside from electrocardiography, cardiac biomarkers are also used to further distinguish between unstable angina and NSTEMI as seen in *figure 15*.

ii. AETIOLOGY

The leading cause of ACS is CAD². However, there are other less prevalent causes, which need to be mentioned. The table below shows the aetiology and possible mechanisms of ACS.

Table 46: Causes of acute coronary syndrome

Aetiology of ACS	Mechanism		
Coronary artery disease	Plaque rupture resulting in sub-totally occlusive thrombus on pre-existing plaque and distal microvascular thromboembolism from plaque-associated thrombus		
	Plaque Erosion resulting in sub-totally occlusive thrombus on pre-existing plaque and distal microvascular thromboembolism from plaque-associated thrombus		
	Progressive mechanical obstruction to coronary flow		
Coronary spasm or vasoconstriction	Dynamic obstruction of epicardial and/or microvascular obstruction to coronary flow		
Coronary artery dissection	Arteritis and thrombus formation		
Thromboembolism from plaque erosion	Plaque-associated coronary thromboembolism		
Secondary unstable angina	Anaemia, hyperthyroidism		

Platelet aggregation and recruitment is key to propagation of the thrombus. The sequalae of coronary artery occlusion, irrespective of the cause depends on the territory supplied by the vessel, the presence or absence of collaterals (new vessel formation due to the chronic ischaemia), duration of the occlusion as well as the metabolic state of the at-risk myocardium, i.e. the adaptation of the myocardial cells to chronic ischaemia prior to the acute or subacute occlusion².

iii. SYMPTOMS

Chest pain/discomfort - the description of this pain/discomfort may be vague.

Usually, it is a left substernal pain but can be from any part of the chest; the pain may or may not radiate to the jaw and arm. In STEMI and NSTEMI, the pain is usually associated with other features such as shortness of breath, syncope/pre-syncope nausea, vomiting, palpitations, diaphoresis and anxiety.

Atypical presentations (with absence of chest pain):

- Shortness of breath
- Excessive belching
- Nausea
- Vomiting
- Epigastric discomfort
- Easy fatigability
- Loss of consciousness
- Cardiac arrest
- Delirium or confusion
- → NOTE: These atypical symptoms are common among diabetics, women, the elderly and patients with deformed chest wall and patients with COPD.

iv. DIFFERENTIAL DIAGNOSES OF ACS

As opposed to stable CAD, ACS patients should not be evaluated based on the triad of gender, age and type of chest pain. All patients presenting with acute chest pain should be presumed to be experiencing one form of ACS or another until proven otherwise. The OPQRST is a mnemonic used to help differentiate the aetiology of acute chest pain.

<i>Table 47:</i> How to use the mnemonic "OPQRST"	Table 47: How 1	to use	the	mnemonic	"OPQRST"
---	-----------------	--------	-----	----------	----------

Historical aspects of chest pain: The OPQRST approach					
Onset	What the patient was doing when it started (active, inactive, stressed), whether the patient believes that activity prompted the pain, and whether the onset was sudden, gradual or part of an ongoing chronic problem?				
Provocation & Palliation	What provoked the pain or what relieved the pain?				
Quality	What is the quality of the pain: burning, aching, squeezing, or stabbing?				
Region & Radiation	Where is the pain located? Is there any radiation of the pain; does it go to the neck, jaw, arm, or back?				
Severity	How severe is the pain? On a scale of 1 to 10, with 10 being the worse pain in one's life, what is the pain now, and how has it changed?				
Timing	What are the temporal aspects of the pain? How long has it been present? Has it occurred before? When?				

Table 48: Clinical characteristics of acute coronary syndrome compared with other causes of acute chest pain using the mnemonic "OPQRST"

Chest pain Aetiology	O Onset	P Provocation and Palliation	Q Quality	R Region and Radiation	S Severity	T Timing
Acute coronary syndrome	Rapid over a few minutes, escalating or recurring	Usually sponta- neous; not relieved by rest or nitrates	Crushing, tight, heavy or band-like	Central anterior chest; radiates to throat, jaw, arms or no radiation	Usually severe	Minutes to few hours, may resolve after completion of infarct
Thoracic aortic dissection	Sudden, severe	Maybe worse with straining	Tearing, sharp, lancinating	Central; radiates to the back	Severe	Minutes to hours
Tension Pneumothorax	Sudden, severe	Relieved by sitting still and breath holding or hypopnoea	Lancinating, tearing, sharp	Unilateral on the side of the pneumothorax	Severe	Minutes to few hours
Pulmonary Embolism	Sudden or gradual	Pleuritic, if pulmonary infarction	Pleuritic, if pulmonary infarction	Unilateral on the side of the PE	Dull ache or sharp pleuritic	Hours to days
Acute Pericarditis with/without effusion	Gradual onset may follow a febrile illness	Worse lying supine; better sitting forward	Sharp, "pleuritic-like"	Central ante- rior; usually no radiation	Severe	Hours to days
Musculoskeletal pain eg: intercostal muscle spasm	Sudden (e.g. intercostal muscle spasm) or gradual (e.g. costochon- dritis)	Worse with movement or activity invol- ving the muscle group or joint, reproducible by palpation; relieved by restriction of movement	Sharp, restric- ting or dull	Anywhere on chest wall; radiates to arms, around the chest to the back	Variable inten- sity: mild to severe	Hours to days, usually chronic, recurrent and reproducible
Ruptured/perforated Oesophagus	Sudden, follo- wing retching and or vomiting	Worse with swallowing	Sharp, tearing	Central	Severe	Minutes to hours
Oesophageal spasm	Sudden, recurrent	Lying flat may provoke pain; sometimes relieved by nitrates but not by rest	Burning, gripping	Central anterior or epigastric; radiates often to the back	Usually mild but can mimic MI	Night-time common, variable dura- tion

v. MANAGEMENT

Patients with myocardial infarct (MI) may present iwth cardiac arrest (fast ventricular tachycardia or ventricular fibrillation). In such cases, refer to *chapter 4 Cardiac arrest* for management (see *page 46*).

Figure 16 (next page) is a pathway for decision making based on the symptoms and availability of ECG.

 \rightarrow All facilities without ECG should immediately refer any patient with acute chest pain.




Figure 16: Pathway for triaging and managing a patient presenting acute Chest Pain

va. TREATMENT OBJECTIVES

- Relief of pain, shortness of breath and anxiety
- Prevent myocardial cell death
- Prevent complications
- Improve prognosis

The above are achieved using the following 5 modalities of treatment depending on the level of care:

- Anti-ischaemic therapy (e.g.; oxygen, nitrates, Beta-blockers)
- Anti-platelet therapy (e.g.; Aspirin, Clopidogrel, Ticagrelor*)
- Anti-coagulation therapy (e.g.; Heparin, Enoxaparin)
- Disease modification therapy (e.g.; statins, ACEi)
- Revascularisation (reserved for specialized centres, depending on capacity of trained cardiologists)

vi. MANAGEMENT ACCORDING TO LEVEL OF CARE

via. HEALTH FACILITY WITHOUT A DOCTOR

NON-LABORATORY INVESTIGATION

- Blood pressure
- ECG, if available

LABORATORY INVESTIGATION

- Full blood cell count
- Blood sugar
- Oxygen saturation
- Sickling test

PHARMACOLOGIC TREATMENT

Aspirin, oral 300mg stat (LOE A)

→ Refer immediately to the nearest hospital with a doctor or to a physician specialist (if immediately accessible).

vib. HEALTH FACILITY WITH A DOCTOR/PHYSICIAN SPECIALIST

NON-LABORATORY INVESTIGATION

- 12-lead ECG
- Blood pressure in both arms
- Chest Xray
- Oxygen saturation

LABORATORY INVESTIGATION

- Blood sugar
- Cardiac biomarkers (Troponin/CKMB)
- Blood lipid profile
- BUE/creatinine

PHARMACOLOGICAL THERAPY

ANTI-ISCHAEMIA (LOE A)

- Give oxygen if oxygen saturation is < 95%
- **Glyceryl trinitrate**, sublingual 500mg then as required for the relief of chest pain; instruct patient to report if pain is not resolving
- → NOTE: Avoid nitrates if hypotensive or inferior wall infarct or if phosphodiesterase inhibitor has been used by the patient in the last three days.

Add any Beta-blocker below:

- → NOTE: Beta-blockers should be avoided in bronchial asthma, bradycardia and hypotension; avoid Beta-blockers in patients with fulminant heart failure.
- Bisoprolol, oral 2.5-10mg daily depending on BP and response

or

- Carvedilol, oral 3.125-25mg 12 hourly depending on BP and response or
- Metoprolol, oral 25-100mg 8-12 hourly depending on BP and response or
- Metoprolol XL, oral 25-200mg daily or
- Atenolol, oral 50-100mg daily depending on BP and response or
- Propranolol, oral 20-80mg 12 hourly depending on BP and response (LOE A)

If patient is asthmatic or requires further antianginal medications consider Verapamil and Diltiazem*:

- Diltiazem⁺, oral 60-120mg 12 hourly or extended release preparations or
- Verapamil, oral 80-160mg 8 hourly or extended release preparations
- \rightarrow Avoid in bradycardia, hypotension and in patients already on Beta-blockers.

ANTIPLATELET (LOE A)

- Aspirin, oral 300mg stat then 75mg daily and
- Clopidogrel, oral 600mg stat then 75mg daily or
- Ticagrelor*, oral 180mg stat then 90mg BD

ANTICOAGULATION (LOE A)

• Heparin 4,500 to 5,000 units iv bolus or 60-80 units per kg iv bolus followed by 18 units per kg per hour infusion for 72 hours

CONTINUATION OF CARE

- Optimise or initiate treatment for hypertension (refer to chapter 5.1 of these guidelines)
- Optimise or initiate treatment for diabetes mellitus per appropriate guideline
- Optimise cholesterol treatment (refer to chapter 2 of these guidelines)
- Identify heart failure early and manage (refer to chapter 5.4 of these guidelines)
- Maximize optimal medical therapy before stress testing in patients with unstable angina
- → Refer patient to a cardiologist if there is no significant improvement in symptoms after the initial treatment above or the patient has worsening signs.

vic. SPECIALISED CENTRE WITH A CARDIOLOGIST

NON-LABORATORY INVESTIGATION

- 12-lead ECG
- Blood pressure in both arms
- Chest X-ray
- Stress test in the case of unstable angina
- Coronary angiography
- Fractional flow reserve
- Intravascular ultrasound

LABORATORY INVESTIGATION

- Blood sugar
- Cardiac biomarkers (Troponin/CKMB)
- Blood lipid profile
- BUE/creatinine

PHARMACOLOGICAL AND INVASIVE TREATMENT (LOE A)

Confirm diagnosis: Ensure guideline medical therapy/optimal medical therapy with adequate doses. Consider emergent revascularisation:

- Fibrinolytic therapy (maximum benefit obtained when given within 3 hours after onset of chest pain but can be given up to 6 hours after onset)
- Coronary angioplasty with or without stenting for obstructive CAD with moderate to severe symptoms or ischaemia while on optimal medical therapy
- \rightarrow If patient cannot afford any of these therapies, maximise medical therapy.
- → Always call for a second opinion when in doubt or refer.

REVASCULARIZATION IN ACS

A critical step in the management of patient with high-risk unstable angina, Non-STEMI and STEMI is revascularisation. Revascularisation is reserved for facilities with trained interventional cardiologist. The flow diagram extracted from ESC guidelines gives a step-by-step approach to managing patients with acute coronary syndrome (unstable angina and NSTEMI). Due to accessibility and socioeconomic factors, in-

tensification of medical therapy is recommended for all patients. And only those capable should be offered an invasive strategy.




Figure 17: Selection of non-ST-elevation acute coronary syndrome (NSTE-ACS) treatment strategy and timing according to initial risk stratification⁸

ST ELEVATION MYOCARDIAL INFARCTION (STEMI)

All patients with STEMI are eligible for reperfusion therapy and should be transferred immediately to the next level of care preferably to the chest pain centres of excellence with experienced cardiologist and/or interventional cardiologist to be evaluated for revascularisation using fibrinolytic therapy or percutaneous coronary angioplasty and stent placement.

Patients for fibrinolytic therapy should be carefully evaluated and contraindications cross-checked and documented.


Contraindications to fibrinolytic therapy		
Absolute	Relative	
Previous intracranial haemorrhage or stroke or stroke of unknown origin	Transient ischaemic attack in the preceding 6 months	
Ischaemic stroke in preceding 6 months	Oral anticoagulant therapy	
Central nervous system damage or neoplasms or arteriove- nous malformation	Pregnancy or within 1 week postpartum	
Recent major trauma/surgery/head injury (within the preceding month)	Refractory hypertension (SBP >180 mmHg and/or DBP >110 mmHg)	
Gastrointestinal bleeding within the past month	Advanced liver disease	
Known bleeding disorder (excluding menses)	Infective endocarditis	
Aortic dissection	Active peptic ulcer	
Non-compressible punctures in the past 24 hours (e.g. liver biopsy, lumbar puncture)	Prolonged or traumatic resuscitation	

Commonly used fibrinolytics and their doses		
Drug	Initial treatment doses	Specific contraindication
Streptokinase*	1.5 million units over 30-60 minutes IV	Previous treatment with Streptokinase or Anistreplase
Alteplase [◆] (tPA)	15mg bolus IV 0.75mg/kg iv over 30 minutes (maximum 50mg) then 0.5mg/kg iv over 60 minutes (up to 35mg)	
Reteplase [◆] (rPA)	10 units iv bolus followed by 10 units I.V. bolus 30 minutes apart	
Tenecteplase* (TNK-tPA)	Single iv bolus based on body weight: If < 60 kg give 30mg (6000 units) If 60 to 70 kg, give 35mg (7000 units) If 70 to <80 kg, give 40mg (8000 units) If 80 to <90 kg, give 45mg (9000 units) If >90 kg, give 50mg (10000 units) It is recommended to reduce to half-dose in patients >75 years of age	
Consult an interventional cardiologist before therapy for possible rescue PCI		

Table 50: Commonly used fibrinolytics and their doses¹¹

The decision to either have patient undergo reperfusion therapy using primary percutaneous coronary intervention (PCI) depends on time of presentation and availability of either therapies. Fibrinolytic therapy is given an equal rating to primary PCI in Ghana.

PCI may be performed hours after the onset of chest pain. It is recommended that patients be referred to see an interventional cardiologist for discussions on whether to pursue an invasive strategy for risk stratification and opening of the affected vessel.



*Figure 18: Reperfusion strategies in the infarct-related artery according to time from symptoms onset PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction*¹¹

REFERENCES

- 1 World Health Organization. Cardiovascular disease. 2018. Available from: https://www.who.int/cardiovascular_diseases/en/
- 2 Bonow RO, Mann DL, Tomaselli GF, Zipes DP, Libby P. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 2018.
- 3 Kumar P, Clark M. Clark's Clinical Medicine. 2016.
- 4 Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Circulation. 2014; 130(19): 1749–1767.
- 5 Montalescot G et al. 2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal. 2013; 34(38): 2949–3003.
- 6 Campeau L. Letter: Grading of angina pectoris. Circulation. 1976; 54(3): 522–523.
- 7 Genders TSS, Steyerberg EW, Alkadhi H, Leschka S, Desbiolles L, Nieman K, et al. A clinical prediction rule for the diagnosis of coronary artery disease: Validation, updating, and extension. European Heart Journal. 2011; 32(11): 1316–1313.
- 8 Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of of the European Society of Cardiology (ESC). European Heart Journal. 2016; 37(3): 267–315.
- 9 Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology 2019 Mar 17; 735-1097
- 10 Sousa-Uva M, Neumann FJ, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-Thoracic Surgery. 2019; 55(1): 4–90.
- 11 Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2018; 33(20): 2569–2619.

5 **DISEASES**

5.4 HEART FAILURE

LIST OF ABBREVIATIONS AND ACRONYMS

ACC	American College of Cardiology	HfrEF	Heart failure with reduced
AF	Atrial fibrillation		ejection fraction
AHA	American Heart Association	LOE	Level of evidence
FBC	Full blood count	LVEF	Left ventricular ejection
FBS	Fasting blood sugar		fraction
HF	Heart failure	NYHA	New York Heart Association
HfpEF	Heart failure with preserved		
	ejection fraction		

5.4.1 INTRODUCTION

i. **DEFINITION**

Heart failure (HF) is a clinical syndrome characterized by abnormal function of the heart leading to dyspnoea and oedema. The abnormal function of the heart may be due to structural or functional impairment of ventricular filling or ejection/pumping of blood. This leads to inadequate cardiac output to meet the requirements of tissue metabolism.

Clinical diagnosis of HF can be generally classified based on whether it is associated with a reduced left ventricular ejection fraction (LVEF) below 50% heart failure with reduced ejection fraction (HFrEF) or preserved LVEF of 50% or more heart failure with preserved ejection fraction (HFpEF)¹.

ii. EPIDEMIOLOGY

HF has a prevalence rate of 1-2% of the adult population is reported, rising to \geq 10% among people >70 years of age in most developed countries².

The lifetime risk of HF at age 55 years is 33% for men and 28% for women. The proportion of patients with HFpEF ranges from 22% to 73%, depending on the definition applied. Compared with HFrEF, patients with HFpEF are older, more often women and more commonly have a history of hypertension and atrial fibrillation (AF), while a history of myocardial infarction is less common¹.

In sub-saharan Africa, unlike in high-income countries, HF is predominantly caused by hypertension, dilated cardiomyopathies and rheumatic heart disease (a form of heart valve disease)⁴. Right heart failure due to pulmonary hypertension secondary to non-smoking related chronic lung disease and HIV-related disease remain other significant causes of heart failure in the region⁵. HF has a prognosis worse than most cancers with a 5-year mortality up to 50%³.

iii. CLASSIFICATION OF HEART FAILURE

The NYHA classification is based on the individual's functional limitation (dyspnoea) due to the heart failure. The ACC/AHA staging of HF is based on pathological changes causing heart failure. This ranges from risk factors of HF to structural abnormalities of the heart and its limitations.

iiia. NEW YORK HEART ASSOCIATION (NYHA) CLASSIFICATION OF HF⁴

- Class 1: No symptoms and no limitation of ordinary physical activity
- Class II: No symptoms at rest but slight limitation of ordinary activity
- Class Ill: No symptoms at rest but marked limitation of ordinary physical activity (activity of daily living)
- Class IV: Symptoms at rest and worse during any physical activity

iiib. THE AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION (ACC/ AHA) STAGING SYSTEM IN HF⁵

- Stage A: High risk of heart failure but no structural heart disease or symptoms of heart failure
- Stage B: Structural heart disease but no symptoms of HF
- Stage C: Structural heart disease and symptoms of HF
- Stage D: Refractory heart failure requiring specialized therapy

5.4.2 AETIOLOGY

Causes of heart failure include:

- Hypertension (most common cause in Sub-Saharan Africa)
- Valvular heart disease; especially rheumatic heart disease
- Dilated cardiomyopathy; usually non-ischaemic
- Arrhythmias; most commonly atrial fibrillation
- Peripartum cardiomyopathy
- Ischaemic heart disease commonly due to CAD
- Pericardial disease
- Endomyocardial fibrosis
- Infective endocarditis
- Congenital heart disease
- Cor pulmonale (right HF due to lung disease)

5.4.3 CLINICAL PRESENTATION

i. SYMPTOMS AND SIGNS

Table 51: Symptoms and signs

Symptoms and signs of heart failure	
Symptoms	Signs
Typical • Breathlessness • Orthopnoea • Paroxysmal nocturnal dyspnoea • Fatigue • Reduced exercise tolerance	 Specific Elevated jugular venous pressure Hepatojugular reflux Third heart sound with or without gallop rhythm Laterally displaced apical impulse
 Atypical Nocturnal cough Wheezing Bloated feeling Loss of appetite Confusion (usually in the elderly) Palpitations Syncope Bendopnea (shortness of breath when bending forward) 	 Less specific Cardiac murmur Peripheral oedema (ankle, sacral, scrotal) Pulmonary crepitations Reduced air entry and dullness to percussion at lung bases (pleural effusion) Tachycardia Irregular pulse Tachypnoea Cheyne-Stokes respiration Hepatomegaly Ascites Cold extremities Narrow pulse pressure

5.4.4 ASPECTS OF MANAGEMENT RELEVANT FOR ALL LEVELS OF CARE The diagnosis of heart failure with reduced ejection fraction requires 3 conditions to be satisfied:

- Typical symptoms of HF
- Typical signs of HF
- LVEF below 50% on Echocardiogram

The diagnosis of of heart failure with preserved ejection fraction requires 4 conditions to be satisfied:

- Typical symptoms of HF
- Typical signs of HF
- LVEF 50% on Echocardiogram
- Presence of structural heart disease and/or diastolic dysfunction

i. NON-PHARMACOLOGICAL TREATMENT RELEVANT FOR ALL LEVELS

- Diet and nutrition
- Decrease salt intake
- Smoking cessation
- Avoidance of alcohol
- Fluid intake
 - Fluid restriction in severe HF to not more than 1500mls/day carried out in accordance with daily weighing
- Supervised exercise training based on the patient's exercise tolerance level

5.4.5 MANAGEMENT ACCORDING TO LEVEL OF CARE

Acute heart failure (AHF) develops when there is rapid onset or deterioration of typical symptoms and/or signs of HF leading to hospital admission. When an AHF occurs for the first time, it is described as a 'de novo' AHF. More commonly, AHF develops as a consequence of acute decompensation of chronic HF.

i. HEALTH FACILITY WITHOUT A DOCTOR

ia. ACUTE HEART FAILURE

LABORATORY INVESTIGATION

- Full blood cell count
- Fasting blood sugar

NON-PHARMACOLOGICAL TREATMENT

In acute situation:

- Admit patient and prop up in bed
- Give oxygen in case of hypoxaemia (SPO2 <90%) (oxygen should not be given routinely in the absence of hypoxaemia)
- Give oxygen from 4-10l per minute until SPO2 >92% in a propped-up position

PHARMACOLOGICAL TREATMENT

Diuretics:

- Furosemide 40-80mg 8-12 hourly iv
- \rightarrow Refer patient to a health facility with a doctor.

ib. CHRONIC HEART FAILURE

 \rightarrow Refer patient to a health facility with a doctor.

ic. ATRIAL FIBRILLATION

 \rightarrow Refer to a health facility with a physician specialist.

ii. HEALTH FACILITY WITH A DOCTOR

iia. ACUTE HEART FAILURE

LABORATORY INVESTIGATION

- Full blood cell count
- Fasting blood sugar
- BUE/Creatinine

OTHER INVESTIGATION

- Chest x-ray
 - Possible findings: upper lobe venous blood diversion, pulmonary oedema or Kerley B lines, cardiomegaly-CTR (cardio-thoracic ratio) of > 0.5, pleural effusions; usually right sided Chest X-ray may also rule out differential diagnoses such as pneumonia, chronic obstructive pulmonary disease or pulmonary tuberculosis
- Electrocardiography (ECG)
 - Possible findings: sinus tachycardia, sinus bradycardia, atrioventricular blocks, a bundle branch block pattern, atrial fibrillation, left ventricular hypertrophy, atrial abnormality, right ventricular hypertrophy, among others

NON-PHARMACOLOGICAL TREATMENT

- Patient should be propped up in bed
- Give oxygen in case of hypoxaemia (SPO2 <90%) (oxygen should not be given routinely in the absence of hypoxaemia)

iib. CHRONIC HEART FAILURE

PHARMACOLOGICAL TREATMENT

Diuretics - LOE B

In patients with resistant oedema (and ascites), a combination of a loop and a thiazide (e.g. **Bendroflumethiazide** 2.5–10mg daily orally) or thiazide-like diuretic (Metolazone 2.5–10mg daily orally) may be needed to achieve adequate diuresis.

Table 52: Diuretics used in heart failure

Diuretics used in heart failure		
Diuretic	Initial dose (mg)	Usual daily dose (mg)
Loop diuretic		
 Furosemide (oral/iv) 	20-80mg 8-12 hourly	20-420mg 8-12 hourly
 Bumetanide⁺ (oral) 	• 0.5-1.0mg b.d.	 1-5mg b.d.
 Torasemide[*] (oral) 	 5-10mg o.d. 	 10-20mg o.d.
Thiazide/thiazide-like diuretic		
 Metolazone (oral) 	■ 5mg o.d.	 2.5-10mg o.d.
 Hydrochlorothiazide (oral) 	 25mg o.d. 	 12.5-100mg o.d.
 Bendroflumethiazide (oral) 	 2.5mg o.d. 	 2.5-10mg o.d.

Digoxin – LOE B

- In patients with symptomatic HF and atrial fibrillation, digoxin may be used, in addition to a Beta-blocker to slow down a rapid ventricular rate
- Digoxin may also be used in patients with HFrEF in sinus rhythm, who are symptomatic despite full tolerated doses of HF standard therapy; digoxin is less effective in the presence of hypokalemia or hypocalcaemia however avoid in hypercalcemia or hypomagnesaemia which may predispose to serious arrhythmias

Neurohomornal blockers (disease modifying drugs)

These have been shown to improve survival in patients with HFrEF; by reducing the risk of death and/or hospitalisation. They include:

- Angiotensin converting enzyme inhibitors (ACEI) LOE A An ACEI is recommended for all patients with symptomatic HFrEF to reduce the risk of death and hospitalisation
- Angiotensin receptor blockers (ARB)

ARBs are recommended for patients with HFrEF who are unable to tolerate an ACEI because of cough (patients should also receive a BB and an MRA); they are also recommended for patients with HFrEF who have persisting symptoms (NYHA class II – IV) despite treatment with an ACEI and a BB, and who are unable to tolerate an MRA. ARBs have not been consistently proven to reduce mortality in patients with HFrEF

- Angiotensin receptor neprilysin inhibitor (ARNI) LOE B An ARNI is recommended to all patients with symptomatic HFrEF to reduce the risk of death and hospitalization
- Beta-blockers LOE A

A Beta-blocker is recommended for all patients with symptomatic HFrEF to reduce the risk of death and hospitalisation; patients should be on an ACEI (or ARB if an ACEI is not tolerated).

Mineralocorticoid receptor antagonists (MRA) – LOE A

An MRA is recommended for all patients with HFrEF and persisting symptoms (NYHA class II - IV) despite treatment with an ACEI (or an ARB if an ACEI is not tolerated) and a Beta-blocker; mine-ralocorticoid receptor antagonists block receptors that bind aldosterone and other corticosteroids; they have been shown to improve survival in patients with HFrEF

See table 53: Disease modifying medication in heart failure and their doses on next page.

Thrombo-embolism prophylaxis is recommended in all patients with no contra-indication to anticoagulation, to reduce the risk of deep vein thrombosis during admission. Long term anticoagulation is not recommended for chronic HF unless there is a cardiac thrombus, embolic event or atrial fibrillation.

Disease modifying medication in heart failure and their doses				
Drug	Initial dose Target dose			
ACE-I • Lisinopril • Captopril* • Ramipril	 2.5-5.0mg o.d. 6.25mg t.i.d. 2.5mg o.d. 	 20-35mg o.d. 50mg t.i.d. 5mg b.d. 		
 Kampril Enalapril 	2.5mg b.d	5mg b.d.10-20mg b.d.		
Beta-blocker Bisoprolol Carvedilol Metoprolol succinate (CR/XL)	 1.25mg o.d. 3.125mg b.i.d. 12.5-25mg o.d. 	 10mg o.d. 25-50mg b.d. 200mg o.d 		
ARB • Candesartan • Valsartan • Losartan	4-8mg o.d.40mg b.d.25mg o.d	32mg o.d.320mg o.d.150mg o.d		
MRA Spironolactone	 25mg o.d. 	 50mg o.d. 		
<i>ARNI</i> ■ Sacubitril [◆] /Valsartan	■ 49/51mg b.d.	■ 97mg/103mg b.d.		

Table 53: Disease modifying medication in heart failure and their doses

iic. ATRIAL FIBRILLATION

PHARMACOLOGICAL TREATMENT

- Digoxin (125-250 micrograms daily orally) and/or Beta-blocker should be considered
- Amiodarone* may be considered as per guidelines
- \rightarrow Refer to a health facility with a physician specialist.

iii. HEALTH FACILITY WITH A PHYSICIAN SPECIALIST

iiia. ACUTE HEART FAILURE

LABORATORY INVESTIGATION

- Full blood cell count
- Kidney function test
- Liver function test
- Thyroid function test
- B-type natriuretic peptides (BNPs) and N-terminal pro-B-type natriuretic peptide (NT-ProBNP) assays (BNP >100pg/ml or NT-ProBNP >300pg/ml in patients who present acutely and BNP >35pg/ml or NT-ProBNP >125pg/ml in patients who present with chronic symptoms virtually exclude the diagnosis of HFrEF.)

For some patients there may be the need to screen for the precipitant of the acute heart failure. These include:

- Infection screen: urine routine examination and culture
- Blood culture

- Chest Xray for pneumonia
- ECG for arrhythmia
- BUE/Cr for CKD
- Markers for acute coronary syndrome: Troponin and CK-MB
- D-Dimer for pulmonary embolism

OTHER INVESTIGATION

- Chest X-ray (possible findings: upper lobe venous blood diversion, pulmonary oedema or Kerley B lines, cardiomegaly-CTR of >0.5, pleural effusions; usually right sided.) CXR may also rule out differential diagnoses such as pneumonia, chronic obstructive pulmonary disease or pulmonary tuberculosis.
- ECG (possible findings: sinus tachycardia, sinus bradycardia, atrioventricular blocks, a bundle branch block pattern, atrial fibrillation, left ventricular hypertrophy, atrial abnormality)⁶.
- Echocardiogram to assess structural heart changes (e.g. valvular defects, congenital defects, ischaemic changes) as the cause of the heart failure. The overall systolic and diastolic function of the ventricles could also be assessed.

NON-PHARMACOLOGICAL TREATMENT

- Admit patient and prop up in bed
- Give oxygen in case of hypoxaemia (SPO₂ <90%) (oxygen should not be given routinely in the absence of hypoxaemia)
- Give oxygen from 4L to 15L per minute until SPO₂ >92% in a propped-up position
- Non-invasive positive pressure ventilation (e.g. CPAP) is recommended in patients with respiratory distress (respiratory rate >30-35 breaths/minute and SpO₂ <90% in spite of intranasal O₂ or rebreather mask); non-invasive positive pressure ventilation reduces blood pressure and should be used with caution in hypotensive patients
- Intubation should be considered if hypoxaemia, hypercapnia and/or acidosis cannot be managed non-invasively and also when patient is fatigued

PHARMACOLOGICAL TREATMENT

- Diuretic therapy important to reduce congestion. This include Furosemide and for resistant cases Metolazone may be combined; Bumetanide⁺, Torasemide⁺ are other options
- \rightarrow Refer to *table 54* for the doses of diuretics.
- Treatment of the precipitant such as infections, arrhythmia, acute coronary syndrome and pulmonary embolism
- Patients in cardiogenic shock with no evidence of coronary artery disease, pulmonary embolism or hypovolaemia, short-term intravenous inotropic support with Dobutamine 0.5-1mg/kg/min should be given as continuous infusion

iiib. CHRONIC HEART FAILURE

PHARMACOLOGICAL TREATMENT

Diuretics-LOE B

They are recommended to patients with symptoms and signs of fluid overload. Loop diuretics are preferred in HFrEF. In patients with marked fluid overload, intravenous loop diuretics should be given as bolus doses or continuous infusion using syringe pump. A combination of loop diuretic and **Metolazone** (a thiazide-like diuretic) is recommended for resistant oedema.

 \rightarrow Example of diuretics used in HF and their doses are shown in the *table next page*:

Table 54: Diuretics used in heart failure

Diuretics used in heart failure		
Diuretic	Initial dose	Usual daily dose
Loop diuretic		
 Furosemide (oral/iv) 	20-80mg 8-12 hourly	20-420mg 8-12 hourly
 Bumetanide⁺ (oral) 	 0.5-1.0mg b.d. 	■ 1-5mg b.d.
 Torasemide⁺ (oral) 	 5-10mg o.d. 	■ 10-20mg o.d.
Thiazide/thiazide-like diuretic		
 Metolazone (oral) 	■ 5mg o.d.	2.5-10mg o.d.
 Hydrochlorothiazide (oral) 	25mg o.d.	12.5-100mg o.d.
 Bendroflumethiazide (oral 	 2.5mg o.d. 	 2.5-10mg o.d.

Digoxin – LOE B

In patients with symptomatic HF and atrial fibrillation, digoxin may be used, in addition to a Betablocker to slow down a rapid ventricular rate.

Digoxin may also be used in patients with HFrEF in sinus rhythm, who are symptomatic despite full tolerated doses of HF standard therapy; digoxin is less effective in the presence of hypokalemia or hypocalcaemia. However avoid in hypercalcemia or hypomagnesaemia which may predispose to serious arrhythmias.

Neurohormonal blockers (disease modifying drugs)

These are medications, which have been shown to improve survival in patients with HFrEF; by reducing the risk of death and/ or hospitalization.

They include:

Angiotensin converting enzyme inhibitors (ACEI) - LOE A

An ACEI is recommended for all patients with symptomatic HFrEF to reduce the risk of death and hospitalisation.

- Angiotensin receptor blockers (ARB) An ARBs is recommended for patients with HFrEF who are unable to tolerate an ACEI because of cough (patients should also receive a BB and an MRA). It is also recommended in patients with HFrEF who have persisting symptoms (NYHA class II - IV) despite treatment with an ACEI and a BB, and who are unable to tolerate an MRA. ARBs have not been consistently proven to reduce mortality in patients with HFrEF.
- Angiotensin receptor neprilysin inhibitor (ARNI) LOE B An ARNI is recommended to all patients with symptomatic HFrEF to reduce the risk of death and hospitalization.
- Beta-blockers LOE A

A Beta-blocker is recommended for all patients with symptomatic HFrEF to reduce the risk of death and hospitalisation. Patients should be on an ACEI (or ARB if an ACEI is not tolerated).

Mineralocorticoid Receptor Antagonists (MRA) – LOE A An MRA is recommended for all patients with HFrEF and persisting symptoms (NYHA class II - IV) despite treatment with an ACEI (or an ARB if an ACEI is not tolerated) and a Beta-blocker. MRAs block receptors that bind aldosterone and other corticosteroids. They have been shown to improve survival in patients with HFrEF.

Disease modifying medication	Initial dose	Target dose
ACEI • Lisinopril • Captopril • Ramipril • Enalapril Beta-blocker	 0.2.5-5.0mg o.d. 6.25mg t.i.d. 2.5mg o.d. 2.5mg b.d 	 20-35mg o.d. 50mg t.i.d. 5mg b.d. 10-20mg b.d.
 Bisoprolol Carvedilol Metoprolol succinate (CR/XL) 	 1.25mg o.d. 3.125mg b.i.d. 12.5-25mg o.d. 	10mg o.d.25-50mg b.d.200mg o.d
ARB • Candesartan • Valsartan • Losartan	 4-8mg o.d. 40mg b.d. 25mg o.d 	32mg o.d.160mg o.d.150mg o.d
MRA Spironolactone	 25mg o.d. 	 50mg o.d.
<i>ARNI</i> ■ Sacubitril [◆] /Valsartan	■ 49/51mg b.d.	■ 97mg/103mg b.d.

Table 55: Disease modifying medication in heart failure and their doses

• Combination of Hydralazine and nitrates - LOE B

A combination of Hydralazine and nitrates is recommended for patients with symptomatic HFrEF who are intolerable to an ACEI or ARB to reduce the risk of death and hospital admission. Patients should be on a Beta-blocker and an MRA. Recommended doses of the combinations are:

- Hydralazine 10-25mg 3 times daily orally, increased to 75mg 3 times daily, orally
- Isosorbide dinitrate 10mg 3 times daily, orally, increased to 40mg 3 times daily, orally

Ivabradine – LOE B

lvabradine[•] slows the heart rate in sinus rhythm by inhibiting the If channel in the sinus node. It is recommended for patients with symptomatic HFrEF in sinus rhythm with heart rate >70 bpm despite maximum doses of Beta-blocker, and, an ACEI (or ARB) and an MRA (or ARB). It has been shown to reduce heart failure hospital admissions in these patients.

iv. HEALTH FACILITY WITH A CARDIOLOGIST

iva. ADDITIONAL NON-LABORATORY INVESTIGATION

- Echocardiography
- Coronary angiography
- Left and right heart haemodynamic evaluation
- Ambulatory ECG monitoring (Holter)
- Ambulatory blood pressure monitoring
- Cardiac magnetic resonance imaging (CMR)
- Genetic testing

ivb. DEVICE/INTERVENTIONAL THERAPY

Implantable cardioverter-defibrillator - LOE B

An implantable cardioverter defibrillator is recommended to reduce sudden cardiac death in patients with symptomatic HFrEF and a LVEF \leq 35%, who are expected to survive for >1 year with good functional status.

Cardiac resynchronizing therapy (CRT)

CRT is recommended to reduce hospital admissions and premature deaths in patients with HFrEF in sinus rhythm with a QRS duration of \geq 120 ms, LBBB QRS morphology, and a LVEF \leq 35%, who are expected to survive with good functional status for >1 year.

CRT should be considered to reduce hospital admissions and premature deaths in patients with HFrEF in sinus rhythm with a QRS duration of \geq 150 ms, irrespective of QRS morphology, and an LVEF \leq 35% who are expected to survive with good functional status for >1 year.

ive. MANAGEMENT OF PATIENTS WITH HYPERTENSION AND HEART FAILURE WITH RE-DUCED EJECTION FRACTION (HFREF)

Calcium channel blockers with negative ionotropic effects such as **Diltiazem**[•] and **Verapamil** should not be used to treat hypertension in patients with HFrEF, and **Moxonidine**[•] should also be avoided in patients with HFrEF as it is associated with increased mortality. Short-acting **Nifedipine** is contraindicated in HFrEF.

ivd. MANAGEMENT OF PATIENTS WITH ANAEMIA AND HEART FAILURE

In patients with NYHA class II and III HF and iron deficiency (Ferritin⁺ <100ng/ml or 100-300ng/ml if transferrin saturation is <20%), intravenous iron replacement given cautiously might be reasonable to improve functional status.

REFERENCES

- 1 National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand (NHFA/CSANZ) Heart Failure Guidelines 2018.
- 2 Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). European Journal of Heart Failure. 2016; 18 (8): 891–975.
- ³ Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM. ACC/AHA/HFSA Focused Update Guideline for the Management of Heart Failure. Circulation. 2017; 136 (6): 137–161.
- 4 New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels/the Criteria Committee of the New York Heart Association. 1964.
- 5 American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2005

5 DISEASES

5.5 VENOUS THROMBOEMBOLISM

LIST OF ABBREVIATIONS AND ACRONYMS

ANA	Antinuclear antibody	LMWH	Low-molecular-weight heparin
CEA	Carcinoembryonic antigen	NOAC	Novel oral anticoagulant
CRP	C-reactive protein	PE	Pulmonary embolism
CTEPH	Chronic thromboembolic	PSA	Prostate specific antigen
	pulmonary hypertension	PTS	Post thrombotic syndrome
CTPA	CT pulmonary angiography	USG	Ultra sonography
DTV	Deep vein thrombosis	VTE	Venous thromboembolism
FBC	Full blood count	WBC	White blood cell count
IPC	Intermittent pneumatic		
	compression		

5.5.1 INTRODUCTION

i. **DEFINITION**

Venous thromboembolism (VTE) has two major clinical manifestations. The first and more common manifestation is deep vein thrombosis (DVT), which usually arises in the deep veins of the lower extremities. DVT may less commonly affect other sites, including the upper limbs, subclavian, superior vena cava, intracranial and splanchnic veins. Pulmonary embolism (PE), the second and more serious manifestation of VTE, commonly occurs as a complication of DVT of the lower extremities¹. It is estimated that about 50–60% of patients are likely to develop DVT, most of which are subclinical². The clinical course of DVT may be complicated acutely by the potentially fatal conditions of pulmonary embolism (PE), and in the long term by recurrent DVT and the debilitating post thrombotic syndrome (PTS)³. The incidence of chronic thromboembolic pulmonary hypertension (CTEPH) among survivors of pulmonary embolism is about 3%⁴.

ii. EPIDEMIOLOGY

Despite the increasing burden of CVDs in african populations, there is no available estimate of the burden of VTE at the continental level⁵.

VTE has been shown to be predominantly a disease of older people in the developed world with incidence rate being somewhat higher among women of childbearing age, while incidence rate after age 45 are generally higher in men⁶.

The prevalence of DVT in Africa varies between 2.4% and 9.6% in patients after surgery, and incident rate between 380 and 448 per 100,000 births per year in pregnant and postpartum women⁵.

iii. RISK FACTORS

VTE is considered to be a consequence of the interaction between patient-related (usually permanent) risk factors, and setting-related (usually temporary) risk factors.

VTE may be provoked (i.e. when it occurs in the presence of an identifiable risk factor within the prior 6 weeks to 3 months before diagnosis) or unprovoked (when there is no such identifiable risk factor)⁷.

Weak risk factors	Moderate risk factors	Strong risk factors
Bed rest for 3 days	Arthroscopic knee surgery	Fracture (hip or leg)
Immobility due to sitting (e.g. prolonged car or air travel)	Central venous lines	Major orthopaedic surgery
Increasing age	Chemotherapy	Major general surgery
Laparoscopic surgery (e.g. cholecystectomy)	Congestive heart failure or chronic respiratory disease	Trauma with multiple injuries
Obesity	Hormone replacement therapy	Spinal cord injury (paralysis/quadri- paresis)
Pregnancy/antepartum	Malignancy	
Varicose veins	Oral contraceptive therapy	
	Stroke (hemiparesis or hemiplegia)	
	Pregnancy/postpartum	
	Previous venous thromboembolism	
	Thrombophilia	

Table 56: Risk factors for VTE³

5.5.2 DEEP VEIN THROMBOSIS

i. CLINICAL PRESENTATION

ia. SYMPTOMS (USUALLY UNILATERAL)

- Leg swelling most specific symptom
- Leg pain
- Warmth or reddening of the skin over the area of thrombosis
- Clinical symptoms of PE as the primary manifestation (refer to PE paragraph of this chapter)

ib. SIGNS

- Low grade fever
- Unilateral lower limb swelling with tenderness
- Variable discoloration of the lower extremity
- Differential warmth

Table 57: Two-level DVT Well's score


Clinical feature	Points	Patient score
Active cancer (diagnosed within the last 6 months or undergoing treatment)	1	
Paralysis, paresis or recent plaster immobilisation of the lower extremities	1	
Recently bedridden for 3 days or more or major surgery within 12 weeks requiring general or regional anaesthesia	1	
Localised tenderness along the distribution of the deep venous system	1	
Calf swelling at least 3 cm larger than normal side	1	
Pitting oedema confined to the affected leg	1	
Collateral superficial veins (non-varicose)	1	
Previously documented DVT	1	
An alternative diagnosis is as likely as DVT	-2	
Clinical probability simplified score		
DVT likely	2 points or more	
DVT unlikely	Less than 2	

→ NOTE:

In patients with symptoms involving both lower limbs, the more affected leg should be used.

- If the score ≥2 points = DVT likely: perform compression venous ultrasound; if positive, treat as DVT
- If compression venous ultrasound is inconclusive, run a D-dimer test; if D-dimer test is positive and compression venous ultrasound is negative, repeat ultrasound in 1 week
- If both D-dimer and compression venous ultrasound are negative, DVT is excluded
- If the score <2 points = DVT unlikely: perform D-dimer test (where available); if D-dimer test is negative, DVT is excluded: if D-dimer test is positive, perform compression venous ultrasound</p>
- If compression venous ultrasound is negative, DVT is excluded; if positive, treat as DVT

Alternative diagnoses may include superficial thrombophlebitis, post thrombotic syndrome, cellulitis, muscle strain, venous insufficiency, popliteal (Bakers) cyst, haematoma and pseudo-aneurysm.



ii. MANAGEMENT ACCORDING TO LEVEL OF CARE

iia. HEALTH FACILITY WITHOUT A DOCTOR

- \rightarrow Score as per algorithm shown in *figure 19*
- → Supportive therapy with analgesic
- \rightarrow Refer to a health facility with a doctor.

iib. HEALTH FACILITY WITH A DOCTOR

 \rightarrow Score as per algorithm shown in *figure 19*

LABORATORY INVESTIGATION

D-dimer:

D-dimer levels are elevated in plasma in the presence of acute thrombosis because of simultaneous activation of coagulation and fibrinolysis.

The negative predictive value of D-dimer testing is high and a normal D-dimer level renders acute PE or DVT unlikely. On the other hand, the positive predictive value of elevated D-dimer levels is low which implies that a positive D-dimer does not mean absolute diagnosis as could be elevated in other medical conditions such as infections⁷.

NON-LABORATORY INVESTIGATION

Imaging for DVT

Compression venous ultrasound

Compression venous ultrasonography (CUS) is currently the first-line imaging examination for suspected DVT because of its relative ease of use.

 \rightarrow Note: Above knee (proximal) DVT have a higher risk of embolisation.

Abdominal ultrasonography USG and chest X-ray may be considered to establish some of the risk factors for DVT such as abdominal/chest malignancies.

PHARMACOLOGICAL TREATMENT

- \rightarrow If DVT is confirmed, start parenteral therapeutic anticoagulation as follows.
- → Refer to a specialist for continuation of treatment, monitoring of anticoagulation and management of associated complications.

Medication	Route of administration	Frequency	
Enoxaparin	subcutaneous	1.5mg/kg daily (1mg/kg twice daily in obese patient) Caution: if eGFR < 30 ml/min: use an alternative medication	
Dalteparin	subcutaneous	100 IU/kg twice daily	
Unfractionated heparin	subcutaneous	Bolus of 80 units per kg, then 300 units per kg in divided doses daily	
Fondaparinux ⁺	subcutaneous	lf body weight <50kg: 5mg daily, 50-100kg: 7.5mg daily, >100kg: 10mg daily	

Table 58: Pharmacological treatment

iic. HEALTH FACILITY WITH A PHYSICIAN SPECIALIST

 \rightarrow Score as per algorithm in *figure 19*

LABORATORY INVESTIGATION

D-dimer

In addition, laboratory investigation for possible risk factors for DVT can be considered. These include:

- C-reactive protein (CRP): non-specific, may be elevated in cancers, infections and inflammation
- Antinuclear antibody (ANA)
- Prostate specific antigen (PSA)
- Carcinoembryonic antigen (CEA)
- Anti-phospholipid syndrome Antithrombin deficiency
- Protein C deficiency
- Protein S deficiency
- Factor V Leiden
- Prothrombin 20210 mutation
- Homocysteine levels

NON-LABORATORY INVESTIGATION

- Compression ultrasound
- Other imaging

Advanced imaging studies used in DVT such as CT scan, venography, impedance plethysmography, MRI, and nuclear imaging are either not readily available or reserved for imaging segments that are not easily accessible by compression ultrasound.

PHARMACOLOGICAL TREATMENT

Anticoagulation for inpatients should include **Heparin** or a low-molecular-weight **Heparin (LMWH)**, followed by the initiation of a vitamin K antagonist usually **Warfarin** or **Novel Oral Anticoagulant (NOAC)**.

See table 59: Pharmacological treatment of Venous Thromboembolism next page.

Medication	Route of administration	Frequency	
Low Molecular Weight Heparin (LMWH): LOE – A			
Enoxaparin	subcutaneous	1.5mg/kg daily (1mg/kg twice daily in obese patient)	
Dalteparin	subcutaneous	100 IU/kg twice daily	
Fondaparinux*	subcutaneous	lf body weight <50kg: 5mg daily Body weight 50-100 kg: 7.5mg daily Body weight > 100 kg: 10 mg daily	
Tinzaparin*	subcutaneous	175 IU/ kg daily	

Table 59: Pharmacological treatment of venous thromboembolism

1. Vitamin K Antagonist (Warfarin)

 Starting dose: 5-10mg daily orally (in healthcare facilities without specialist, and in the elderly patients, the starting dose of Warfarin should not exceed 5mg)

Initiate Warfarin on day 1 of parenteral anticoagulation therapy

- Check INR on the 3rd day and adjust dose accordingly
- Overlap Warfarin and parenteral anticoagulant until desired INR is maintained for 2 consecutive days, and then discontinue parenteral anticoagulation therapy
- Typical maintenance dose: 2 to 10mg orally once a day
- Dosage must be individualised according to the patient's INR
- Target INR: 2.5 (range: 2 to 3)
- Renal dose: no dosage adjustment is necessary for patients with renal failure

or

2. Novel oral anticoagulants (NOACs): LOE: B			
Rivaroxaban ◆	oral	15mg twice daily for 21 days, then 20mg daily for at least 3 months	
Apixaban◆	oral	10mg twice daily for 7 days, then 5mg twice daily for at least 3-6 months	
Dabigatran◆	oral	150mg twice daily for at least 3-6 months (must be preceded by 5-10 days of LMWH)	
Edoxaban◆	oral	60mg once daily for at least 3-6 months (30 mg once daily if CrCl <30 ml/min); must be preceded by 5-10 days of LMWH therapy	

On discontinuation of anticoagulation, a venous compression ultrasound should be performed to at least establish a baseline comparative exam in case of recurrence.

Vena caval filters

These are indicated in patients who have absolute contraindications to anticoagulation. Other indications are PE despite adequate anticoagulation and preoperatively when manipulation puts DVT at high risk of embolisation.

Duration of therapy

- For provoked DVTs, where there is a reversible risk factor, consider treatment for 3 months
- For unprovoked DVTs, consider treatment for 6 months; however, if there is recurrence, consider lifelong treatment

Special populations (consider lifelong anticoagulation)

- Recurrent DVT
- Active malignancy
- Thrombophilia/antiphospholipid syndrome

5.5.3 ACUTE PULMONARY EMBOLISM (PE)

i. CLASSIFICATION OF ACUTE PE

A classification of pulmonary embolism is based on the stage (acute or chronic) and the size or haemodynamic consequences of the emboli (massive or sub-massive).

Massive PE: It is characterised by systemic arterial hypotension defined as:

- A systolic arterial pressure <90 mmHg sustained for at least 15 minutes or
- A drop in systolic arterial pressure of at least 40 mmHg for at least 15 minutes which is not caused by new onset arrhythmias or
- Shock (manifested by evidence of tissue hypoperfusion and hypoxia, including an altered level of consciousness, oliguria, or cold, clammy extremities)

Sub-massive PE:

A subgroup of patients with non-massive PE who are haemodynamically stable but with right ventricular dysfunction or hypokinesia confirmed by echocardiogram (McConnel sign) or CTPA.

Non-massive PE:

It may not show any clinical or haemodynamic signs or right ventricular dysfunction based on echocardiogram⁸.

ii. CLINICAL PRESENTATION

The diagnosis of PE may be easily missed since the clinical signs and symptoms are non-specific and may vary widely. When the clinical presentation raises the suspicion of PE in an individual patient, it should prompt further objective testing.

PE may be completely asymptomatic and be discovered incidentally during diagnostic workup for another disease or at autopsy.

iia. SYMPTOMS

- Dyspnoea (difficulty in breathing)
- Pleuritic chest pain
- Cough
- Haemoptysis
- Sudden collapse/syncope
- Low grade fever
- Decreased level of consciousness

iib. SIGNS


- Tachypnoea (respiratory rate >20/min)
- Accentuated second heart sound
- Tachycardia (heart rate >100/min)
- Fever (temperature >37.5°C)
- Diaphoresis (profuse sweating)
- S3 or S4 gallop
- Clinical symptoms and signs suggesting DVT
- Cardiac murmur
- Cyanosis

See table 60: Assessment of clinical probability in acute PE on the next page.

Table 60: Assessment of clinical probability in acute PE

Clinical characteristic	Simplified Well's score		
Previous pulmonary embolism or deep vein thrombosis	1		
Heart rate >100 beats per minute	1		
Recent surgery or immobilisation (within the last 30 days)	1		
Clinical signs of deep vein thrombosis	1		
Alternative diagnosis less likely than pulmonary embolism	1		
Haemoptysis	1		
Cancer (treated within the last 6 months)	1		
Clinical probability score			
PE unlikely	less than 2		
PE likely	=2 or more		

Use the Well's or Geneva rules to choose tests based on a patient's risk for PE.



For non-massive PE

→ If the score ≥2 points = PE likely: Perform CT-PA; if positive, treat as PE; if negative, consider alternative diagnosis → If the score <2 points = PE unlikely: Perform D-dimer test (where available); if D-dimer test is negative, PE is excluded; if D-dimer test is positive, perform CT-PA. If CT-PA is negative, PE excluded; if positive, treat as PE




Figure 21: Diagnostic algorithm for pulmonary embolism with shock or hypotension

→ Note: In the absence of immediate CT-PA and/or echocardiogram, administer iv bolus unfractionated heparin 5000-7500 IU in the average adult and refer.

iii. MANAGEMENT ACCORDING TO LEVEL OF CARE

iiia. HEALTH FACILITY WITHOUT A DOCTOR

- → Assess on Well's Score (figure 19)
- \rightarrow Immediate referral to health facility with a doctor.

While waiting for transport:

- Intranasal oxygen
- Elevate head of the bed
- Hydration with normal saline

iiib. HEALTH FACILITY WITH A DOCTOR/PHYSICIAN SPECIALIST

- Assess on Well's score for PE and follow algorithm, figure 19
- If score is less than 2 (PE unlikely), request D-dimer test and follow as per algorithm, figure 20
- \rightarrow If score >2 (PE likely), administer stat dose of LMWH and follow algorithm, figure 20
- \rightarrow If score >2 (PE likely) with shock, follow algorithm, *figure 21*
- \rightarrow Note: if D-dimer test not available refer to facility with a specialist.

LABORATORY INVESTIGATION

- Full blood cell count
- White blood cell count may be elevated (risk of confusion with pneumonia-always risk stratify if PE suspected)
- Clotting profile
- Doppler USG of lower limb and pelvis if indicated

NON-LABORATORY INVESTIGATION

Chest radiographs may be normal in pulmonary embolism, but where abnormal the findings may be non-specific as follows:

- pleural effusion
- parenchymal opacities
- elevation of a hemidiaphragm

These classic radiographic findings of pulmonary embolism are infrequently observed:

- Hamptons hump: wedge-shaped, pleura-based triangular opacity with an apex pointing toward the hilum.
- Westermark sign: decreased vascularity or focal area of oligemia.




Figure 22: Westermark sign and Hampton's Hump

Electrocardiogram (ECG)

Electrocardiographic abnormalities which may be suggestive of PE include sinus tachycardia (most common finding):

- Atrial fibrillation usually new onset
- Nonspecific ST-T wave abnormalities
- S₁ Q₃ T₃ (classical finding) is nonspecific and insensitive in the absence of clinical suspicion for pulmonary embolism
- Right heart strain findings such as
 - tall, peaked P waves in lead II (P pulmonale);
 - right axis deviation;
- right bundle-branch block (complete or incomplete)

See figure 23: ECG (if available) findings in PE on next page.




Figure 23: ECG findings in PE

Echocardiogram

- This modality generally has limited accuracy in the diagnosis of PE; it may allow diagnosis of other conditions that may be confused with PE, such as pericardial effusion
- Haemodynamically unstable patients with suspected PE should have urgent echocardiogram; the presence of signs of RV pressure overload and dysfunction should justify immediate reperfusion treatment (e.g. thrombolysis) for PE; in such cases CT angiography should be done when patients are stable
- Echocardiographic examination is not recommended as part of the diagnostic work-up in haemodynamically stable, normotensive patients with suspected PE

CT pulmonary angiography

Computed tomography pulmonary angiography (CTPA) is the earliest imaging modality of choice for stable patients with suspected PE⁷.

PHARMACOLOGICAL TREATMENT

MASSIVE PE

Initial anticoagulation

Besides haemodynamic and respiratory support, intravenous UFH should be administered to these patients as the preferred mode of initial anticoagulation (refer algorithm). The dosing of UFH is adjusted, based on the activated partial thromboplastin time (APTT).

Thrombolysis

 \rightarrow Thrombolytic therapy is recommended for PE patients with shock who remain hemodynamically unstable after initial preferred anticoagulation and supportive therapy⁷.

In patients with contraindications to thrombolysis, and in those in whom thrombolysis has failed to improve the haemodynamic status; percutaneous catheter-directed treatment or surgical embolectomy is recommended when available⁷.

Table 61: Dosage for thrombolysis medication

Medications	Route of administration	Frequency
Streptokinase*	iv	250,000 IU as a loading dose over 30 minutes, followed by 100,000 U/hour over 12-24 hours
Recombinant tissue plasminogen activator (rt-PA)/alteplase LOE – B	iv	90mg as a continuous infusion over 2 hours; a 10mg bolus is administered first, followed by 85mg administered over 2 hours

→ Note: Heparin infusion must be discontinued during thrombolysis with Streptokinase but resume after thrombolysis.

NON-MASSIVE PE

For cases of acute PE without shock or hypotension, treatment is the same as treatment for DVT (refer to *section on DVT* of this chapter).

Patients with non-massive PE require further risk stratification after the diagnosis of PE has been confirmed. In these patients, risk assessment should begin with a validated clinical score, preferably the Pulmonary Embolism Severity Index (PESI) or simplified PESI (sPESI).

Low-risk patients with sPESI of 0, should be considered for early discharge and outpatient treatment, if this appears feasible based on the patient's anticipated compliance as well as his/her family and social background.

Non-pharmacological management

- Educating patients on risk factors of VTE
- Counselling patients on anticoagulation medication adherence; advise patients on drugs that may interfere with anticoagulation
- Carrying anti-coagulation medication card/bracelet

Duration of anticoagulation

- Unprovoked PE should generally be treated with anticoagulation for at least 6 months
 A compression ultrasound should be repeated at 3 months before cessation of therapy for all confirmed DVTs and in the case of a PE a CT-PA; where resources are limited an echocardiogram may be
 performed instead of a CT-PA; treatment may be extended if PE persist
- Anticoagulants are only discontinued when the perceived risk of anticoagulation-related bleeding and the inconvenience of remaining on treatment outweigh the risk of recurrent VTE
- For patients with irreversible risk factors (unprovoked PE), or those presenting with recurrent PE, lifelong anticoagulation therapy should be considered

Table 62: Simplified PESI⁹

Variable	Score
Age > 80 years	1
History of cancer	1
History of heart failure or lung disease	1
Pulse ≥ 110 bpm	1
Systolic bp < 100	1
Arterial oxygen saturation <90	1
Score summary	0 points - low risk ≥ 1 points - high risk

5.5.4 MANAGEMENT OF VTE IN SPECIAL POPULATIONS (RELEVANT FOR ALL LEVELS OF CARE)

i. PREGNANCY AND LACTATION

In pregnancy, establishing a clear guideline for the treatment of VTE is difficult from an evidence-based perspective. LMWH is the anticoagulant of choice, given its relative safety for the foetus⁷. Warfarin is safe during lactation but not advised in pregnancy. There is not enough evidence to warrant use of NOACs in pregnancy and lactation due to limited evidence.

ii. PATIENTS WITH CANCER

LMWH is usually preferred in patients with VTE and cancer⁷.

iii. CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)

Chronic thromboembolic pulmonary hypertension (CTEPH) usually results from obstruction of the pulmonary vascular bed by non-resolving thromboemboli in patients with DVT, acute or recurrent PE. Increased pulmonary vascular resistance subsequently leads to progressive pulmonary hypertension, right atrial dilatation, right ventricular hypertrophy and right ventricular failure. Studies suggest that 1%-3.8% of patients with acute PE may develop CTEPH two years after diagnosis¹⁰.

First-line imaging for diagnosis of CTEPH is planar ventilation-perfusion (V/Q) lung scan. However, echocardiography, CT pulmonary angiography, right heart catheterisation and pulmonary angiography should be done when available.

Pulmonary endarterectomy (surgical) in addition to secondary prevention with medical therapy as well insertion of vena caval filters are the management of choice. Without surgical treatment, the prognosis of patients with CTEPH is poor.

5.5.5 PREVENTION OF VTEs

The rationale for use of thromboprophylaxis is based on solid principles and scientific evidence. Almost all hospitalised patients have at least one risk factor for VTE, and approximately 40% have three or more risk factors. Without thromboprophylaxis, the incidence of objectively confirmed, hospital-acquired DVT is approximately 10 to 40% among medical or general surgical patients and 40 to 60% following major orthopaedic surgery¹¹. The mortality, acute and long-term morbidities, and resource utilisation related to unprevented VTE strongly support effective preventive strategies at least for moderate-risk and high-risk patients¹¹.

i. MECHANICAL THROMBOPROPHYLAXIS FOR ALL LEVELS OF CARE

- Early and frequent ambulation of hospitalised patients
- Specific mechanical methods of thromboprophylaxis include graduated compression stockings (GCS), intermittent pneumatic compression (IPC) devices, and the venous foot pump (VFP)
- The primary advantage of mechanical thromboprophylaxis is its use in patients at high risk of bleeding

ii. PHARMACOLOGICAL THROMBOPROPHYLAXIS FOR HEALTH FACILITIES WITH A DOCTOR/SPECIALIST

For acutely ill medical patients admitted to hospital with congestive heart failure or severe respiratory disease, or who are confined to bed and have one or more additional risk factors, including active cancer, previous VTE, sepsis, acute neurologic disease, or inflammatory bowel disease, it is recommended that thromboprophylaxis with LMWH, unfractionated **Heparin** or **Fondaparinux**⁺ be administered.

Thromboprophylaxis should also be considered in surgical patients with moderate to high risk for VTE and also for those undergoing pelvic and orthopaedic surgeries.

Medications	Route of administration	Frequency
Dalteparin	subcutaneous	5,000 IU once daily
Enoxaparin	subcutaneous	40mg once daily
Unfractionated Heparin	subcutaneous	5000 IU twice daily
Fondaparinux*	subcutaneous	2.5mg daily

Table 63: Dosage of pharmacologic thromboprophylaxis

REFERENCES

- 1 Jenkins D, Mayer E, Screaton N, Madani M. State-of-the-art chronic thromboembolic pulmonary hypertension diagnosis and management. European Respiratory Review. 2012 Mar 1; 21(123): 32–39.
- 2 Stein P, Matta F, Musani M H, Diaczok B. Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review. The American Journal of Medicine. Elsevier. 2010 May; 123 (5): 426–431.
- 3 Anderson FA, Spencer FA. Risk Factors for Venous Thromboembolism. Circulation. 2003 Jun 17; 107(23): 9-16.
- 4 Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P, Mairuhu ATA, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. European Respiratory Journal. 2017 Feb; 49(2): 1601–1792.
- 5 Danwang C, Temgoua MN, Agbor VN, Tankeu AT, Noubiap JJ. Epidemiology of venous thromboembolism in Africa: a systematic review. Journal of Thrombosis and Haemostasis. 2017 Sep; 15(9): 1770–1781.
- 6 Heit JA. The epidemiology of venous thromboembolism in the community. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008 Mar; 28(3): 370–372.
- 7 Konstantinides S V., Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal. 2014 Nov 14; 35(43): 3033-3380.
- 8 Sekhri V, Mehta N, Rawat N, Lehrman SG, Aronow WS. State of the art paper Management of massive and nonmassive pulmonary embolism. Archives of Medical Science. 2012; 8(6): 957–969.
- 9 Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, et al. Validation of simplified PESI score for identification of low-risk patients with pulmonary embolism: From the COMMAND VTE Registry. European Heart Journal Acute Cardiovasc Care. 2018 Sep 11; 204887261879999.
 - Available from: http://www.ncbi.nlm.nih.gov/pubmed/30203659.
- 10 Rose-Jones LJ, Mclaughlin V V. Pulmonary hypertension: types and treatments. Current Cardiololgy Review. 2015 ; 11(1): 73–79.
- 11 Moores LK, Chan CM, Shorr AF. Prevention of Venous Thromboembolism in Hospitalized Medical Patients Clinical. Chest Physician. 2009.

5 **DISEASES**

5.6 ACUTE RHEUMATIC FEVER

LIST OF ABBREVIATIONS AND ACRONYMS

ARF	Acute Rheumatic Fever	FBC	Full Blood Count
BPG	Benzathine Penicillin G	GAS	Group A beta-haemolytic
CRP	C-Reactive Protein		Streptococcus
ECG	Electrocardiography	RHD	Rheumatic Heart Disease
ESR	Erythrocyte Sedimentation	WBC	White Blood Cell
	Rate		

5.6.1 INTRODUCTION

i. **DEFINITION**

Acute rheumatic fever (ARF) is an immune-mediated, non-suppurating complication of an infection of the pharynx (and less commonly the skin) with group A beta-haemolytic streptococcus (GAS)¹. A preceding pharyngitis, with an ensuing two to three-week symptom-free period occurs before the first symptoms or signs of ARF appear. There is an acute, generalised inflammatory response usually involving only certain parts of the body, especially the skin, brain, heart and joints.

ii. EPIDEMIOLOGY

Most cases occur in children between 5 to 15 years of age but may occur at any age. Previous ARF patients are much more likely than most others to develop repeat episodes with majority of mortalities found in developing countries². The incidence and prevalence of ARF is reduced in the developed world after measures to reduce transmission of streptococci and improvement in general hygiene were implemented. Additionally, treatment measures were stringently implemented. However, ARF remains common in many developing countries including Ghana³.

iii. AETIOLOGY

The pathophysiologic mechanisms that lead to acute rheumatic fever (ARF) are not completely known. Streptococcal pharyngeal infection is a prerequisite, and genetic susceptibility may be present. GAS skin infections may play a role in ARF pathogenesis. As a result of molecular mimicry, antibodies directed against GAS antigens cross-react with host antigens⁴. Cellular immunity is also thought to play a role in ARF. About 3–5% of the population may have an inborn susceptibility to ARF, the basis of which is uncertain⁴.

5.6.2 CLINICAL PRESENTATION

The diagnosis of ARF is usually guided by the modified Jones criteria, 2015. Currently, there is no diagnostic laboratory test for ARF, so diagnosis remains a clinical decision.

See table 64: Modified Jones criteria for the diagnosis of ARF⁵ next page.

i. MAJOR MANIFESTATIONS

ARTHRITIS

- Swollen and hot joint with pain on movement
- Asymmetrical and migratory
- Joints may be involved one after the other or several of them involved simultaneously without remitting
- Large joints are usually affected, particularly the ankles and knees
- Extremely painful arthritis

SYDENHAM'S CHOREA

- Abrupt, uncoordinated movements, especially affecting the hands, feet, tongue and face, which are not present during sleep
- May involve only one side of the body (hemichorea)
- Adolescent females are particularly affected⁶

The presence of chorea may be a predictor of future carditis in a patient managed for ARF⁷.

Definition			
Definite initial episode of ARF	2 major or 1 major with 2 minor manifestations plus evidence of a preceding GAS infection		
Definite recurrent episode of ARF in a patient with known past ARF or RHD	2 major or 1 major and 1 minor or 3 minor manifestations with evidence of a previous GAS infection		
Probable ARF (first episode or recurrence)	A clinical presentation lacking one major or one minor manifestation, or the unavailabi- lity of streptococcal serology results, but with ARF being thought of as the likely diagno- sis; in these cases, there is further categorisation according to the level of confidence with which the diagnosis is made: highly suspected ARF uncertain ARF 		
Manifestations	Moderate/high-risk groups	Low-risk groups (ARF incidence ≤2 per 100,000 school-aged children or all-age)	
Major manifestations	 Carditis (including subclinical evidence of rheumatic valvulitis on echocardiogram) Polyarthritis or aseptic mono-arth- ritis or polyarthralgia Chorea Erythema marginatum Subcutaneous nodules 	 Carditis (excluding subclinical evidence of rheumatic valvulitis on echocardio- gram) Polyarthritis Chorea Erythema marginatum Subcutaneous nodules 	
Minor manifestations	 Monoarthralgia Fever ESR ≥30 mm/h CRP ≥30 mg/L Prolonged P-R interval on ECG 	 Fever Polyarthralgia or aseptic monoarthritis ESR ≥30 mm/h CRP ≥30 mg/L Prolonged P-R interval on ECG 	

Table 64: Modified Jones criteria for the diagnosis of ARF⁵

CARDITIS

- Florid inflammation of the myocardium, endocardium and pericardium with involvement of the endocardium being predominant
- Mainly affecting the mitral and aortic valves
- Incidence of carditis in initial attacks of ARF lies between 30% and 82%⁸
- Carditis may present early on in the disease but usually presents within the first 2–6 weeks, making repeated physical examination during admission critical
- There are four clinical findings of carditis:
- (a) significant murmur due to valvulitis
- (b) cardiac enlargement
- (c) cardiac decompensation
- (d) pericardial friction rub or effusion⁹

VALVULITIS

- Most commonly affects the mitral valve
- Results in regurgitation or stenotic lesions occurring due to extensive scar formation
- Mitral regurgitation is an apical blowing, holosystolic murmur which may have an associated mid-diastolic flow murmur (Carey Coomb's murmur)
- In aortic valvulitis, usually seen as aortic regurgitation, an early diastolic murmur is heard at the base of the heart (enhanced by leaning forward and also in expiration)¹⁰
- Valvulitis usually leads to heart failure and eventually rheumatic heart disease

When there is enlargement of the heart, it can be diagnosed clinically by the displaced apex and subsequently confirmed with echocardiography^{11,12}.

Pericarditis is uncommon in ARF. It should be considered in patients with ARF, who have chest pain and/or a friction rub⁵.

SUBCUTANEOUS NODULES

- Uncommon (usually below 2% of cases) but very specific for ARF
- The usual size is 0.5–2 cm in diameter and are mobile, painless and nodular crops of up to 12 over the elbows, wrists, knees and ankles
- They appear 1–2 weeks after the onset of the other symptoms and resolve after 1–2 weeks¹³

ERYTHEMA MARGINATUM

- Found in less than 2% of cases in developing countries and also very specific for ARF
- They are dark blanching maculopapular rash
- Lesions may be recurrent and unresponsive to medication and show up more after taking a bath
- They are found on the trunk and proximal extremities, are not painful or itchy and are almost never on the face¹³

ii. MINOR MANIFESTATIONS

ARTHRALGIA

- It is a non-specific symptom described as migratory, asymmetrical and affecting large joints
- There is pain on moving the joint with no associate swelling or differential warmth

FEVER

- Mostly associated with other manifestations of ARF
- Described as peak oral, tympanic or rectal temperatures commonly more than 38°C⁵
- Fever, like arthritis and arthralgia, usually responds well to salicylates

ELEVATED ACUTE-PHASE REACTANTS

- ARF patients usually have a raised serum C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR)
- The peripheral white blood cell (WBC) count is <15×109/l in 75% of patients, making elevated WBC an insensitive marker of inflammation in ARF
- Most patients have both a serum CRP level of >30mg/l and an ESR of >30 mm/h¹³
- The serum CRP concentration rises more rapidly than the ESR, and also falls more rapidly with resolution of the attack, the ESR may remain elevated for 3–6 months

PROLONGED P-R INTERVAL (PR >200MS/0.2SECONDS)/CONDUCTION ABNORMALITIES

- A prolonged P-R interval that resolves over days to weeks may be a useful diagnostic feature especially adjunctive to other clinical features
- Severe first-degree block may lead to a junctional rhythm, second-degree or complete heart block
- Electrocardiography (ECG) should be documented in all cases of possible ARF and if a prolonged P-R interval is detected, the ECG should be repeated after 2 weeks, and again at 2 months to document a normal tracing; the return of the ECG to normal supports the diagnosis of ARF¹⁴

5.6.3 MANAGEMENT ACCORDING TO LEVEL OF CARE

Confirmation of the diagnosis and timely treatment are key. All patients with suspected ARF (first episode or recurrence) should be hospitalised.

i. HEALTH FACILITY WITHOUT A DOCTOR

LABORATORY INVESTIGATION

- Full blood cell count
- Malaria parasite RDT/Blood film
- Diagnosis of ARF at a health facility without a doctor may be difficult.

→ Patient with persistent fever, joint pains and skin rashes should be referred to a facility with a doctor.

ii. HEALTH FACILITY WITH A DOCTOR

LABORATORY INVESTIGATION

- Full blood cell count
- Blood cultures
- Erythrocyte sedimentation rate (ESR)
- C-reactive protein (CRP)

PHARMACOLOGICAL TREATMENT

Intramuscular (im) Benzathine Penicillin G (LOE A)

- Adults: 1,200,000 U as a single shot
- Children less than 20 kg: 600,000 U as a single shot or

Oral Penicillin V (LOE A)

- Adults: 500mg twice daily for 10 days
- Children: 250mg twice daily for 10 days
- → Patients with a known allergy to Penicillin: oral Erythromycin (LOE B)

Arthritis and fever

- Aspirin starting at a dose of 50–60mg/kg/day, titrated up to 80–100mg/kg/day (4–8 g/day in adults) and administered in divided doses; the dose may be increased to 125mg/kg/day at which time signs of toxicity must be looked for (LOE A)
- Naproxen, (10–20mg/kg/day) or Ibuprofen are suitable alternatives given twice-daily¹⁵ (LOE B)
- If the diagnosis is uncertain, Paracetamol or Codeine may be administered for pain relief (LOE C)
- → Note: If clinical signs do not resolve within 3 days of start of medications, look for an alternative diagnosis.
- → Anti-inflammatory medication may be given for 1–2 weeks; however, it may be continued for as long as 6 weeks depending on how drastically the clinical symptoms and inflammatory markers improve.

Carditis/heart failure

- Bed rest with mobilisation
- Gradual ambulation, especially in patients with heart failure
- → Refer patient to a health facility with a physician specialist, when there is severe carditis with persistent heart failure, or poor resolution of symptoms despite optimal treatment.

iii. HEALTH FACILITY WITH A PHYSICIAN SPECIALIST

LABORATORY INVESTIGATION

- Full blood cell count (FBC)
- Blood cultures
- Erythrocyte sedimentation rate (ESR)
- C-reactive protein (CRP)
- Throat swab (before giving antibiotics): culture for GAS
- Antistreptococcal serology: Anti Streptolysin O titre and anti-DNase B titres which may be repeated in two weeks if the result is not confirmatory

NON-LABORATORY INVESTIGATION

- Electrocardiogram
- Chest X-ray
- Echocardiogram (consider repeating after 1 month, if negative)

PHARMACOLOGICAL TREATMENT

Intramuscular (im) Benzathine Penicillin G (LOE A)

- Adults: 1,200,000 U as a single shot
- Children less than 20 kg: 600,000 U as a single shot or

Oral Penicillin V (LOE A)

- Adults: 500mg twice daily for 10 days
- Children: 250mg twice daily for 10 days
- → Patients with a known allergy to Penicillin: oral Erythromycin (LOE B)

Arthritis and fever

- Aspirin starting at a dose of 50–60mg/kg/day, titrated up to 80–100mg/kg/day (4–8g/day in adults) and administered in divided doses; the dose may be increased to 125 mg/kg/day at which time signs of toxicity must be looked for (LOE A)
- Naproxen (10–20mg/kg/day) or Ibuprofen suitable alternatives given twice-daily¹⁵ (LOE B)
- If the diagnosis is uncertain, Paracetamol or Codeine for pain relief (LOE C)
- → Note: If clinical signs do not resolve within 3 days of start of medications, look for an alternative diagnosis
- → Anti-inflammatory medication may be given for 1–2 weeks however may be continued for as long as 6 weeks depending on how drastically the clinical symptoms and inflammatory markers improve

Carditis/heart failure

→ Refer to *chapter 5.4* on heart failure.

5.6.4 SECONDARY PREVENTION (APPLIES FOR HEALTH FACILITIES WITH A DOCTOR AND A PHYSICIAN SPECIALIST)

This is the continual use of antibiotics in patients with a history of rheumatic fever, or rheumatic heart disease. By this treatment, infection with GAS and the subsequent development of recurrent attacks of rheumatic fever is curtailed¹⁷. This is an effective ARF prevention strategy¹⁸.

Intramuscular (I.M) Benzathine Penicillin G (BPG) (LOE A)

- Adults: 900mg (1,200,000 U) as a single shot monthly
- Children less than 30 kg: 450mg (600,000 U) as a single shot monthly
- → The rates of allergic and anaphylactic reactions to monthly BPG are 3.2% and 0.2%, respectively, and fatalities are rare¹⁸.
- → Before the start of Penicillin treatment, allergies to these medicines must be assessed (allergy history) in patients and erythromycin used instead in cases of penicillin allergy¹⁸.

In pregnancy

Erythromycin considered to be safe in patients with known allergies to Penicillin¹⁸.

Duration of secondary prevention

The appropriate duration of secondary prevention is determined by factors such as age, risk factors in the environment, the most recent episode of ARF among others.

Table 65: Prophylaxis for acute rheumatic fever

Category	Definition of category	Duration
All persons with ARF or Rheumatic Heart Disease (RHD)		Minimum 10 years after most recent episode of ARF or until age 21 years (whichever is longer)
Status after initial period	l elapsed:	
No RHD	No pathological mitral or aortic regurgitation, but may have minor morphological changes to mitral or aortic valves on echocardiography	Discontinue at that time
Mild RHD	Mild mitral or aortic regurgitation clinically and on echocar- diography, with no clinical evidence of heart failure, and no evidence of cardiac chamber enlargement on echocardiogra- phy	Discontinue at that time
Moderate RHD	 Any valve lesion of moderate severity clinically (e.g. mild-moderate cardiomegaly and/or mild-moderate heart failure) or on echocardiography Mild mitral regurgitation, together with mild aortic regurgitation clinically or on echocardiography Mild or moderate mitral or aortic stenosis Any pulmonary or tricuspid valve lesion coexisting with a left-sided valve lesion 	Continue until 35 years of age
Severe RHD	 Any severe valve lesion clinically (e.g. moderate to severe cardiomegaly or heart failure) or on echocardiography Any impending or previous cardiac valve surgery for RHD 	Continue until age 40 years or longer




Figure 24:

Algorithm for diagnosis and management of ARF (Adapted from the 2012 Australian Guidelines for Diagnosis and Management of ARF)

REFERENCES

- 1 Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. The Lancet Infectious Diseases. 2005; 5(11): 685–694.
- 2 Carapetis JR, Currie BJ, Mathews JD. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population? Epidemiology & Infection. 2000; 124(2): 239–244.
- ³ Rothenbühler M, O'Sullivan CJ, Stortecky S, Stefanini GG, Spitzer E, Estill J, et al. Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents. The Lancet Global Health. 2014; 2(12): 717–726.
- 4 Van de Rijn I, Zabriskie JB, McCarty M. Group A streptococcal antigens cross-reactive with myocardium. Purification of heart-reactive antibody and isolation and characterization of the streptococcal antigen. Journal of Experimental Medicine. 1977; 146(2): 579–599.
- ⁵ Gewitz MH, Baltimore RS, Tani LY, Sable CA, Shulman ST, Carapetis J, et al. Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography. Circulation. 2015; 31(20): 1806–1818.
- 6 Lessof M. Sydenham's chorea. Guy's Hospital Reports. 1958; 107(3): 185–206.
- 7 Carapetis JR, Currie BJ. Rheumatic chorea in northern Australia: a clinical and epidemiological study. Archives of Disease in Childhood. 1999; 80(4):3 53–358.
- 8 World Health Organization. Rheumatic fever and rheumatic heart disease. Report of a WHO expert consultation. 2004. Available from: http://whqlibdoc.who.int/trs/WHO_TRS_923.pdf?ua=1.
- 9 Abernethy M, Bass N, Sharpe N, Grant C, Neutze J, Clarkson P, et al. Doppler echocardiography and the early diagnosis of carditis in acute rheumatic fever. Australian and New Zealand Journal of Medicine. 1994; 24(5): 530–535.
- 10 Gentles TL, Colan SD, Wilson NJ, Biosa R, Neutze JM. Left ventricular mechanics during and after acute rheumatic fever: contractile dysfunction is closely related to valve regurgitation. Journal of the American College of Cardiology. 2001; 37(1): 201–207.
- 11 Vasan RS, Shrivastava S, Vijayakumar M, Narang R, Lister BC, Narula J. Echocardiographic Evaluation of Patients With Acute Rheumatic Fever and Rheumatic Carditis. Circulation. 1996; 94(1): 73–82.
- 12 Kamblock J, Payot L, lung B, Costes P, Gillet T, Le Goanvic C, et al. Does rheumatic myocarditis really exists? Systematic study with echocardiography and cardiac troponin I blood levels. European Heart Journal. 2003; 24(9): 855–862.
- 13 Carapetis JR, Currie BJ. Rheumatic fever in a high incidence population: the importance of monoarthritis and low grade fever. Archives of Disease in Childhood. 2001; 85(3): 223–227.
- 14 Stewart T, McDonald R, Currie B. Use of the Jones Criteria in the diagnosis of acute rheumatic fever in an Australian rural setting. Australian and New Zealand Journal of Public Health. 2005; 29(6): 526–529.
- 15 Hashkes PJ, Tauber T, Somekh E, Brik R, Barash J, Mukamel M, et al. Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial. The Journal of Pediatrics. 2003; 143(3): 399–401.
- 16 Genel F, Arslanoglu S, Uran N, Saylan B. Sydenham's chorea: clinical findings and comparison of the efficacies of sodium valproate and carbamazepine regimens. Brain & Development. 2002; 24(2): 73–76.
- 17 Steer AC, Carapetis JR. Prevention and treatment of rheumatic heart disease in the developing world. Nature Reviews Cardiology. 2009; 6(11): 689–698.
- 18 International Rheumatic Fever Study Group. Allergic reactions to long-term benzathine penicillin prophylaxis for rheumatic fever. The Lancet. 1991; 337(8753): 1308–1310.

5 **DISEASES**

5.7 RHEUMATIC HEART DISEASE

LIST OF ABBREVIATIONS AND ACRONYMS

RF	Rheumatic fever	LFT	Liver function test
GAS	Group A streptococcus	ECG	Electrocardiogram
CRP	C-reactive protein	JVP	Jugular venous pulsation/
ESR	Erythrocyte sedimentation rate		pressure
FBC	Full blood count	S1, S2,	First, second, third
MR	Mitral regurgitation	S3, S4	and fourth heart sounds
MS	Mitral stenosis	A1, A2	First and second heart sounds
RHD	Rheumatic heart disease		at the aortic area
BUE	Blood, urea, and electrolytes	P2	Second heart sound at the
AS0	Anti-streptolysin O		pulmonary area
CXR	Chest X-ray		

5.7.1 INTRODUCTION

i. **DEFINITION**

The long-term damage to cardiac valves caused by acute rheumatic fever, which can result from a single severe episode or from multiple recurrent episodes of the illness is known as rheumatic heart disease (RHD). It is a known cause of cardiac associated morbidity and mortality in resource poor settings¹.

It is the most serious consequence of acute rheumatic fever with rheumatic carditis. Patients may sometimes present with the complications of RHD, which include heart failure, endocarditis, atrial fibrillation and embolic stroke¹.

ii. EPIDEMIOLOGY

RHD remains the leading cause of acquired heart disease among the young worldwide. The exact mortality rate due to RHD is underestimated in Africa. A large multinational african study demonstrated that RHD is the most frequent cause of heart failure among children and young adults, and importantly that the 180-day mortality rate is as high as 17.8%².

Risk factors for RHD:

- Age: RHD starts in children but its prevalence peaks in adulthood between 25 years to 45 years
- Sex: RHD occurs more commonly in females, relative risk of 1.6 to 2 compared with males
- Environmental factors e.g. household overcrowding
- Rural residence²
- Poverty
- Reduced access to medical care

iii. CLASSIFICATION

- Mitral regurgitation
- Mitral stenosis
- Aortic regurgitation
- Aortic stenosis
- Pulmonic valve involvement
- Tricuspid valve involvement

5.7.2 AETIOLOGY RHD is a late complication of ARF → Refer to *chapter on ARF*.

The valves most affected by rheumatic fever, in descending order, are the mitral, aortic, tricuspid, and pulmonary valves. In most cases, the mitral valve is involved with one or more of the other 3. In acute disease, small thrombi form along the lines of valve closure. In chronic disease, there is thickening and fibrosis of the valve resulting in stenosis and regurgitation².

5.7.3 SYMPTOMS AND SIGNS

i. MITRAL REGURGITATION (MR)

- Mitral regurgitation, as an isolated lesion or in combination with other valvar defects, is probably the most common valvular dysfunction resulting from the acute rheumatic process; in developing countries, severe forms have necessitated early surgical intervention in young patients³
- Unlike mitral stenosis, when there is a variable latent period between the establishment of the valvular lesion and the acute episode, mitral regurgitation on the other hand is frequently present from the onset of the active process³
- Initial regurgitation has been noted to disappear over periods ranging from 2 months to 9 years, while new lesions such as mitral stenosis, or stenosis combined with regurgitation, appeared over a period of up to 12 years³
- Patients with mitral regurgitation are far more likely to have suffered a more severe acute episode than those with mitral stenosis

ia. SYMPTOMS

The severity, and to a lesser extent the chronicity, of the regurgitant valve are the main factors in determining the symptoms.

- Patients with mild lesions completely asymptomatic
- Patients with moderate mitral regurgitation symptoms may be relatively unimpressive
- Patients with severe valvular incompetence effort dyspnoea, easy fatiguability, poor weight gain, palpitations on effort, paroxysmal nocturnal dyspnoea, and finally congestive heart failure (CHF)³

ib. SIGNS

- Radial pulse may be normal but increased with low volume in severe regurgitation
- Blood pressure normal with a slightly widened pulse pressure, giving a brisk pulse
- Jugular venous pressure normal when there is no CHF, elevated in CHF
- Apical impulse usually normal in those with mild lesions, with no major precordial pulsations
- In significant mitral regurgitation, there is a hyperdynamic forcible left ventricular heaving apex which may be palpable, displaced downwards and laterally
- The first heart sound is normal in intensity or somewhat soft; the second heart sound is usually normal; in severe lesions markedly split because of the shortening of left ventricular systole³
- The presence of a loud third heart sound excludes the coexistence of significant mitral stenosis
- → The most important clinical feature is the characteristic apical pan-systolic murmur
- It is heard best at the apex, radiates to the left axilla and left sternal edge and has a blowing quality with no accentuation in mid- or late systole
- Occasionally, especially in the presence of acute valvulitis, the murmur may be short
- A low-pitched third heart sound, which is often palpable and is caused by the considerable early diastolic filling of the ventricle, is heard in those with significant mitral regurgitation and left ventricular failure⁴
- Associated pulmonary hypertension:
 - right ventricular parasternal lift/heave
 - a loud palpable pulmonary sound
 - murmurs of pulmonary and/or tricuspid incompetence
 - The clinical signs of mitral regurgitation are much less clear-cut than those of mitral stenosis¹ as a secondary cause of pulmonary hypertension

ii. MITRAL STENOSIS

iia. SYMPTOMS

Those with mild stenosis may be completely asymptomatic⁵. Exercise intolerance and atrial fibrillation are among the precipitating causes of the initial presentation of symptoms.

Critical or significant mitral stenosis is present when the area of the valvular orifice is reduced to about one-quarter of the expected normal for age.

- The common symptoms in critical stenosis are cough with frothy or blood-stained sputum, effort dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea and episodes of pulmonary oedema
- These symptoms may be aggravated by recurrence of carditis, intercurrent infections, and uncontrolled tachycardia or atrial fibrillation
- Congestive cardiac failure usually occurs with severe stenosis and moderate-severe pulmonary hypertension⁵

iib. SIGNS

With chronic mitral stenosis, reduced cardiac output and vasoconstriction can result in mitral facies (violaceous papules on the cheeks). Other signs include:

- Jugular venous distension
- Right ventricular heave in the left parasternal region in the patient with superimposed pulmonary hypertension; a loud P2 might be heard in the left 2nd intercostal space
- Apex beat is usually not displaced unless there is associated mitral regurgitation
- Apical beat may be tapping in nature
- On apical auscultation, there is an opening snap, loud first heart sound, and a low-pitched mid-diastolic rumble murmur
- A high-pitched decrescendo diastolic murmur secondary to pulmonary regurgitation (Graham-Steel's murmur) may be audible at the upper sternal border⁶

iii. AORTIC REGURGITATION (AR)

iiia. SYMPTOMS

Patients with chronic AR are often asymptomatic for several years. When symptoms develop, cardiac function deteriorates quickly, and mortality rate might exceed 10% a year. Symptoms include:

- Palpitations
- Shortness of breath
- Chest pain
- Orthopnoea

iiib. SIGNS

Most of the physical signs of AR are a result of the widened pulse pressures that are characteristic of this condition:

- Visible systolic pulsations of retinal arterioles (fundoscopy)
- Water-hammer pulse
- Bobbing motion of head with each heartbeat
- Systolic murmur over the femoral artery with proximal compression of the artery, and diastolic murmur over the femoral artery with distal compression of the artery
- On palpation, the point of maximal impulse (apex beat) may be diffuse or hyperdynamic but is often displaced inferiorly and laterally, peripheral pulses are prominent or bounding

RHD

- Auscultation may reveal an S3 gallop, if left ventricular dysfunction is present⁷
- Early diastolic murmur at right parasternal area which radiates to the apex
- For severe AR, ejection systolic murmur could be heard over the aortic area due to large stroke volume

iv. AORTIC STENOSIS

iva. SYMPTOMS

Usually asymptomatic for up to 20 years. However, the following might be elicited as left ventricular outflow obstruction and myocardial pressure load worsen:

- Exertional dyspnoea (most common initial complaint)
- Paroxysmal nocturnal dysponea
- Orthopnoea
- Exertional chest pain⁸
- Syncope

ivb. SIGNS

- Soft S1 and diminished/absent A2
- Paradoxical splitting of S2
- Prominent S4
- Systolic crescendo-decrescendo murmur at the second intercostal space at the right upper sternal border which radiate to the carotid arteries⁸

v. TRICUSPID REGURGITATION (TR)

va. SYMPTOMS

The general presentation is that of right-sided heart failure.

- Exertional dyspnoea
- Abdominal swelling
- Bodily swelling⁹

vb. SIGNS

- S3 gallop
- Jugular venous distension
- Right ventricular heave
- Ascites
- Peripheral oedema
- Pulsatile hepatomegaly⁹

vi. PULMONARY VALVE

SYMPTOMS AND SIGNS

- Pulmonic regurgitation is rarely noticed by the patient; however, right ventricular enlargement and/ or pulmonary hypertension can ensue and result in heart failure, leading to dyspnoea on exertion (most common), easy fatigability, light-headedness, peripheral oedema, chest pain, palpitations, and frank syncope; the JVP will likely be increased¹⁰
- Clinical features of pulmonic stenosis include dyspnoea, cyanosis, fatigue, dizziness and syncope, and chest pain¹¹

5.7.4 MANAGEMENT ACCORDING TO LEVEL OF CARE

i. HEALTH FACILITY WITHOUT A DOCTOR

Clinical suspicion or diagnosed based on symptoms and signs.

Place the patient in the cardiac position and perform the following basic labs when available:

- Full blood cell count
- Erythrocyte sedimentation rate
- \rightarrow Refer to a health facility with a doctor or physician specialist.

ii. HEALTH FACILITY WITH A DOCTOR

LABORATORY INVESTIGATION

Perform the following:

- Full blood cell count
- Erythrocyte sedimentation rate
- C-reactive protein
- Blood urea electrolytes and creatinine
- Liver function test

PHARMACOLOGICAL TREATMENT

Provide symptomatic relief with medical treatment when patient has symptoms and signs of heart failure.

- Furosemide:
 - Adults:
 - 20-80mg orally once daily; may be increased by 20-40mg 6-8 hourly; not to exceed 600mg/day
 - Alternative: 20-40mg iv/im once; may be increased by 20mg 2 hourly; individual dose not to exceed 200mg/dose¹²
 - Infants and children:
 - 1-2mg/kg iv/im/orally once initially; increased by 1-2mg/kg q6-8hrs (orally) or 1mg/kg q2hrs (iv/im); individual dose not to exceed 6mg/kg¹²
- → Refractory chronic heart failure may necessitate larger doses
- \rightarrow Additional medication can be discussed with specialist before initiation (please note precautions)
- \rightarrow Refer to health facility with a physician specialist.

iii. HEALTH FACILITY WITH A PHYSICIAN SPECIALIST

LABORATORY INVESTIGATION

Perform the following:

- Full blood cell count
- Erythrocyte sedimentation rate
- C-reactive protein
- Blood urea electrolytes and creatinine
- Liver function tests
- Throat swab
- Anti-streptolysin 0 titres

NON-LABORATORY INVESTIGATION

- CXR
- ECG
- Echocardiography

PHARMACOLOGICAL TREATMENT

MANAGEMENT OF HEART FAILURE

Treat based on New York Heart Association staging of heart failure for classes III-IV:

A. Oxygen by nasal prongs or face mask if hypoxaemia is present (Sp0₂ <90%)

B. Cardiac position

C. Diuretics

- Furosemide
 - Adults: 20-80mg orally once daily; may be increased by 20-40mg 6-8 hourly; not to exceed 600mg/day

Alternative: 20-40mg iv/im once; may be increased by 20mg 2 hourly; individual dose not to exceed 200mg/dose¹⁵

Infants and children: 1-2mg/kg iv/im/orally once initially; increased by 1-2mg/kg 6-8 hourly (orally) or

1mg/kg 2 hours (iv/im). Individual dose not to exceed 6mg/kg¹⁵

- → Maintenance after stabilization¹⁴:
- Furosemide iv
 - Adults: 40-80mg 12 hourly
 - Children: 12-18 years: 20-40mg 8 hourly as required
 1 month 12 years: 0.5-1mg/kg 8 hourly (max. 4mg/kg/dose)
- → Patient not improving after initial treatment:
- Furosemide iv
 - Adults: 40-80mg 12 hourly
 - Children: 12-18years: 20-40mg repeated 8 hourly as necessary
 1 month 12 years: 0.5-1mg/kg 8 hourly (max. 4mg/kg/dose)

and

- Morphine iv for patients with acute left ventricular failure
 - Adults: 2.5-10mg (for the elderly 2.5-5mg slowly)
 - Children: not recommended

and

- Metoclopramide iv
 - Adults: 10mg to prevent vomiting
 - Children: not required
- D. Angiotensin converting enzyme/receptor blocker therapy
 - Enalapril
 - Adults: Initial: 2.5mg orally daily or twice daily
 - → Maintenance: 5-20mg/day orally daily; titrate slowly over 2 weeks
 - → Avoid in unstable heart failure or patients which hypotension¹⁶
 - or
 - Losartan
 - Adults: 25mg orally daily initially; may increase to 100mg¹⁷

E. Digoxin¹⁴:

- Adults: 250mcg 12 hourly for 1-2 days, then 250mcg daily
- Elderly: 125mcg 12 hourly for 1-2 days, then 125mcgs daily
- Children >10 years old: 0.5-1mg in 3 divided doses over 24hrs, then 62.5-250mcg daily
- Children 2-10 years old: 20-30mcgs/kg in 3 divided doses over 24 hours, then 8-10mcg/kg daily
- Children <2 years old: 30-40mcg/kg in 3 divided doses/24 hours, then 10-1mcg/kg daily
- Neonates (full term): 20mcg/kg in 3 divided doses/24 hours, then 8-10mcg/kg daily
- Neonates <1.5 kg: 25mcg/kg in 3 divided doses/24 hours</p>
 - Premature: 15mcg/kg daily, then 5mcg/kg daily

ANTICOAGULATION

 \rightarrow Anticoagulation, if there is a history of thromboembolism and/or atrial fibrillation.

- \rightarrow Anticoagulation: maintain INR of 2-3.
- Adults: Warfarin

Initial dose: 2-5mg orally day \times 2 days, or 10mg orally \times 2 days in healthy individuals¹³

It is important to bridge the initiation of Warfarin with unfractionated or low molecular weight heparin; check INR after 2 days and adjust dose according to results

Typical maintenance dose ranges between 2-10mg/day¹³

RATE CONTROL IN PATIENTS WITH ATRIAL FIBRILLATION

For patients with atrial fibrillation, control of ventricular response could be achieved with the following:

Adults:

Atenolol orally 25-100mg daily

or

Bisoprolol orally 2.5-10mg daily

or

Metoprolol tartrate orally 50-100mg twice or three times daily (max. 300mg daily)¹⁴

SECONDARY PROPHYLAXIS AGAINST RECURRENT ARF AND CARDITIS

- Intramuscular (im) Benzathine Penicillin G (BPG)
 - Adults: 900mg (1,200,000 U) as a single shot monthly
 - Children less than 30 kg: 450mg (600,000 U) as a shot monthly
- or
- Penicillin V
 - Adults: 250mg orally twice daily²

Duration of prophylaxis:

- RF with carditis and residual heart disease (persistent valvular disease):
 10 years or until age 40 years (whichever is longer)
- RF with carditis but no residual heart disease (no valvular disease):
 10 years or until age 21 years (whichever is longer)
- RF without carditis:
 5 years or until age 21 years (whichever is longer)²

INFECTIVE ENDOCARDITIS PROPHYLAXIS IN PATIENTS WITH RHD

- Antibiotic prophylaxis before major dental, oral, respiratory tract, or oesophageal procedures is targeted towards *S viridans*
- Standard general prophylaxis is a single dose **Amoxicillin** 2g orally 30-60 minutes before the procedure.
- If unable to take oral medication, consider a single dose of Ampicillin, 2g IV/IM 30-60 minutes before the procedure¹⁹
- Activity restrictions based on severity of valvular disease
- \rightarrow Refer to a facility with a cardiologist/cardiothoracic surgeon for definite treatment of the RHD.

iv. HEALTH FACILITY WITH A CARDIOLOGIST OR CARDIOTHORACIC SURGEON

PERCUTANEOUS BALLOON VALVULOPLASTY

Valvuloplasty might become necessary for symptom relief, especially with rheumatic mitral stenosis. American Heart Association (AHA)/American College of Cardiology (ACC) guideline recommendations are as follows²⁰:

- Perform percutaneous mitral balloon valvuloplasty (PMBV) for patients with severe mitral stenosis Mitral valve area (MVA) <1.5 cm2, favourable valve morphology and absence of contraindications such as left atrial thrombus or significant mitral regurgitation (class 1)
- Asymptomatic patients with MVA <1.5 cm², pulmonary hypertension (systolic pulmonary pressure >50 mmHg at rest or >60 mmHg with exercise), and favourable valve morphology should also be considered for PMBV (class 1)
- Patients with calcific mitral stenosis who are at high risk for surgical commissurotomy should be considered for PMBV when advanced heart failure (NYHA class III-IV) and severe mitral stenosis (MVA <1.5 cm²) are present (class IIa)
- Similar patients who are at lower risk for surgical commissurotomy may also be considered for PMBV (class 1lb)
- Symptomatic patients (NYHA class II-IV) with milder stenosis (MVA >1.5 cm²) and pulmonary hypertension may be considered for PMBV (class IIb)

• Asymptomatic patients with MVA less than 1.5 cm² with new atrial fibrillation may also be considered for PMBV (class 1lb)

Similar recommendations have been made by the European Society of Cardiology. Palliative treatment may be considered in patients who are not suitable candidates for surgery even when valve morphology is not ideal.

SURGICAL VALVE REPAIR/REPLACEMENT²¹

Current guidelines limit mitral valve replacement to irreparable valve pathology that will result in poor durability outcomes, especially in patients unlikely to tolerate future reinterventions.

Valve replacement for mitral stenosis (MS) may be considered in patients who are candidates for surgical therapy when the valve is not suitable for valvotomy (either surgical or percutaneous). The recommendations for surgery in patients with mitral stenosis, according to the current ACC/AHA guidelines, are described below:

- Mitral valve surgery (repair if possible) is indicated in patients with symptomatic (New York Heart Association [NYHA] functional class III–IV) moderate or severe MS under any of the following circumstances:
 - Percutaneous mitral balloon valvotomy is unavailable
 - Percutaneous mitral balloon valvotomy is contraindicated because of left atrial thrombus despite anticoagulation or because concomitant moderate to severe mitral regurgitation (MR) is present
 - The valve morphology is not favourable for percutaneous mitral balloon valvotomy in a patient with acceptable operative risk (class 1)
 - Symptomatic patients with moderate to severe MS who also have moderate to severe MR should receive mitral valve replacement (MVR) unless valve repair is possible at the time of surgery (class I)
 - Mitral valve replacement is reasonable in patients with severe MS and severe pulmonary hypertension (pulmonary artery systolic pressure >60 mmHg) who have NYHA functional class 1–11 symptoms and who are not considered candidates for percutaneous mitral balloon valvotomy or surgical mitral valve repair (class 11a)

5.7.5 PATIENT INFORMATION

- Counselling: patients should be counselled at diagnosis and prior to discharge on disease condition
- Within 4 weeks of discharge, patient should be reviewed or reassessed
- Patient management should be individualised in relation to comorbidities and disease severity
- Counsel on diuretics, febrile illness and diarrhoeal illness, salt and fluid restriction
- Infective endocarditis prophylaxis be considered and individualised in patients undergoing dental procedures
- Report to the cardiologist once pregnancy occurs; planned pregnancy is preferred with prior cardiologist consult

REFERENCES

- ¹ Rheumatic Heart Disease in Developing Countries. N Engl J Med. 2007 Nov 15; 357 (20): 2089–2089.
- ² Rheumatic Fever: Background, Pathophysiology, Epidemiology. 2019 Jan 17. Available from: https://emedicine.medscape.com/article/236582-overview#a6.
- ³ Mitral Regurgitation: Practice Essentials, Background, Pathophysiology. 2019 Feb 2. Available from: https://emedicine.medscape.com/article/155618-overview.
- ⁴ Gewitz Michael H., Baltimore Robert S., Tani Lloyd Y., Sable Craig A., Shulman Stanford T., Carapetis Jonathan, et al. Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography. Circulation. 2015 May 19; 131 (20): 1806–18.
- ⁵ Mitral Stenosis Treatment & Management: Medical Care, Surgical Care, Consultations . Available from: https://emedicine.medscape.com/article/155724-treatment.
- ⁶ Rheumatic Heart Disease: Pathogenesis and Vaccine: Ingenta Connect. Available from: https://www.ingentaconnect.com/contentone/ben/cpps/2018/00000019/0000009/art00010.
- Aortic Regurgitation Clinical Presentation: History, Physical Examination.
 Available from: https://emedicine.medscape.com/article/150490-clinical.
- ⁸ Aortic Stenosis Pathology: Overview, Etiology, Clinical Features. 2019 Feb 1; Available from: https://emedicine.medscape.com/article/2018199-overview.
- ⁹ Tricuspid Regurgitation Clinical Presentation: History, Physical Examination. Available from: https://emedicine.medscape.com/article/158484-clinical.
- ¹⁰ Pulmonary Regurgitation (Pulmonic Regurgitation) Clinical Presentation: History, Physical Examination, Stages of Progression of Valvular Heart Disease. Available from: https://emedicine.medscape.com/article/157639-clinical.
- Pulmonic Valvular Stenosis Clinical Presentation: History, Physical, Causes. Available from: https://emedicine.medscape.com/article/759890-clinical.
- Heart Failure: Practice Essentials, Background, Pathophysiology. 2019 Jan 4; Available from: https://emedicine.medscape.com/article/163062-overview.
- ¹³ Coumadin, Jantoven (warfarin) dosing, indications, interactions, adverse effects, and more]. Available from: https://reference.medscape.com/drug/coumadin-jantoven-warfarin-342182.
- ¹⁴ Standard Treatment Guidelines. Ministry of Health Ghana; 2017.
- ¹⁵ Lasix (furosemide) dosing, indications, interactions, adverse effects, and more. Available from: https://reference.medscape.com/drug/lasix-furosemide-342423.
- ¹⁶ Enalaprilat, Vasotec (enalapril) dosing, indications, interactions, adverse effects, and more. Available from: https://reference.medscape.com/drug/vasotec-enalaprilat-enalapril-342317.
- ¹⁷ Cozaar (losartan) dosing, indications, interactions, adverse effects, and more. Available from: https://reference.medscape.com/drug/cozaar-losartan-342323.
- ¹⁸ Nipride RTU, Nitropress (nitroprusside sodium) dosing, indications, interactions, adverse effects, and more. Available from: https://reference.medscape.com/drug/nipride-rtu-nitropress-nitroprusside-sodium-342312.
- ¹⁹ Centre for Clinical Practice at NICE (UK). Prophylaxis Against Infective Endocarditis: Antimicrobial Prophylaxis Against Infective Endocarditis in Adults and Children Undergoing Interventional Procedures. London: National Institute for Health and Clinical Excellence (UK); 2008. (National Institute for Health and Clinical Excellence: Guidance). Available from: http://www.ncbi.nlm.nih.gov/books/NBK51789/.
- ²⁰ Mitral Valvuloplasty: History of the Procedure, Problem, Epidemiology. 2019 Feb 1. Available from: https://emedicine.medscape.com/article/1533651-overview#a11.
- ²¹ van der Merwe J, Casselman F. Mitral Valve Replacement—Current and Future Perspectives. Open J Cardiovasc Surg. 2017 Jul 13; 9.

5 **DISEASES**

5.8 INFECTIVE ENDOCARDITIS

LIST OF ABBREVIATIONS AND ACRONYMS

ARF	Acute rheumatic fever	HF	Heart failure
ASO	Antistreptolysin O	IE	Infective Endocarditis
BUE	Blood urea electrolytes	MI	Myocardial infarction
CHD	Congenital heart disease	NVE	Native valve endocarditis
CRP	C-reactive protein	PVE	Prosthetic valve endocarditis
ECG	Electrocardiogram	TOE	Transoesophageal
ESR	Erythrocyte sedimentation rate		echocardiogram
GAS	Group A Streptococcus	WBC	White blood cell count
FBC	Full blood cell count		

5.8.1 INTRODUCTION

i. **DEFINITION**

Infective endocarditis (IE) is an infection involving the endocardial surface (inner lining) of the heart which may include heart valves and congenital defects. Infections are mainly bacterial and fungal in origin. The process of endocarditis involves infection, inflammation and immune response to the bacteria or fungi. The process of endocarditis leads to the formation of vegetation on the valve or endocardium, which is made up of bacteria/fungi, clots and inflammatory substances.

The vegetation can dislodge (embolize) to distant organs like the brain¹.

ii. CLASSIFICATION

IE is classified into five main types

- Native (natural) valve (NVE)
- Prosthetic (artificial) valve endocarditis (PVE)
- Intravenous drug abuse (IVDA) endocarditis
- Fungal endocarditis
- Nosocomial/hospital acquired

iii. RISK FACTORS

- Congenital heart defects
- Rheumatic valvular disease
- Degenerative heart disease including calcific aortic stenosis due to either a bicuspid valve, Marfan's syndrome or syphilitic disease
- Mitral valve prolapse
- Prosthetic (artificial) valve

Rarely do we have endocarditis involving normal valves.

5.8.2 AETIOLOGY

See table 66: Aetiology of infective endocarditis based on classification on next page.

Classification	Characteristics	Causative organism
Native (natural) valve endocarditis (NVE)	Complications arise due to slowly progressive valvular destruction, embolic or immunologic phenomena	 Streptococcus spp S. viridans S. bovis Enterococci Staphylococcus spp
Prosthetic (artificial) valve endocarditis (PVE)	 A complication of surgery (early or late): Early complication of the surgery (less than a year) runs an aggressive acute course with local abscess, valve dehiscence, and fistula formation resulting in shock, heart failure, emboli and pericardial tamponade Late complication of surgery (>1 year) runs a sub-acute course 	 Staphylococcus aureus Corynebacterium, Fungi (candida spp, aspergillus spp) Legionella Haemophilus spp Actinobacillus spp Cardiobacterium hominis Eikenella corrodens Kingella kingae
Intravenous drug abuse (IVDA) endocarditis	Right-sided endocarditis is the most common presentation, which involves the tricuspid valve, and a murmur is not always present	Staph. aureusGroup A strepEnterococci
Fungal endocarditis	Commonly found in intravenous drug users and intensive care unit patients who receive bro- ad-spectrum antibiotics	 Candida spp Aspergillus spp blood cultures are usually negative
Nosocomial (hospi- tal-acquired) endocarditis	A rare complication of nosocomial sepsis usually from intravascular devices e.g. central lines/ catheters, peripheral intravenous catheters and intracardiac devices such as pacemakers	Staph. aureusEnterococci

Table 66: Aetiology of infective endocarditis based on classification

5.8.3 CLINICAL PRESENTATION

A high index of suspicion (alertness) is required in the diagnosis of infective endocarditis. The clinical presentation (signs and symptoms) of infective endocarditis is highly variable. Presentation depends on the causative organism, the presence or absence of pre-existing cardiac disease, and the presence or absence of prosthetic valves or cardiac devices. Symptoms are therefore commonly non-specific constitutional symptoms (fever, weight loss, joint pains, etc.), symptoms associated with primary cardiac defects, or secondary embolic phenomena.

i. COMMON SYMPTOMS

- Fever
- Chills
- Anorexia
- Malaise
- Myalgia
- Headache

Night sweatsDyspnoea

Weight loss

- Chest pain
- Cough
- Joint pains

ii. SYMPTOMS ASSOCIATED WITH SECONDARY EMBOLIC PHENOMENA

- Symptoms of acute meningitis (fever, severe headache, seizures, photophobia, confusion)
- Focal neurologic complaints (e.g. hemiplegia) due to embolic stroke (infarct or haemorrhage)
- Angina/myocardial infarction
- Back pain associated with vertebral osteomyelitis
- Unilateral blindness
- Painless haematuria

Dyspnoea, cough, and chest pain are common complaints of intravenous drug users. This is due to the predominance of tricuspid valve endocarditis in this group and secondary emboli to the pulmonary vasculature.

iii. SIGNS

- Fever
- Heart murmurs
- Change in a pre-existing murmur
- Petechiae
- Splinter haemorrhages: dark red linear lesions in the nailbeds
- Janeway lesions: non-tender maculae on the palms and soles
- Osler nodes: tender subcutaneous nodules usually found on the distal pads of the digits
- Roth spots: retinal haemorrhages with small, clear centres (rare)
- Splenomegaly

iv. DIAGNOSTIC CRITERIA

Other signs include the following:

- Stiff neck
- Paralysis, hemiparesis, aphasia
- Delirium
- Pallor
- Conjunctival haemorrhage
- Crackles
- Pleural friction rub
- Cardiac arrhythmia
- Gallops
- Pericardial rub

Diagnosis of infective endocarditis is based on the modified Duke's criteria which differentiates diagnoses into definite, possible or rejected infective endocarditis².

Table 67: Major and minor	criteria for the diagnosis	of infective endocarditis	$(A danted from \cdot 1 i et al3)$
Table 07. Major and minor	cificila for the diagnosis	or infective chuocarulus	(Auapicu nomi Li ci al. j

Major and minor	criteria for the diagnosis of infective endocarditis	
Major criteria	 Two positive blood cultures for organisms typical of All of 3 or a majority of 4 or more positive blood culture) for organisms consistent with endocarditis Serologic evidence of Coxiella burnetii (IgG titre > 1 burnetii Echocardiographic evidence of endocardial involvem Oscillating intracardiac mass (vegetation) on a hearegurgitant jets, or on implanted material without a Cardiac abscess New dehiscence of prosthetic valve New valvular regurgitation 	tures (with at least 1 h between first and last cul- :800) or one positive blood culture for Coxiella ent: rt valve, on supporting structures, in the path of
Minor criteria	 Predisposing heart disorder IV drug abuse Fever ≥38.0° C Immunologic phenomena: Glomerulonephritis Osler nodes Roth spots Rheumatoid factor Microbiologic evidence of infection consistent with but Serologic evidence of infection with organisms consistent 	

Modified Duke's criteria for infective endocarditis			
Clinical diagnostic status	Criteria		
Definite endocarditis	One of the following: • 2 major criteria • 1 major and 3 minor • 5 minor		
Possible endocarditis	One of the following: 1 major and 1 minor 3 minor 		
Endocarditis rejected (excluded)	 One of the following: Firm alternative diagnosis explaining the findings of infective endocarditis Resolution of symptoms and signs after ≤ 4 d of antimicrobial therapy No pathologic evidence of infective endocarditis found during surgery or autopsy Failure to meet the clinical criteria for possible endocarditis 		

Table 68: Modified Duke's criteria for infective endocarditis (Adapted from Li et al.³)

5.8.4 MANAGEMENT ACCORDING TO LEVEL OF CARE

i. HEALTH FACILITY WITHOUT A DOCTOR

The diagnosis of Infective endocarditis in a facility without a doctor may be very difficult. IE should be suspected in a patient with a known heart condition presenting with fever, weight loss and worsening heart failure or any patient who presents with fever, weight loss and no response to antimalarial and antibiotic therapy for >4 days.

LABORATORY INVESTIGATION

- Full blood cell count
- Urine dipstick

PHARMACOLOGICAL TREATMENT

Oral analgesics/antipyretic in case of fever 1g Paracetamol t.d.s (oral)

 \rightarrow Refer to a health facility with a doctor.

ii. HEALTH FACILITY WITH A DOCTOR

IE should be suspected in a patient with a known heart condition presenting with fever, weight loss and worsening heart failure or any patient who presents with fever, weight loss and no response to antimalarial and antibiotic therapy for >4 days and a high ESR/CRP.

LABORATORY INVESTIGATION

- Full blood cell count
- Blood cultures: at least three samples containing 10ml of blood each, taken at 30 minutes intervals from a peripheral vein
- Erythrocyte sedimentation rate (ESR)
- Urinalysis: proteinuria, microscopic haematuria

PHARMACOLOGICAL TREATMENT

Patients with non-complicated native valve endocarditis (NVE) with normal renal function:

- Penicillin G, iv (Evidence rating B)
 Adults: 12-18 million U/day in 4-6 daily doses (or continuous infusion) for 2 weeks
 Children: 200,000 U/kg/day in 4-6 doses for 2 weeks
 or
- Ceftriaxone, iv or im (Evidence rating B) Adults: 2g/day in 1 dose for 2 weeks Children: 100mg/kg/day in 1 dose for 2 weeks with
- Gentamycin, iv or im (Evidence rating B)
 Adults: 3mg/kg/day in 1 dose for 2 weeks
 Children: 3mg/kg/day in 1 dose or 3 equally divided doses for 2 weeks
- → Patients ≥65 years or with impaired renal or VIII (Vestibulocochlear) cranial nerve dysfunction: avoid Gentamycin
- Penicillin G, iv (Evidence rating B) Adults: 12-18 million U/day in 4-6 daily doses (or continuous infusion) for 4 weeks Children: 200,000 U/kg/day in 4-6 daily doses for 4 weeks or
- Ceftriaxone, iv or im (Evidence rating B)
 Adults: 2g/day in 1 dose for 4 weeks
 Children: 100mg/kg/day in 1 dose for 4 weeks
- \rightarrow NB: A 6-week therapy is recommended for patients with prosthetic valve endocarditis (PVE)

Beta-lactam (Penicillin) allergic patients:

- Vancomycin, iv (Evidence rating C)
 Adults: 30mg/kg/day in 2 doses for 4 weeks
 Children: 40mg/kg/day in 2 or 3 equally divided doses for 4 weeks
- \rightarrow NB: A 6-week therapy is recommended for patients with PVE

Patients with strains relatively resistant to Penicillin (MIC) 0.250-2mg/l):

- Penicillin G, iv (Evidence rating B)
 Adults: 24 million U/day in 4-6 daily doses (or continuous infusion) for 4 weeks or
- Ceftriaxone, iv or im (Evidence rating B) Adults: 2g/day in 1 dose for 4 weeks with
- Gentamycin, iv or im (Evidence rating B) Adults: 3mg/kg/day in 1 dose for 2 weeks

For strains relatively resistant to Penicillin (MIC 0.250-2mg/l) in Beta-lactam allergic patients:

Vancomycin, iv (Evidence rating C)
 Adults: 30mg/kg/day in 2 doses for 4 weeks
 Children: 40mg/kg/day in 2 or 3 equally divided doses for 4 weeks

with

- Gentamycin, iv or im (Evidence rating C) Adults: 3mg/kg/day in 1 dose for 2 weeks Children: 3mg/kg/day in 1 dose or 3 equally divided doses for 2 weeks
- → Refer all cases of infective endocarditis to physician specialist.
- → Refer all cases of complicated infective endocarditis to cardiologist/cardiothoracic surgeon.

iii. HEALTH FACILITY WITH A PHYSICIAN SPECIALIST

LABORATORY INVESTIGATION

- Full blood cell count
- Blood cultures: at least three samples containing 10ml of blood each, taken at 30 minutes intervals from a peripheral vein
- Erythrocyte sedimentation rate (ESR)
- Urinalysis- proteinuria, microscopic haematuria

NON-LABORATORY INVESTIGATION

- Echocardiography
- Chest X-ray

PHARMACOLOGICAL TREATMENT

Patients with non-complicated native valve endocarditis (NVE) with normal renal function:

Penicillin G, iv (Evidence rating B)
 Adults: 12-18 million U/day in 4-6 daily doses (or continuous infusion) for 2 weeks
 Children: 200,000 U/kg/day in 4-6 doses for 2 weeks

or

• Ceftriaxone, iv or im (Evidence rating B) Adults: 2g/day in 1 dose for 2 weeks

Children: 100mg/kg/day in 1 dose for 2 weeks

with

Gentamycin, iv or im (Evidence rating B)
 Adults: 3mg/kg/day in 1 dose for 2 weeks

Children: 3mg/kg/day in 1 dose or 3 equally divided doses for 2 weeks

- → Patients ≥65 years or with impaired renal or VIII (vestibulocochlear) cranial nerve dysfunction: avoid Gentamycin
- Penicillin G, iv (Evidence rating B)
 Adults: 12-18 million U/day in 4-6 doses (or continuous infusion) for 4 weeks
 Children: 200,000 U/kg/day in 4-6 doses for 4 weeks

or

Ceftriaxone, iv or im (Evidence rating B)
 Adults: 2g/day in 1 dose for 4 weeks
 Children: 100 mg/kg/day in 1 dose for 4 weeks

 \rightarrow NB: A 6-week therapy is recommended for patients with prosthetic valve endocarditis (PVE).

Beta-lactam (Penicillin) allergic patients:

- Vancomycin, iv (Evidence rating C)
 - Adults: 30mg/kg/day in 2 doses for 4 weeks

Children: 40mg/kg/day in 2 or 3 equally divided doses for 4 weeks

\rightarrow NB: A 6-week therapy is recommended for patients with PVE.

Patients with strains relatively resistant to penicillin (MIC 0.250-2mg/l):

- Penicillin G, iv (Evidence rating B)
 Adults: 24 million U/day in 4-6 doses (or continuous infusion) for 4 weeks
- or
- Ceftriaxone, iv or im (Evidence rating B) Adults: 2g/day in 1 dose for 4 weeks with
- Gentamycin, iv or im (Evidence rating B) Adults: 3mg/kg/day in 1 dose for 2 weeks

For strains resistant to Penicillin (MIC 0.250-2mg/l) in Beta-lactam allergic patients:

- Vancomycin, iv (Evidence rating C) Adults: 30mg/kg/day in 2 doses for 4 weeks Children: 40mg/kg/day in 2 or 3 equally divided doses for 4 weeks with
- Gentamycin, iv or im (Evidence rating C)
 Adults: 3mg/kg/day in 1 dose for 2 weeks
 Children: 3mg/kg/day in 1 dose or 3 equally divided doses for 2 weeks
- → Refer all cases of complicated infective endocarditis to a centre with cardiothoracic surgical facilities.

Indications for surgery	
Heart failure	 Aortic or mitral NVE or PVE with severe acute regurgitation, obstruction or fistula causing refractory pulmonary oedema or cardiogenic shock Aortic or mitral NVE or PVE with severe regurgitation or obstruction causing symptoms of HF or echo-cardiographic signs of poor haemodynamic tolerance
Uncontrolled infection	 Locally uncontrolled infection (abscess, false aneurysm, fistula, enlarging vegetation) Infection caused by fungi or multi-resistant organisms Persistent positive blood cultures despite appropriate antibiotic therapy and adequate control of septic metastatic foci PVE caused by staphylococci or non-HACEK gram-negative bacteria
Prevention of embolism	 Aortic or mitral NVE or PVE with persistent moderate size vegetation (10mm) after one or more embolic episode despite appropriate antibiotic therapy Aortic or mitral NVE with moderate size vegetation (10mm) associated with severe valve stenosis or regurgitation, and low operative risk Aortic or mitral NVE or PVE with isolated very large vegetations (30mm) Aortic or mitral NVE or PVE with isolated large vegetations (15mm) and no other indication for surgery HACEK = Haemophilus spp, Actinobacillus spp, Cardiobacterium spp., Eikenella spp., Kingella spp.

Table 69: Indications for surgery⁴

5.8.5 COMPLICATIONS

Cardiac

- Myocardial infarction
- Pericarditis
- Cardiac arrhythmia
- Cardiac valvular insufficiency
- Congestive heart failure
- Sinus of Valsalva aneurysm
- Aortic root or myocardial abscesses
- Arterial emboli, infarcts, mycotic aneurysms

5.8.6 PREVENTION

Antibiotic prophylaxis should not routinely be prescribed for:

- Patients undergoing dental procedures.
- Patients undergoing non-dental procedures at the following sites:
 - Gastrointestinal tract
 - Genitourinary tract (including urological, gynaecological and obstetric procedures, and childbirth)
 - Respiratory tract (including ear, nose and throat procedures and bronchoscopy)⁵
- → Antibiotic prophylaxis is recommended only for the highest risk patients during certain high risk procedures⁵.

Cardiac conditions at highest risk of infective endocarditis for which preventive treatment should be considered when a high-risk procedure is performed are:

- Patients with any prosthetic valve, including a transcatheter valve, or those in whom any prosthetic material was used for cardiac repair
- Patients with previous episode of IE
- Patients with congenital heart disease (CHD)
- Any type of CHD repaired with a prosthetic material, whether placed surgically or by percutaneous techniques, up to 6 months after the procedure or lifelong if residual shunt or valvular regurgitation remains⁵

Extra-cardiac

- Arthritis, myositis
- Glomerulonephritis
- Acute renal failure
- Stroke syndromes
- Mesenteric or splenic abscess or infarct

Table 70: Recommendations for prophylaxis of infective endocarditis in the highest-risk patients according to the type of at-risk procedure (Adapted from the 2015 ESC Guidelines for the management of infective endocarditis⁶)

Risk Score	Recommendations	Level of evidence
Dental Procedures	Antibiotic prophylaxis should only be considered for dental procedures requiring manipulation of the gingival or periapical region of the teeth or perforation of the oral mucosa	С
	Antibiotic prophylaxis is NOT recommended for local anaesthetic injections in non-infected tissues, treatment of superficial caries, removal of sutures, dental X-rays, placement or adjustment of remova- ble prosthodontic or orthodontic appliances or braces or following the shedding of deciduous teeth or trauma to the lips and oral mucosa	с
Respiratory tract procedures	Antibiotic prophylaxis is NOT recommended for respiratory tract procedures, including bronchoscopy or laryngoscopy, or transnasal or endotracheal intubation	С
	Patients who undergo an invasive respiratory tract procedure to treat an established infection (i.e. drainage of an abscess) should receive an antibiotic regimen that contains an anti-staphylococcal drug	
Gastrointestinal or urogenital procedures or	Antibiotic prophylaxis is NOT recommended for gastroscopy, colono- scopy, cystoscopy, vaginal or caesarean delivery or TOE	С
TOE	In the case of an established infection or if antibiotic therapy is indicated to prevent wound infection or sepsis associated with a gastrointestinal or genitourinary tract procedure in patients, it is recommended that the antibiotic regimen includes an agent active against enterococci	В
Skin and soft tissue	Antibiotic prophylaxis is not recommended for any procedure	с
procedures	For patients undergoing surgical procedures involving infected skin (including oral abscesses), skin structure or musculoskeletal tissue, it is advised that the therapeutic regimen contains an agent active against staphylococci and beta-haemolytic streptococci	С
Cardiac and vascular procedures	Perioperative prophylaxis is recommended before placement of a pacemaker or implantable cardioverter defibrillator	с
	Perioperative antibiotic prophylaxis should be considered in patients undergoing surgical or transcatheter implantation of a prosthetic valve, intravascular prosthetic or other foreign material	В

Table 71: Recommended	prophylaxis	regimen f	or high-risk a	dental procedure	s in high risk patients

Clinical situation	Antibiotic	Single-dose 30-60 minutes before procedure		
		Adults	Children	
No allergy to Penicillin	Amoxicillin or	2g orally or iv	50mg/kg orally or iv	
	Ceftriaxone	1g iv	50mg/kg iv	
Allergy to Penicillin	Clindamycin	600mg orally or iv	20mg/kg orally or iv	

OTHER PREVENTIVE MEASURES

Although antibiotic prophylaxis is not recommended for patients at intermediate risk of IE, i.e. any other form of native valve disease (including the most commonly identified conditions such as bicuspid aortic valve, mitral valve prolapse and calcific aortic stenosis), both intermediate- and high-risk patients should be advised on the importance of dental and skin hygiene. These measures of general hygiene apply to patients and healthcare workers and should ideally be applied to the general population, as IE can occur without known cardiac disease⁶.

Recommended general hygiene measures include

- Strict dental and skin hygiene; dental follow-up should be performed twice a year in high-risk patients and yearly in the others
- Disinfection of wounds
- Curative antibiotics for any focus of bacterial infection
- No self-medication with antibiotics
- Strict infection control measures for any at-risk procedure
- Discourage piercing and tattooing
- Limit the use of infusion catheters and invasive procedure when possible. Favour peripheral over central catheters, and systematic replacement of the peripheral catheter every 3-4 days; strict adherence to care bundles for central and peripheral cannulae should be performed

5.8.7 PATIENT INFORMATION/EDUCATION

- Patients should be educated about the symptoms and signs of IE after discharge
- Patients should be informed that IE could recur and that new onset of fever, chills or other signs of infection mandate immediate evaluation, including procurement of blood cultures before empirical use of antibiotics
- Patients should be advised to attend regular clinical and echocardiographic follow-up during the first year following completion of treatment
- Patients should also be educated on good oral health maintenance, preventive dentistry and advised about skin hygiene, including tattoos and skin piercing⁶

REFERENCES

- 1 Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E. Braunwald's heart disease : a textbook of cardiovascular medicine. 2005. 1633–1658.
- 2 Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications. Circulation. 2015 Oct; 132(15): 1435–1486.
- ³ Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T, et al. Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis. Clinical Infectious Diseases. 2000 Apr; 30(4): 633–638.
- 4 Hoen B, Duval X. Infective Endocarditis. New England Journal of Medicine. 2013 Apr 11; 368(15): 1425–33.
- 5 National Institute for Health and Care Excellence. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. NICE; 2018.
- 6 Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis. European Heart Journal. 2015 Nov; 36(44): 3075–3128.

5 DISEASES

5.9 CARDIAC ARRHYTHMIAS

LIST OF ABBREVIATIONS AND ACRONYMS

AF	Atrial fibrillation	HR	Heart rate
BP	Blood pressure	INR	International normalised ratio
Bpm	beats per minute	LOE	Level of evidence
CPR	Cardiopulmonary resuscitation	SVT	Supraventricular tachycardia
СТ	Computed tomography	VF	Ventricular fibrillation
ECG	Electrocardiography	VT	Ventricular tachycardia

5.9.1 INTRODUCTION


i. DEFINITION

Arrhythmias are abnormal heart rate or rhythm. This definition includes an increase in the rate of occurrence of impulses (tachyarrhythmias), a decrease in the rate of occurrence of electrical impulses (bradyarrhythmias) or a change in the normal rhythm of impulses. The commonest form of arrhythmia worldwide is atrial fibrillation¹.

ii. EPIDEMIOLOGY

Atrial fibrillation, the commonest and most persistent form of cardiac arrhythmia was shown to affect 33.5 million people worldwide (20.9 million males and 12.6 million females) in the year 2010¹. Ventricular arrhythmias include a spectrum that ranges from premature ventricular complex (PVC) to ventricular fibrillation (VF). Incidence and prevalence of ventricular arrhythmias has been shown to increase with age and in the presence of structural heart disease².

iii. CLASSIFICATION OF ARRHYTHMIAS



5.9.2 AETIOLOGY

Figure 25:

Arrhythmias could arise from both cardiac and non-cardiac causes. These include:

Table 72: Causes of arrhythmias

,	
Cardiac causes	Non-cardiac causes
Myocardial infarction	Hypertension
Rheumatic heart disease and other valvular heart diseases	Thyroid dysfunction (hypo- and hyperthyroidism)
Ischaemic heart disease	Alcoholism
Cardiomyopathies	Smoking
Post-cardiac surgery	Drugs (beta 2 agonists, L- Dopa, Digoxin, Doxorubicin)
Pericardial disease	Electrolyte imbalance
Myocarditis	Metabolic imbalance (hypoxia, hypercapnia, acidosis)
Infiltrative heart diseases	Pulmonary embolism
Channelopathies (e.g. Brugada syndrome and Long-QT Syndrome)	Pneumonia
	Physiologic causes: Sleep, exercise, anaemia, fever, changes in autonomic tone

→ Note: Sinus arrhythmias are due to fluctuations of autonomic tone during respiration, resulting in phasic changes of the sinus discharge rate (acceleration and deceleration). This variation is normal, particularly in children and young adults and typically results in predictable irregularities of the pulse. Hence non-patho logical or of no clinical relevance.

5.9.3 CLINICAL PRESENTATION

Patients may have arrhythmias without symptoms. relevant symptoms usually occur as a result of haemodynamic compromise/instability.

i. SYMPTOMS AND SIGNS

Table 73: Sympto	ms and signs	of cardiac	arrhythmias

Symptoms	Signs
Palpitations	Pulse rate abnormalities (tachycardia or bradycardia)
Dizziness	Rhythm irregularities e.g. atrial fibrillation
Shortness of breath	Diaphoresis
Chest pain	Hypotension (low blood pressure)
Light-headedness/feeling faint	Signs of heart failure
Loss of consciousness	Signs of structural heart disease: heaves, thrills, murmurs
Seizures	Altered mental state (restlessness, agitation, confusion, unresponsiveness)
Fatigue	Absent central or peripheral pulse

5.9.4 BASIC INVESTIGATION ACCORDING TO LEVEL OF CARE

i. HEALTH FACILITY WITHOUT A DOCTOR

Health facility without a doctor usually do not have ECG machine or the interpretation of ECG is difficult. Hence, any patient suspected of SIGNIFICANT arrhythmia (tachycardia or bradycardia) from clinical examination should be referred as soon as possible.

→ Refer if diagnosis of arrhythmia is suspected; do not delay referral if ECG is not readily available.

ii. HEALTH FACILITY WITH A DOCTOR:

- 12-lead ECG (LOE A)
- Serum electrolytes, calcium, magnesium assay (LOE C)
- Chest Xray
- Full blood count

iii. HEALTH FACILITY WITH A PHYSICIAN SPECIALIST

- ECG
- Full blood count
- ESR/CRP
- Serum electrolytes, calcium, magnesium assay (LOE C)
- Chest X-ray
- Thyroid function test, particularly, thyroxin stimulating hormone (TSH) (LOE C)
- Serum cardiac enzyme levels particularly troponins and CK-MB during acute episodes
- Arterial blood gases (ABG) if available

iv. HEALTH FACILITY WITH A CARDIOLOGIST

- Echocardiography to detect valvular and other structural abnormalities (LOE B)
- Holter monitoring (ambulatory ECG) (LOE B)
- Exercise stress test
- Coronary angiogram

5.9.5 TACHYARRYTHMIAS: GENERAL OVERVIEW

Life-threatening tachyarrhythmia may present at any facility. The most important aspect of care is to determine whether this patient is in danger. Diagnosis and management of life-threatening arrhythmias depend on the level of care (availability of diagnostic tools, drugs and expertise of attending clinician). *Figure 26* shows the algorithm for the management of patient with significant tachyarrhythmia.

i. MANAGEMENT ACCORDING TO LEVEL OF CARE

ia. HEALTH FACILITY WITHOUT A DOCTOR

- → Refer if diagnosis of SYMPTOMATIC arrhythmia is suspected.
- \rightarrow Identify and treat reversible causes of arrhythmia while awaiting referral (see *table 75*)

Reversible Cause	Management
Нурохіа	 Check and maintain airway (prop up in bed, perform jaw thrust and chin lift, oropharyngeal airway, if available, etc.) Check oxygenation and ventilation Administer oxygen
Hypovolaemia	Replace blood or fluid loss with: Crystalloid (e.g. normal saline, Ringer's lactate)
Hypo-/Hyperthermia	Hypothermia: • Warmed intravenous fluids • Warm blankets Hyperthermia: • Cooling blankets • Tepid sponging • Cooling packs/wet towel application to head, axilla, groin
Toxins/Medications	Activated charcoal (within 1 hour of ingestion)Supportive measures ABCDE

Table 74: Management of reversible causes of arrhythmia in health facility without a doctor

ib. HEALTH FACILITY WITH DOCTOR

LABORATORY INVESTIGATION

- Serum electrolytes, calcium, magnesium assay (LOE C)
- Full blood cell count

OTHER INVESTIGATION

- 12-lead electrocardiography (LOE A)
- Chest X-ray

See next page for table 75: Management of reversible causes of cardiac arrhythmias in health facility with a doctor.

Table 75: Management of reversible causes of cardiac arrhythmias in health facility with a doctor (Adapted from Liverpool Hospital ICU Guideline on Management of Arrhythmias)

Reversible Cause	Management	
Acidosis (Respiratory/metabolic/renal)	 Adequate hydration Treat the underlying cause: Metabolic: e.g. diabetic ketoacidosis: give insulin, hydrate Renal: e.g.acute kidney injury: hydrate, dialysis Respiratory: e.g. severe asthma/COPD or pneumonia: ventilation with a self-in- flating mask, non-invasive ventilation, mechanical ventilation Administer sodium bicarbonate (50-100ml of 8.4% NaHCO₃ intermittently) Consider if acidosis persists despite the treatment outlined above 	
Hypokalaemia or hyperkalaemia	 Hypokalaemia (from diuretics, GIT loss): hydrate, administer iv potassium chloride (KCL) 40-120mmol slowly over 24 hours; ideally using a perfuser Hyperkalaemia Give 10mls of 10% Ca gluconate iv 10 IU soluble Insulin in 50ml of 50% glucose (or in 250ml of 10% glucose) Nebulized Salbutamol 10mg 	
Other reversible causes include pulmonary embolism, myocardial infarction, cardiac tamponade		

ic. HEALTH FACILITY WITH A PHYSICIAN SPECIALIST

LABORATORY INVESTIGATION

- Serum electrolytes, calcium, magnesium assay (LOE C)
- Full blood cell count
- TSH
- Troponins, especially CK-MB
- ABG (if available)
- Further investigation to be requested by cardiologist

OTHER INVESTIGATION

- 12-lead ECG (LOE A)
- Chest X-ray




Figure 26: Tachycardia algorithm

ii. ATRIAL FIBRILLATION

iia. CLINICAL PRESENTATION

- Palpation of the pulse as a basic screening tool may help detect AF³
- The pulse is characteristically described as being "irregularly irregular" (in both volume and rhythm)
- A definitive diagnosis of AF requires rhythm documentation using an ECG showing a typical pattern of no discernible, distinct P waves and irregular RR interval (*figure 27*)



Figure 27: Atrial fibrillation

iib. CLASSIFICATION (ALL LEVELS)

Atrial fibrillation can be classified into five groups based on the pattern (table 76):

AF pattern	Definition
First diagnosed	Prior diagnosis of AF has not been made, irrespective of duration of symptoms
Paroxysmal	Typically, self-limiting- resolves within 48 hours or may persist up to 7 days (Includes atrial fibrillation cardioverted within one week of onset)
Persistent	Episode lasts longer than 7 days. Includes episodes terminated by cardioversion after \geq 7 days
Longstanding persistent	Continuous AF lasting for \geq 1 year when a decision is made to adopt a rhythm control strategy
Permanent	AF accepted by both patient and physician hence rhythm control not pursued. A decision to adopt a rhythm control strategy converts it to a "Longstanding persistent AF"

iic. MANAGEMENT OF STABLE ATRIAL FIBRILLATION

HEALTH FACILITY WITHOUT A DOCTOR/WITH A DOCTOR

- \rightarrow Refer if diagnosis is suspected.
- \rightarrow Do ECG where available
- \rightarrow Identify and treat reversible causes (refer to *table 74*)

HEALTH FACILITY WITH A PHYSICIAN SPECIALIST

This involves:

- A. Identification and treatment of precipitating factors (e.g. thyrotoxicosis, sepsis, or postoperative AF) and underlying cardiovascular conditions
- B. Anticoagulation
- C. Rate control
- D. Rhythm control

IDENTIFICATION OF PRECIPITATING FACTORS → Refer to *table 75.*

ANTICOAGULATION (STROKE PREVENTION THERAPY, LEVEL OF EVIDENCE A)

- Anticoagulation is mandatory in valvular AF (i.e. AF with moderate-severe mitral stenosis and in those who had mitral valve repair or mechanical or bioprosthetic heart valve)
- The need for anticoagulation in patients with non-valvular AF should be determined using the CHA₂DS₂VAS_c score (*table 77*)
- → Give anticoagulant if $CHA_2DS_2VAS_c$ score is ≥ 1

Table 77: The CHA₂DS₂VAS_c score for stroke risk prediction⁴ of anticoagulant therapy (LEVEL A)

CHA ₂ DS ₂ VAS _c Risk factor	Points
Congestive heart failure (signs and symptoms or evidence of reduced LVEF)	+1
Hypertension	+1
Age >75 years	+2
Diabetes mellitus	+1
Previous stroke, TIA	+2
Vascular disease (peripheral artery disease, previous MI, aortic plaque)	+1
Age 65-74 years	+1
Sex category (female)	+1
Maximum score	9 points

After the need for anticoagulation is determined, it is important to assess bleeding risk using the HAS-BLED score (*table 78*) prior to commencement of anticoagulant therapy (LEVEL A).

Table 78: The HAS-BLED bleeding risk score⁵

Letter	Clinical characteristic	Points awarded
н	Hypertension	1
А	Abnormal renal and liver function (1 point each)	1 or 2
S	Stroke	1
В	Bleeding tendency or predisposition	1
L	Labile INRs (if taking vitamin K antagonists	1
E	Elderly (e.g. age >65, frail condition)	1
D	Drugs (concomitant Aspirin, NSAID) or alcohol	1 or 2
Maximum		9 points

NOTE:

- → A high HAS-BLED score (≥3) is not an indication for withholding anticoagulant therapy in patients in whom it is indicated (CHA₂DS₂VAS_c ≥1 in males/≥2 in females or in patients with mitral stenosis)
- \rightarrow Rather, such high-risk patients require regular review and cautious anticoagulation
- → Manipulation of modifiable risk factors for bleeding such as hypertension, drugs and alcohol intake may reduce bleeding risk in such patients and hence enable anticoagulant therapy commencement

PHARMACOLOGICAL TREATMENT

Table 79: Oral anticoagulant therapy

Drug Group	Drug	Dosage (oral)
Vitamin K antagonists	Warfarin	Starting dose: 10mg for first two days, 5mg for third day, after which INR is checked and dose adjusted to achieve therapeutic INR
Factor X antagonists	Rivaroxaban*	20mg daily as maintenance dose
	Apixaban ◆	5mg twice daily as maintenance dose
Direct thrombin inhibitors	Dabigatran*	150mg twice daily as maintenance dose

CONSIDERATIONS FOR ANTICOAGULANT THERAPY

- Warfarin use requires monitoring of INR. Target INR is between 2-3 and during initiation of therapy, INR should be determined on the third day after initiation of the Warfarin, with dose modification until target is reached, after which INR monitoring can be done every two months
- The Novel Oral Anticoagulants (NOACs) have a less risk of bleeding and do not require INR monitoring⁶
- Renal function should be evaluated before commencement of NOAC therapy

RATE CONTROL

ACUTE RATE CONTROL

This can be achieved in atrial fibrillation with very fast ventricular response using one of the the following medication in *table 80*.

Table 80: Acute rate control in atrial fibrillation

Drug Group	Drug (route)	Dosage
Beta-blockers	Metoprolol (iv)	5mg over 1-2 minutes every 5 minutes (total maximum: 15mg)
	Esmolol⁺ (iv)	500mcg/kg over 1 minute, then 50mcg/kg/min, increasing every 4 minutes (maximum dose 200mcg)
Calcium channel blockers	Verapamil (iv)	5-10mg (0.075- 0.15mg/kg) over 2 minutes; repeat as needed
	Diltiazem* (iv)	20mg (0.35mg/kg) bolus over 2 minutes; repeat if response is poor
Cardiac glycosides	Digoxin (iv)	0.5mg iv loading, then 0.25mg 6 hourly twice, followed by once daily

LONG-TERM RATE CONTROL

For long term rate control of AF, the following medication could be used (*table 81*) to achieve a target HR of <110bpm.

Drug Group	Drug	Dosage	Level of evidence
Beta-blockers	Bisoprolol	1.25 - 20mg daily	
	Metoprolol	25-200mg daily (oral)	
	Carvedilol	3.125-50mg twice daily	В
	Nebivolol*	2.5-10mg daily	5
	Atenolol	25-100mg daily (oral)	
Calcium channel blockers	Verapamil	40-120mg 6-8 hourly (oral)(max 480mg)	
	Diltiazem*	60mg tds or 120-360mg daily as modified release (max 360mg)	
Cardiac glycosides	Digoxin	0.0625-0.25mg (oral)	

RHYTHM CONTROL

- \rightarrow Refer patient to cardiologist for further management.
- → Health facility with a physician specialist: in addition to the investigation/management mentioned for health facility with a doctor, rhythm control, if indicated is done at this level

iii. ATRIAL FLUTTER

Atrial flutter is a cardiac arrhythmia characterized by atrial rate of 240-400bpm and some degree of atrioventricular node conduction block. Causes include Structural heart diseases especially post-surgery, hypertensive heart disease and ischaemic heart disease.

HEALTH FACILITIES WITHOUT A DOCTOR

Diagnosis of Atrial flutter may be difficult in a facility without a doctor because ECG may not be available and interpretation of ECG may be difficult.

 \rightarrow A patient suspected of having arrhythmia or atrial flutter should be referred to a facility with a doctor.

PHARMACOLOGICAL TREATMENT

- \rightarrow Refer if diagnosis is suspected.
- \rightarrow Identify and treat reversible causes (refer to *table 74*)

HEALTH FACILITY WITH A DOCTOR/PHYSICIAN SPECIALIST

INVESTIGATION

- Pulse is usually regular and rapid on palpation
- ECG: shows "saw-toothed" flutter (p) waves especially in the inferior leads (II, III, aVf) with RR intervals which are usually regular (*figure 28*)
- \rightarrow May come with 2:1, 3:1, 4:1 or variable block.
- → May be confused with atrial fibrillation and is often initiated by a brief episode of atrial tachycardia or by AF.



Figure 28: Atrial flutter on an ECG showing regular RR intervals and saw-toothed P waves

PHARMACOLOGICAL TREATMENT \rightarrow Refer to treatment of AF.

iv. MANAGEMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA

A narrow complex tachycardia that arises from the atria or AV node with an abrupt onset or termination.

CLINICAL PRESENTATION

- Regular HR approximately 140-280 bpm
- Usually narrow QRS complex <120 ms
- P waves may be absent or if visible may be inverted or buried in the QRS complex or come after the QRS complex (*figure 29*)



Figure 29: ECG showing supraventricular tachycardia

NON-PHARMACOLOGICAL TREATMENT

If haemodynamically stable for all levels:

- \rightarrow Vagal manoeuvres such as carotid sinus massage, valsalva manoeuvre may help abort the arrhythmia (LOE B).
- \rightarrow Patients should be referred to the cardiologist for assessment and long-term management (LOE C).

Steps for the performance of the modified vasalva maneuver⁷

- Explain procedure to patient
- With patient approval, place patient in a semi-recumbent position
- Ask patient to blow into a 10ml syringe hard enough to shift plunger for 15 seconds while in semirecumbent position
- Patient is made to lie supine or head end of bed is flattened immediately after the strain while passively elevating both lower limbs at the same time
- Patient should maintain this position for 15 seconds

HEALTH FACILITY WITHOUT A DOCTOR

PHARMACOLOGICAL TREATMENT

 \rightarrow None recommended, refer to health facility with a doctor.

HEALTH FACILITY WITH A DOCTOR

- → Treat reversible causes refer to table 75
- → Vagal manoeuvre as above

PHARMACOLOGICAL TREATMENT

Options available include:

- iv Adenosine* or
- iv Verapamil or
- iv Diltiazem* or
- iv Beta-blocker
- → Refer to cardiologist for further assessment and management.

HEALTH FACILITY WITH A PHYSICIAN SPECIALIST

 \rightarrow Attempt vagal manoeuvre

PHARMACOLOGICAL TREATMENT

Options available include:

- iv Adenosine* or
- iv Verapamil or
- iv Diltiazem* or
- iv Beta-blocker
- \rightarrow Refer to cardiologist for further assessment and management.

v. MANAGEMENT OF VENTRICULAR TACHYARRHYTHMIA IN STABLE PATIENTS

Ventricular tachycardia (VT) is a broad complex tachycardia arising from either the right or left ventricle. It is said to be slow VT when the rate is <150 bpm and fast when >180 bpm. However, the haemodynamic compromise is the best determinant of how severe the VT is but not the heart rate. *Figure 30* shows an ECG with VT. It is the most common form of broad complex tachycardia with increased risk of morbidity and mortality⁸.

INVESTIGATION

- ECG
 - A diagnosis of VT is supported by the presence of:
 - AV dissociation
 - QRS complex >0.14s
 - Monophasic R wave in lead aVR
 - Absence of an RS complex in all precordial leads
 - RS interval >100 ms in at least 1 precordial lead

$ \land \land \land$	$\wedge \wedge$	\wedge	$ \land $	$\wedge \land$	\cap	Nr		\wedge	\wedge	\cap
					1 1		NIN		1 • • • • • • • • • • • • • • • • • • •	$ \setminus $
					$\langle \rangle \rangle$	$ \times $				
	V V									1
	V	VV	V		V		V.	V V		V
· V	Y	۷ V		V			V	¥ V	V	

Figure 30: ECG of ventricular tachycardia

HEALTH FACILITY WITHOUT A DOCTOR


 \rightarrow Refer to health facility with a doctor/physician specialist.

HEALTH FACILITY WITH A DOCTOR/PHYSICIAN SPECIALIST

PHARMACOLOGICAL TREATMENT

Useful medications in management of VT are summarised in the *table 82. Figure 31* shows the algorithm for the management of ventricular tachycardia.


Agent	Indication(s) for use
Beta-blocker: Metoprolol Esmolol* Carvedilol	Heart failure with reduced left ventricular ejection fraction; (reduces risk of sudden cardiac death) Polymorphic VT due to myocardial ischaemia Recent MI with VT
Procainamide⁺ Sotalol⁺	Stable patients with monomorphic VT and normal LV function; (NB: Procainamide* may further prolong QT interval and lead to torsades de pointes)
Lidocaine	 Polymorphic VT with: QT prolongation Ongoing MI Cardiac arrest unresponsive to defibrillation and may increase overall mortality; harmful if given as prophylaxis for VT in acute MI
Amiodarone*	Haemodynamically unstable VT persisting after maximal energy shock; in combination with Beta-blocker for VT with left ventricular dysfunction
Magnesium sulphate	Polymorphic VT with QT prolongation, torsades de pointes



Algorithm for the management of ventricular tachycardia

- → For VT that does not terminate with cardioversion or antiarrhythmic medication, catheter ablation is recommended, hence, immediate referral to a cardiologist.
- → CPR according to the Advanced Cardiac Life Support (ACLS) protocol should be administered in patients who develop cardiac arrest.
- \rightarrow Refer patient to cardiologist for post-stabilisation management.
- vi. MANAGEMENT OF VENTRICULAR FIBRILLATION HEALTH FACILITY WITH A DOCTOR/PHYSICIAN SPECIALIST
- → Ventricular fibrillation is a rapid, grossly irregular ventricular activity with marked variability in electrocardiographic waveform (AHA 2017). Ventricular rate is usually > 300 bpm. The disorganised excitation and irregular ventricular contractions result in heart failure and rapidly progress to cardiac arrest and ultimately death⁹.

NON-LABORATORY INVESTIGATION



→ ECG (figure 32)

Figure 32: ECG ventricular fibrillation

Findings on a 12-lead ECG suggestive of ventricular fibrillation include:

- Irregular waves which are coarse initially but flatten out as the arrhythmia progresses and heart failure worsens
- Shapeless rapid oscillations

TREATMENT

- \rightarrow Begin CPR immediately.
- → Refer to figure 7 on page 52: Advance Cardiac Life Support (ACLS) Algorithm.

5.9.6 BRADYARRHYTHMIAS

i. SINUS BRADYCARDIA

General description:




Figure 33: ECG showing sinus bradycardia

→ This may be due to sinus node dysfunction or external influences (such as Beta-blockers, hypothyroidism) on a relatively normal sinus node.

AETIOLOGY

Extrinsic: hypothermia, hypothyroidism, cholestatic jaundice and raised intracranial pressure, drugs (Beta-blockers, digitalis and other anti-arrhythmic drugs) and neurally mediated causes (carotid sinus syndrome, vasovagal syndrome etc.)

Intrinsic: Acute ischaemia and infarction of the sinus node, fibrosis of the atrium and sinus node (sick sinus syndrome)

ii. ATRIOVENTRICULAR BLOCK

First degree:

 \rightarrow This is seen as prolonged PR interval (>0.20s or 5 small boxes) on ECG (figure 34)




Figure 34: ECG showing prolonged PR interval in first degree heart block

Second degree:

 \rightarrow This occurs when some atrial impulses fail to reach the ventricles (figure 35)



Figure 35: ECG showing second degree heart block

Third degree:

 \rightarrow Complete dissociation between P wave and QRS complex, also known as complete heart block (figure 36)




Figure 36: ECG of complete heart block showing complete dissociation between P waves and QRS complexes

DIAGNOSIS

- \rightarrow A history of symptoms as mentioned above with pulse rate <60 bpm on examination.
- \rightarrow A detailed physical examination should be carried out to detect signs of possible underlying disease.

TREATMENT IN GENERAL

Treatment objectives include restoration of sinus rhythm where possible, and prevention of complications. Treatment is indicated if patient is haemodynamically unstable with symptoms and signs of inadequate perfusion (hypotension, altered mental status, signs of shock, ongoing ischaemic chest pain) and evidence of acute pulmonary oedema.

HEALTH FACILITY WITHOUT A DOCTOR

NON-PHARMACOLOGICAL TREATMENT

- Nurse propped up (bed at 30° to the horizontal)
- Give oxygen if hypoxic or cyanotic
- Provide warmth
- Initiate CPR if haemodynamically unstable
- → Prompt referral.

HEALTH FACILITY WITH A DOCTOR/PHYSICIAN SPECIALIST

- Nurse propped up (bed at 30° to the horizontal)
- Give oxygen if hypoxic or cyanotic
- Provide warmth
- Initiate CPR if haemodynamically unstable
- Investigate and treat underlying cause
- Administer atropine, cautiously (500mcg up to 3mg) iv
- \rightarrow Refer to cardiologist for investigation and management.
- To assess the cause of the sinus bradycardia with both invasive and/or non-invasive diagnostics

- Give more advanced therapeutics in the event when the sinus bradycardia is persistent or recurrent
- Treat reversible causes (see *table 75 on page 178*)
- → Refer to cardiologist for pacemaker implantation (either temporary or permanent depending on patient's history and clinical examination findings).

ATRIOVENTRICULAR BLOCKS IN GENERAL

First degree:

→ No pharmacologic treatment indicated in stable patients; patient requires follow up with ECG monitoring

Second and third degree:

→ Pacemakers are beneficial hence patient requires referral to cardiologist

REFERRAL

- → Cardiologist referral required in:
 - Symptomatic patients with pulse rate less than 50 bpm
 - Patients with underlying structural heart disease
- → Specialist referral based on underlying condition: i.e. neurologist referral in patients with raised intracranial pressure, Endocrinologist referral in patients with hypothyroidism

iii. SICK SINUS SYNDROME (SINUS NODE DYSFUNCTION)

It is caused by fibrosis of the sinus node, which is usually idiopathic and associated with old age^{10, 11}.

DIAGNOSIS

Made by correlating symptoms of end-organ hypoperfusion with occurrence of bradycardia, with or without tachycardia in the presence of ECG abnormalities.

ECG abnormalities in sinus node dysfunction include periods of:

- Sinus bradycardia
- Sinus pauses
- Sinus arrest
- 3rd degree SA nodal exit block
- Supraventricular tachycardia (as part of tachy-brady syndrome)

Presence of ECG findings in the absence of symptoms may be explained by physiologic and pathologic processes such as increased vagal tone during sleep or obstructive sleep apnoea.

Other helpful investigations for health facility with a physician specialist include:

- Serum electrolyte assay (LOE B)
- Holter monitoring

HEALTH FACILITIES AT ALL LEVELS OF CARE

Figure 38 shows the algorithm for the management of sinus nodal dysfunction.

ACUTE NON-PHARMACOLOGICAL TREATMENT

- Rapid assessment of ABCs
- → Identification and elimination of reversible causes such as medications in symptomatic patients (LOE C)
- Cardiologist referral for:
- → Transvenous temporary or permanent pacemaker in haemodynamically unstable patients who are refractory to medical therapy; this will take care of bradyarrhythmic phase of the disease (LOE C)
- → NOTE: Atropine should not be used to treat sinus bradycardia in patients who have undergone cardiac transplant (LOE C)¹²

HEALTH FACILITY WITH A PHYSICIAN SPECIALIST

PHARMACOLOGICAL TREATMENT

- iv Atropine 4microg/kg every 2-4 hours (for the bradyarrhythmias) and/or:
- iv lsoproterenol* 0.05- 0.5mcg/kg/min (for the bradyarrhythmias)

In patients with coexisting (paroxysmal) tachyarrhythmias, these should be given after pacemaker has been implanted for the bradycardia episodes:

- Beta-blockers
- Antiarrhythmic medication

HEALTH FACILITY WITH A CARDIOLOGIST

LONG-TERM NON-PHARMACOLOGICAL MANAGEMENT

Permanent dual-chamber pacemakers (LOE B):

Pacemaker therapy is the only effective and definitive therapy for patients with chronic symptomatic sinus node dysfunction. The therapy has not been shown to increase survival in patients. It however relieves symptoms and improves quality of life.

Table 83: Indications for permanent cardiac pacing in sinus node dysfunction (LOE C) (Adapted from The 2018 Bradycardia Clinical Practice Guidelines¹³⁾

Indications for permanent cardiac pacing in sinus node dysfunction							
Compelling indications	Relative indications						
Documented symptomatic bradycardia with frequent sinus pause that is symptomatic	Significant symptoms of bradycardia and documented heart rate less than 40 beats per minute without documentation of bradycardia in the presence of symptoms						
Symptomatic sinus bradycardia caused by medication required for medical condition (essential drug therapy)	Syncope of unexplained origin with dysfunction of sinoatrial node discovered or provoked in electrophysiologic studies						
Symptomatic chronotropic incompetence	Minimally symptomatic patients with chronic heart rate less than 40 beats per minute while awake						




Figure 37:

Bradycardia algorithm (Adapted from Liverpool ICU guidelines)

5.9.7 PREVENTION

Multiple clinical risk factors have been associated with the development of arrhythmias. Thus it may be possible to prevent some arrhythmias by risk factor modification.

Prevention includes:

- Lifestyle modification (refer to *chapter 2* of these guidelines on risk factors and *chapter 5.1* on hyper-tension)
- Target control of predisposing and precipitating factors, such as thyrotoxicosis, rheumatic heart diseases and hypertension

5.9.8 PATIENT INFORMATION/EDUCATION

- Patients should be taught to recognise symptoms of arrhythmia and danger signs
- Avoid precipitants such as binge drinking, excessive caffeine intake etc
- Patients on anticoagulants should be told about possible interactions with other medications and diets and when to report
- Patient's family should be counselled about condition and how to offer support, both life-saving (e.g. CPR) and emotional support
- Asymptomatic family members may require screening in arrhythmias with genetic linkage (LOE C)

REFERENCES

- 1 Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2013; 129(8): 837–847.
- 2 Hiss RG, Lamb LE. Electrocardiographic findings in 122,043 individuals. Circulation. 1962; 25(6): 947–961.
- 3 Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thrombosis and Haemostasis. 2013; 110(1): 213–222.
- 4 Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137(2): 263–272.
- 5 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A Novel User-Friendly Score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5): 1093–1100.
- 6 Diener HC, Eikelboom, Connolly SJ, Joyner CD, Hart RG, Lip GY, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. The Lancet Neurology. 2012; 11(3): 225–231.
- 7 Appelboam, Andrew, Reuben A, Mann C, Gagg J, Ewings P, Barton A, et al. Postural modification to the standard Vasalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): A randomised controlled trial. The Lancet. 2015; 386(100054): 1747–1753.
- 8 Dresen F, Ferguson JD. Ventricular arrhythmias. Clinical Cardiology. 2018; 36(1): 129–139.
- 9 Goyal, Sandeep K. Ventricular Fibrillation: Background, Pathophysiology, Etiology. Available from: https://emedicine.medscape.com/article/158712-overview.
- 10 Kantharia, Bharat K., et al. Sinus Node Dysfunction. 2019. Available from: https://emedicine.medscape.com/article/158064-overview#a1.
- 11 Semelka, M, Gera, J and Usman, S. Sick Sinus syndrome: a review. American Family Physician. 2013; 87(10): 691-694.
- 12 Link MS, Berkow LC, Kudenchuk, PJ, Halperin HR, Hess EP, Moitra VK, et al. Part 7: Adult Advanced Cardiovascular Life Support. 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015; 132(18 Suppl 2): 444–464.
- 13 Kusumoto FM, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay: An Executive Summary. Journal of the American College of Cardiology. Circulation. 2018; Available from: https://www.ahajournals.org/doi/pdf/10.1161/CIR.00000000000627.

LIST OF TABLES

Table 1	Level of evidence	18
Table 2	Various levels of care and recommended resources	20
Table 3	Traditional and emerging cardiovascular risk factors	25
Table 4	Recommended action per risk category	26
Table 5	General nutritional recommendations	28
Table 6	Recommendations for physical activity	29
Table 7	Sedentary time	29
Table 8	Substance use and abuse	29
Table 9	Target levels for important cardiovascular risk factors	30
Table 10	Categories of statin based on potency	31
Table 11	Risk category and pharmacological intervention	31
Table 12	Causes of dyspnoea	39
Table 13	Differentiating features of cardiac vs. respiratory dyspnoea	39
Table 14	Causes of chest pain	40
Table 15	Clinical classification of angina	40
Table 16	Causes of body swelling	40
Table 17	Causes of haemoptysis	41
Table 18	Causes of syncope	41
Table 19	Symptoms of syncope and seizure	42
Table 20	Causes of palpitation	42
Table 21	General signs of CVD	42
Table 22	Pulse and associated condition	43
Table 23	Heart sounds	44
Table 24	Cardiac murmurs	45
Table 25	Classification of hypertension	55
Table 26	Risk factors of primary or essential hypertension	56
Table 27	Causes of secondary hypertension and important clinical features	56
Table 28	Hypertension cutoff values for office and out-of-office BP measurements	59
Table 29	Non-pharmacological treatment for all levels	59
Table 30	Preferences for antihypertensive drugs by comorbidity for health facility	
	with a physician specialist	65
Table 31	Antihypertensive medications, indications and contraindications	68
Table 32	Antihypertensive medications and the common side effects	69
Table 33	Hypertensive emergency management options	71
Table 34	,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,, ,,	72
	Classification of strokes	76
	Aetiology of stroke	76
	Risk factors of stroke	77
Table 38	Indications and contraindications for iv thrombolysis	82
	ABCD score	83
	The recognition of stroke in the emergency room (ROSIER) scale	87
Table 41	Pathological changes affecting myocardial blood supply and demand	93
Table 42	Characteristics of angina versus other forms of chest pain	94

Table 43	Functional classification of angina	94
Table 44	CAD pretest probabilities (%) in patients with stable chest pain symptoms	94
Table 45	Mimics of angina/other causes of chest pain	95
Table 46	Causes of acute coronary syndrome	102
Table 47	How to use the mnemonic "OPQRST"	103
Table 48	Clinical characteristics of acute coronary syndrome compared with other causes	104
	of acute chest pain using the mnemonic "OPQRST"	
Table 49	Contraindications to fibrinolytic therapy	109
Table 50	Commonly used fibrinolytics and their doses	110
Table 51	Symptoms and signs	114
Table 52	Diuretics used in heart failure	116
Table 53	Disease modifying medication in heart failure and their doses	118
Table 54	Diuretics used in heart failure	120
Table 55	Disease modifying medication in heart failure and their doses	121
Table 56	Risk factors for VTE	125
Table 57	Two-level DVT Well's score	126
Table 58	Pharmacological treatment	128
Table 59	Pharmacological treatment of venous thromboembolism	129
Table 60	Assessment of clinical probability in acute PE	131
Table 61	Dosage for thrombolysis medication	135
Table 62	Simplified PESI	135
Table 63	Dosage of pharmacologic thromboprophylaxis	137
Table 64	Modified Jones criteria for the diagnosis of ARF	140
Table 65	Prophylaxis for acute rheumatic fever	144
Table 66	Aetiology of infective endocarditis based on classification	162
Table 67	Major and minor criteria for the diagnosis of infective endocarditis	163
Table 68	Modified Duke's criteria for infective endocarditis, adapted from Li et al.	164
Table 69	Indications for surgery	167
Table 70	Recommendations for prophylaxis of infective endocarditis in the highest-risk patients	
	according to the type of at-risk procedure	169
Table 71	Recommended prophylaxis regimen for high-risk dental procedures in high risk patients	169
Table 72	Causes of arrhythmias	173
Table 73	Symptoms and signs of cardiac arrhythmias	174
Table 74	Management of reversible causes of arrhythmia in health facility without a doctor	175
Table 75	Management of reversible causes of cardiac arrhythmias in health facility with a doctor	176
Table 76	Classification of atrial fibrillation	178
Table 77	The $CHA_2DS_2VAS_c$ score for stroke risk prediction of anticoagulant therapy (LEVEL A)	179
Table 78	The HAS-BLED bleeding risk score	179
Table 79	Oral anticoagulant therapy	180
Table 80	Acute rate control in atrial fibrillation	180
Table 81	Long-term rate control	180
Table 82	Useful medications in acute management of VT and their indications	184
Table 83	Indications for permanent cardiac pacing in sinus node dysfunction (LOE C)	189

LIST OF FIGURES

Figure 1	Worldwide NCD mortalities: 2008 verse 2030	17
Figure 2	WHO/ISH CVD risk chart for Africa zone D	27
Figure 3	Measurement of jugular venous pressure	43
Figure 4	Causes of cardiac arrest and sudden cardiac death	48
Figure 5	The three phases of cardiac arrest by Westfeldt and Becker	48
Figure 6	Basic Life Support (BLS) Algorithm	51
Figure 7	Advance Cardiac Life Support (ACLS) Algorithm	52
Figure 8	Threshold for initial management of hypertension	67
Figure 9	Antihypertensive regimen for patients	67
Figure 10	Non-contrast CT scan showing haemorrhagic stroke	80
Figure 11	Non-Contrast CT scan showing ischaemic stroke	81
Figure 12	Echocardiogram showing an intracardiac embolus at the apex of the left ventricle	81
Figure 13	Stroke unit protocol for patient referral	86
Figure 14	Chest pain algorithm & summary of management of stable CAD	96
Figure 15	Acute coronary syndromes: STEMI, NSTEMI and UA	102
Figure 16	Pathway for triaging and managing a patient presenting acute Chest Pain	105
Figure 17	Selection of non-ST-elevation acute coronary syndrome (NSTE-ACS) treatment strategy	109
	and timing according to initial risk stratification	
Figure 18	Reperfusion strategies in the infarct-related artery according to time from symptoms onset	110
Figure 19	Diagnostic algorithm for suspected DVT	127
Figure 20	Diagnostic algorithm for pulmonary embolism without shock or hypotension	131
Figure 21	Diagnostic algorithm for pulmonary embolism with shock or hypotension	132
Figure 22	Westermark sign and Hampton's Hump, adapted from slideshare.com	133
Figure 23	ECG findings in PE	134
Figure 24	Algorithm for diagnosis and management of ARF	145
Figure 25	Classification of cardiac arrhythmias	173
Figure 26	Tachycardia algorithm	177
Figure 27	Atrial fibrillation	178
Figure 28	Atrial flutter on an ECG showing regular RR intervals and saw-toothed P waves	181
Figure 29	ECG showing supraventricular tachycardia	182
Figure 30	ECG of ventricular tachycardia	183
Figure 31	Algorithm for the management of ventricular tachycardia	184
Figure 32	ECG ventricular fibrillation	185
Figure 33	ECG showing sinus bradycardia	186
Figure 34	ECG showing prolonged PR interval in first degree heart block	186
Figure 35	ECG showing second degree heart block	186
Figure 36	ECG of complete heart block showing complete dissociation between P waves	
	and QRS complexes	187
Figure 37	Bradycardia algorithm, adapted from Liverpool ICU guidelines	190



GHS REFERRAL FORM 2013Z 0000175 DATE DAY..... MONTH..... YEAR..... **REFERRING HEALTH FACULTY INFORMATION** NAME OF REFERRING CLINICS / HOSPITAL ADDRESS OF REFERRING CLINIC (INCLUDE TELEPHONE NO) **PATIENT/CLIENT INFORMATION** SURNAME OTHER NAMES DATE OF SEX INSURANCE INSURANCE (IF INSURANCE STATE IDM) MALE FEMALE BIRTH DAY/MONTH/YEAR AGE STATUS UN INSURED ADDRESS OF CONTACT PERSON / RELATIVE (INCLUDE TEL NO) SURNAME **REFERRAL DETAILS** CLINIC / HOSPITAL REFERRED TO DIAGNOSIS PRESENTING COMPLAINT(S) HEIGHT WEIGHT TEMPERATURE BP PULSE EXAMINATION FINDINGS EXAMINATION FINDINGS RESULTS OF ANY INVESTIGATIONS CARRIED OUT TREATMENTS GIVEN COMMENTS HEIGHT

REFERRING OFF	ICER	neight			
NAME OF OFFICER SIGNATURE	REFERRING	POSITION OF OFFICER REFERRING			
RECEIVING CL	INICIAN				
NAME OF OFFICER REFERRING SIGNATURE		POSITION OF OFFICER RECEIVING			
COMMENTS (PLEASE WRITE SUMMARY OF					
FINAL DIAGNOSIS AND TREATMENT GIVEN					
		DATE			

ANNEX 2

GHANA HEALTH SERVICE REFERRAL FEEDBACK FORM

PATIENT REG NO.....

SERIAL NO

DAY MONTH YEAR

Kindly fill this form in duplicate and return to the facility which referred this client HEALTH FACILITY INFORMATION

NAME % ADDRESS OF HEALTH FACILITY PROVIDING FEEDBACK

NAME % ADDRESS OF HEALTH FACILITY TO WHICH FEEDBACK IS BEING SENT

NAME AND POSITION OF CLINICAL WHO RECEIVED CLIENT

PATIENT / CLIENT INFORMATION									
SURNAME				ОТ	OTHER NAME				
SEX MALE FEMALE			E OF BIRTH		AGE				
NAME AND ADDRESS OF C	NAME AND ADDRESS OF CONTACT PERSONAL RE								
DATE OF REFERRAL DATE OF ARRIV REFERRAL FAC					D	DIAGNOSIS ON	REFERRAL	-	
DAY MONTH YEAR	DA	Y MONT	H YE	AR					
FINAL DIAGNOSIS	FINAL DIAGNOSIS								
	MEDICAL MANAGEMENT TREATMENT GIVEN (PLEASE WRITE HOW PATIENT WAS MANAGED)								
OUTCOME (PLEASE TICK)		DISCHARGED		D]	DAY	MONTH	YEAR	
					J	DAY	MONTH	YEAR	
IF CLIENT IS BEING REFERF MANAGEMENT AND ANY OT							DE ADVANC	e for fuf	RTHER
NEXT REVIEW DATE (WHERE APPLICABLE)									
NAME OF OFFICER PROVI	DING FEED	DBACK							
POSITION									
SIGNATURE	SIGNATURE			DATE					
CONTACT (S) OF OFFIC	ER PROVI	DING FEED	BACK						

NOTES

NOTES